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  Abstract 
Abstract 
Phosphorylation of the glycan portion of glycoproteins is an important posttranslational 
modification. In particular, the presence of mannose-6-phosphate (M6P) residues on high 
mannose glycans of lysosomal enzymes is important for the transfer of these enzymes to 
the lysosomes. The synthesis of different types of N-glycan structures containing M6P 
residues have been reported by various groups. This thesis work concerns the 
chemoenzymatic synthesis of phosphorylated glycoproteins, wherein M6P containing N-
glycans were synthesised chemically and then enzymatically coupled to give 
homogeneous glycoproteins.  
Endo-β-N-acetylglucosaminidases (ENGases), have been employed by various research 
groups for the synthesis of variety of homogeneous glycopeptides and proteins by using 
oxazolines as activated donors. This thesis reports the synthesis of bis-phosphorylated 
tetrasaccharide and hexasaccharide oxazoline donors, and the use of ENGases to catalyse 
their transfer to peptides and proteins. 
Chapter 1 provides an overview of the current literature regarding the synthesis of 
glycoproteins, with particular attention paid to the use of glycoprotein remodelling. A 
detailed description about lysosomal storage diseases and the commercially available 
enzyme replacement therapy (ERT) is included. The objectives of the project are 
outlined. 
Chapter 2 and 3 details the synthesis of a bisphosphorylated tetrasaccharide and 
hexasaccharide oxazoline donors. 
  Abstract 
Chapter 4 reports the results of ENGase-catalysed glycosylation reactions using the 
phosphorylated tetrasaccharide and hexasaccharide oxazoline donors. Glycosylation of a 
model glycosyl amino acid acceptor was carried out with these donors using Endo A, 
Endo M and the commercially available Endo M mutant N175Q as the catalyst. 
Glycosylation of RNase B which had been trimmed back to contain only a GlcNAc at the 
single glycosylation (GlcNAc-RNase B) site using Endo A as catalyst with the oxazoline 
donors is reported. The binding of phosphorylated tetrasaccharide- RNaseB to the cation-
independent mannose-6-phosphate receptor (CI-MPR) is demonstrated by the use of a 
fluorescent antibody assay. Finally, an investigation into glycoprotein remodeling using 
partially de-glycosylated Fabrazyme is also reported.  
Chapter 5 contains the experimental details for compounds synthesised and procedures 
described in Chapters 2 to 4. 
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1.1 General introduction 
Oligosaccharides / glycans are the most abundant and the most diverse biopolymers in 
Nature. Together with nucleic acids, proteins, and lipids, they are one of the most 
important types of natural organic products in living systems.
1
 In contrast to the other 
two classes of biological polymers, carbohydrates can be highly branched, and their 
monomeric units can be connected to one another by linkages differing in regio- and 
stereochemistry. The majority of carbohydrates within cells are present as 
glycoconjugates, being attached to lipids to form glycolipids, or to proteins to form 
glycoproteins. 
1.2 The biological importance of carbohydrates 
Initially the roles of carbohydrates in biological systems were only thought to involve the 
formation of structural materials, such as chitin and cellulose, or as sources of energy, 
such as glucose. However, more recently carbohydrates have been found to play 
important roles in numerous biological events. For example, glycosylation plays a pivotal 
role in many key biological processes such as cell adhesion, cell-cell signaling, 
fertilization, neuronal development, inflammation, and the development of immune 
responses.
1-4
 The glycosylation of proteins plays a significant role in protein folding,
5
 and 
in the modulation of important protein properties, such as conformation and stability, 
6-8
 
their susceptibility to proteases,
6 
and their circulatory lifetimes.
7,9
 Enhanced proteolytic 
stability as a result of glycosylation has been demonstrated, for example by comparison 
of RNase A, an unglycosylated pancreatic ribonuclease, and RNase B, which bears a 
single high mannose oligosaccharide at Asn34.
10-12
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In Nature glycans in glycoproteins fall into two categories: N-linked, in which the 
oligosaccharide chains are attached to asparagine residues, and O-linked, in which the 
carbohydrates are attached to serine or threonine residues. N-Linked glycosylation is the 
more common of the two. N-Linked glycans can be divided into three main types, each 
possessing a common “core pentasaccharide” structure which is attached to asparagine, 
and differing in the residues that extend outwards from this core: high-mannose 
(containing only mannose residues), complex (the core mannoses are typically further 
elongated with GlcNAc, galactose and sialic acid residues), and hybrid which has (at 
least) one antenna corresponding to each of the previous two types (Figure 1.1).  








Figure 1.1 Types of N-linked glycan 
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1.3 Lysosomes and lysosomal storage diseases 
Lysosomes are membrane-enclosed organelles that contain ~60 different degradative 
enzymes (acid hydrolases) that can hydrolyze all types of biological polymers; proteins, 
nucleic acids, carbohydrates, and lipids. Lysosomes function as the digestive system of 
the cell, serving both to degrade material taken up from outside the cell, and to digest 
obsolete components of the cell itself. The polypeptide chains of these lysosomal 
enzymes are synthesized in the rough endoplasmic reticulum where they undergo co-
translational N-glycosylation.
13
 The resultant glycoproteins then enter the Golgi 
apparatus and undergo various post-translational modifications. One such post-
translational modification is the attachment of mannose-6-phosphate (M6P) residues to 
their N-glycans. The transfer of proteins carrying such tagged glycans to the lysosome 
takes place via interaction with the mannose-6-phosphate receptors (M6PR). 
Deficiency or loss of activity of one of the lysosomal enzymes typically leads to the 
accumulation of macromolecules
13
 resulting in lysosomal storage diseases (LSDs). LSDs 
comprise a group of more than 40 different diseases. Lysosomal storage diseases can be 
classified depending on the pathway affected and the nature of accumulated substrate. 
For example ten different enzyme deficiencies can affect the degradation of 
mucopolysaccharides, five defects are known in the degradation pathways of 
glycoproteins, one is known for the intra-lysosomal storage of glycogen, and eight 
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1.3.1 The mannose-6-phosphate receptors 
Two mannose-6-phosphate specific receptors are known.
15
 These receptors can be 
differentiated by their dependence on divalent cations.
16
 The cation-independent 
mannose-6-phosphate receptor (CI-MPR), which was initially isolated from bovine liver 
membranes, has a molecular mass of 215-300 kDa, and binds M6P containing ligands in 
the absence of cations. The cation-dependent receptor (CD-MPR), originally isolated 
from bovine testes and liver, has a subunit size of 41-46 kDa, and binding of M6P by the 
CD-MPR is enhanced by cations. Hoflack and Kornfield suggested that CD-MPR could 
serve as an alternate carrier for lysosomal enzymes in cells that lack the CI-MPR.
15
 In 
fact later studies have shown that the CI-MPR is multifunctional receptor;
17
 it can bind to 
proteins bearing the M6P recognition marker, as well as the peptide hormone, IGF-II. 
The CI-MPR also binds to M6P containing proteins that are not lysosomal hydrolases. 
These include transforming growth factor-β (TGF-β) precursor,
18
 the placental 
angiogenic hormone proliferin,
19
 the cytokine leukemia inhibitory factor
20
 and the T-cell 
activation antigen CD26 
21




1.3.2 Enzyme replacement therapy for lysosomal storage disorders 
The term Enzyme Replacement Therapy (or ERT) refers to a treatment using an enzyme 
produced by genetically engineered cells. Enzyme replacement therapy is a medical 
treatment involving replacing an enzyme in patients in whom that particular enzyme is 
deficient or absent. The concept of enzyme replacement therapy for lysosomal storage 
diseases was enunciated by de Duve in 1964.
13
 Initial investigations were limited by the 
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difficulties in extracting and purifying sufficiently large quantities of enzyme.
23
 
However, the development of modern molecular biology meant that lysosomal enzymes 
could be developed into pharmaceuticals. 
In 1991, the first clinical trials for treatment of Gaucher disease with human 
glucocerebrosidase were reported. Gaucher disease is the most common lysosomal 
storage disorder. A deficiency of the enzyme glucocerebrosidase causes accumulation of 
the glycolipid glucocerebroside in macrophages of the internal organs like the spleen, 
liver, lungs, bone marrow and brain.
24
 Various symptoms result, including skeletal 
abnormalities, an enlarged liver or spleen, anemia and epilepsy. Glucocerebrocidase is a 
glycoprotein with four N-glycosylation sites, three of which possess complex-type 
oligosaccharides.
25
 Glycosylation plays a vital role for any ERT to be effective. They are 
responsible for the enzymatic activity, stability and macrophage uptake capacity.
26
 Today 
ERT for type I Gaucher disease is well established, and is available commercially as 
imiglucerase (Cerezyme)
27
 and VPRIV (velaglucerase alfa), recombinant human 
formulations produced from cultured Chinese hamster ovary (CHO) cells and modified to 
expose the mannose residues on glycans.  
GAA (acid α-glucosidase) is a lysosomal enzyme that is involved in the normal 
catabolism of glycogen, and deficiency in GAA which causes Pompe disease, also 
referred to as glycogen storage disease type II or acid maltase deficiency.
28
 Reduction or 
loss of GAA activity results in the cellular deposition of glycogen in a variety of cells, 
with the myocytes of the cardiac, respiratory and skeletal muscles being most severely 
affected. GAA has seven N-glycosylation sites
29
 and its targeting from the Golgi 
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apparatus to the lysosome occurs via the M6P receptor system. Initial ERT for Pompe 
disease involved using human placental GAA, but was unsuccessful because this form of 
GAA was not phosphorylated and therefore could not be taken up by the heart and 
muscle cells. When GAA which possessed M6P residues was tested, it was found to be 
effective for the treatment of Pompe disease.
30
 Later, Genzyme manufactured 
alglucosidase (Myozyme) for ERT, which is now used worldwide. Genzyme also 
manufacture ERT agalsidase beta (Fabrazyme) for the treatment of Fabry disease.
31
 
Fabry disease is caused by a deficiency in the lysosomal enzyme, α-galactosidase A (α-
galA), the enzyme responsible for the catabolism of globotriaosylceramide.
31
 
Globotriaosylceramide accumulation leads to multi-organ pathology that seriously affects 
the kidneys, heart, and the cerebrovascular system. The initial signs and symptoms of 
Fabry disease emerge during childhood and adolescence, and typically include 
neuropathic pain crises, angiokeratomas, hypohidrosis, and gastrointestinal problems, 
including diarrhea, constipation, abdominal pain, and nausea and vomiting. However, 
because these signs and symptoms are not specific to Fabry disease, patients are 
frequently misdiagnosed, and the correct diagnosis may be delayed. α-galactosidase A 
contains three N-glycosylation sites, which are occupied mainly by complex and high 
mannose type oligosaccharides. Other ERT’s that are currently available are listed in the 
Table 1.1. 
This causes the
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to complex type. 
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high mannose 
type. 
In affected males, early symptoms of 
the disease include acroparesthesias, 
angiokeratoma, and corneal and 
lenticular opacities. Over time the 
accumulation of glycolipids also 
leads to cardiovascular and renal 
disease, which ultimately leads to 















sites (N19, N59, 
N146, N270) 
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Excessive fatigue,low number of 
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(hypotonia), Enlarged liver 
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(cardiomegaly) Lumizyme 
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Abnormal bones in the spine, claw 
hand, cloudy corneas, deafness, 
halted growth, heart valve problems, 
Joint disease, including stiffness. 
Intellectual disability that gets worse 
over time, thick, coarse facial 

















Growth delay, joint stiffness, and 
coarsening of facial features. In 
severe cases, patients experience 
respiratory and cardiac problems, 
enlargement of the liver and spleen, 
and neurological deficits. The 
disorder can lead to premature death 
in severe cases. 




























Maroteaux-Lamy syndrome is a 
progressive condition that causes 
many tissues and organs to enlarge 
and become inflamed or scarred. 
Skeletal abnormalities are also 
common in this condition. The rate at 
which symptoms worsen varies 
among affected individuals. 
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1.3.3 The importance of the N-glycosylation of glycoproteins 
As mentioned earlier glycosylation play important roles in many key biological 
processes. N-Glycosylation is a major co- and post-translational modification of proteins 
in all eukaryotes. Indeed it has been estimated that the majority of all secretory proteins 
are N-glycosylated. N-glycans play important roles in the folding of nascent 
polypeptides
32
 and play vital a role during ER-quality control processes and ERAD 
(endoplasmic-reticulum-associated protein degradation) of misfolded or incompletely 
assembled glycoproteins.
33
 N-glycans also play a crucial role in maintaining the structure 
and function of the finally folded proteins.
33
 In addition to the involvement in assuring 
the correct folding of glycoproteins, glycosylation also has other effects on the 
physicochemical properties of these proteins. For example, glycosylation is well known 
to play a role in modulating the thermostability of proteins as well as their overall 
charge.
34
 N-Glycosylation can also play a vital role in receptor function. For example, 
one of the best-studied glycoproteins is the HIV viral coat protein, gp120.
35
 The gp120 
protein is integral to the initiation of contact between the HIV virus particle and its host 
cell by mediating the adhesion of the viral particle to the host cell surface. It is a heavily 
glycosylated protein; nearly half of its mass is due to the presence of 27 glycosylated 
residues. This protein acts as part of a co-receptor complex with the host cell CD4 
protein. Association between CD4 and gp120 leads to conformational changes in these 
proteins that ultimately leads to membrane fusion between the host cell and the virus 
particle. The presence of this dense glycosylation of gp120 also acts as a natural barrier 
to defending immune cells and antibodies so that it is difficult for the natural immune 
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system to recognize and target the HIV virus for elimination. N-Glycosylation also plays 
an important role in trafficking of enzymes using different receptors. For example, the 
Mannose receptor (MR) is a C-type lectin, that recognizes a range of carbohydrates 
present on the surface and cell walls of micro-organisms.
36
 The MR is primarily 
expressed on macrophages and dendritic cells and is involved in MR-mediated 
endocytosis and phagocytosis. The MR recognizes oligosaccharides terminating in 
mannose, fucose or N-acetylglucosamine through its C-type lectin like carbohydrate 
recognizing domain.
37
 Another example is the asialoglycoprotein receptor (ASGPR). The 
ASGPRs are lectins which bind to asialoglycoprotein, a glycoprotein from which a sialic 
acid has been removed to expose galactose residues. Asialoglycoprotein is a 
transmembrane protein that links the cell surface to several membranous intracellular 
compartments. It binds galactose-terminal molecules and transports them to lysosomes 
inside the cell for catabolism, and is recycled.
36
 Also, as described in section 1.3.1 
mannose-6-phosphate receptors play an important role in transferring lysosomal enzymes 
via interaction with the mannose-6-phosphate receptors (M6PR). 
1.3.4 N-Glycan biosynthesis 
N-Glycan biosynthesis is a cellular process that takes place in the endoplasmic reticulum 
(ER) and the Golgi-apparatus, which is mediated by several enzymes, including 
glycosyltransferases and endoglycosidases. 
The initial step of the biosynthetic pathway takes place on the endoplasmic side of the 
ER, and during this step, the addition of a phosphorylated N-acetylglucosamine to 
dolichol phosphate takes place.
38
 The dolichol pyrophosphate N-acetylglucosamine that 
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is formed undergoes subsequent elongation at the N-acetylglucosamine unit by the 
addition of six additional monosaccharides (one GlcNAc and five mannoses), prior to 
translocation to the lumenal side of the ER (Figure 1.2). Here the further addition of four 
more mannoses takes place, and the assembly of the precursor is completed with the 
linear addition of three glucose residues. The complete precursor is transferred from the 
dolichol-linked precursor to an aspargine side chain of the growing polypeptide chain by 
the action of a protein complex called oligosaccharyltransferase (OST). The next step 
involves removal of some of the glucose residues, and interaction of the remaining 
glycan with the chaperone proteins, calnexin and calreticulin, which facilitate the correct 
folding of the protein. When the protein is folded correctly, any remaining glucose 
residues, as well as one mannose are enzymatically removed from the glycoprotein prior 
to transfer to the Golgi apparatus for further processing by an extensive set of 
glycosidases and glycosyltransferases. Any misfolded proteins are transferred to the 
proteasome for degradation. 
As a result of the differential activity of these various enzymes, glycoproteins are usually 
produced as complex heterogeneous mixtures in which the same protein backbone is 
attached to various oligosaccharide structures. These mixtures are known as glycoforms. 
Different protein glycoforms may have different biological functions but have almost 
identical in physical properties, rendering them extremely difficult to separate.
12 Access 








Figure 1.2 N-glycan biosynthesis 
1.3.5 The biosynthesis of glycans containing mannose-6-phosphate 
residues 
Phosphorylation of the terminal mannose residues of N-glycans is a post-translational 
protein modification that occurs via a two-step process involving the sequential action of 
two enzymes.
40,41
 In the first step (Scheme 1.1), N-acetylglucosamine-1-phosphate is 
added to the C-6-hydroxyl groups of selected mannose residues by the enzyme N-
acetylglucosamine-1-phosphotransferase (phosphotransferase).
40,42
 Then, an 
“uncovering” enzyme (UCE) N-acetylglucosamine-1-phosphodiester α-N-






































The primary purpose of the installation of these mannose-6-phosphate (M6P) residues at 
the non-reducing termini of high mannose oligosaccharides is to facilitate the trafficking 
of proteins carrying such ‘tagged’ glycans to the lysosome via interaction with the 
mannose-6-phosphate receptors (M6PR). 
1.4 Previous syntheses and investigations of N-glycans containing 
M6P residues 
Targeting enzymes to the lysosome via the M6P receptor has become an interesting area 
of research for the enhancement of the range of enzyme replacement therapies (ERTs) 
that have been developed for the treatment of LSD’s. 
In order to clarify the detailed structural features required for the specific recognition by 
the M6PR’s, Hindsgaul and co-workers synthesized a variety of different phosphorylated 
oligomannosides all of which corresponded to fragments of the natural Man9 high 
mannose N-glycan.
45-47
 The same group also performed a series of inhibition studies 
utilizing a series of chemically synthesized di-, tri-, and bi-antennary mannosides that 
contained M6P residues (Table 1.2).
15
 They performed an inhibition assay to 
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quantitatively probe the effect each compound had on the binding of bovine testicular β-
galactosidase to each M6P receptor. They examined the effects of each of the following 
parameters on the binding of ligand to receptor: a) the effects of the regio and 
stereochemistry of glycosidic linkages between mannose residues; b) which mannose 
was phosphorylated in any given oligomannose sequence; c) the chain length of the 
oligomannose; d) the number of M6P residues per oliomannose sequence and e) the 
presence of an N-acetylglucosamine linked via a phosphodiester linkage to M6P. 
In order to try and enhance the delivery of recombinant human acid α-glucosidase 
(rhGAA), Zhu et al. conjugated high mannose oligosaccharides bearing one or two M6P 
residues onto rhGAA using carbonyl-coupled hydrazine chemistry.
48
 Very recently, the 
same group synthesized similarly modified neo-rhGAA via oxime chemistry,
28
 which 
showed an increase in the stability of the modified enzyme without significant loss of the 
CI-MPR affinity.  
The total synthesis of a variety of N-glycan structures containing M6P residues has also 
been reported, which were then attached to a protein via a non-native linker. For example  
Chen and co-workers successfully synthesized a bisphosphorylated mannose-6-phosphate 
containing N-glycan
49
 and also an N-glycan carrying both mannose-6-phosphate and 
GlcNAc-mannose-6-phosphate motifs.
50
 Furthermore, they have also synthesized several 



















Figure 1.3 Previously synthesized bivalent mimetic ligands for CI-MPRs
51
 
1.5 The chemical synthesis of N-glycans 
Pure glycans of defined structure are essential research tools in glycobiology. Unlike 
proteins and nucleic acids, which can be obtained in homogeneous forms using biological 
methods such as recombinant expression and polymerase chain reaction (PCR), glycans 
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produced in a biological system are generally heterogeneous.
52
 Furthermore, with some 
exceptions like that of SGP and high mannose glycans, it is frequently difficult to obtain 
sufficient quantities of glycans for study from biological sources. Chemical strategies can 
be used to obtain homogeneous glycans in larger quantities. The chemical synthesis of 
oligosaccharides offers tremendous flexibility. It is possible to obtain diverse glycans, 
including those obtained in minute quantities from biological sources, or those for which 
the biosynthetic enzymes are unknown. Moreover, using chemical synthesis, the 




1.5.1 The glycosylation reaction 
The glycosylation reaction involves the formation of glycosyl bond, a reaction first 
described in 1893 by Fischer.
54,55
 A ‘donor’ monosaccharide 1.5, equipped with a leaving 
group at the anomeric position, undergoes reaction with a hydroxyl group of an 
‘acceptor’ 1.6 (Scheme 1.2). In general a promoter is added to the reaction to facilitate 
the departure of the leaving group. The anomeric centre of the donor should possess a 
good leaving group, so that a relatively poor nucleophile, such as a hydroxyl group, can 



















Scheme 1.2 A typical glycosylation mechanism 
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1.5.2 Control of regiochemistry 
The inherent chemical complexities of oligosaccharides make their synthesis difficult. 
One of the primary challenges of glycan synthesis is the requirement of access to a single 
specific hydroxyl groups in presence of many others. Glycan synthesis therefore 
invariably requires the manipulation of various protecting groups, chemical moieties that 
mask other potentially reactive hydroxyl groups and prevent them from reacting to 
produce regioisomeric mixtures of products. The choice of protecting groups
56
 and the 
sequence of their installation is very important for an efficient and  successful synthetic 
route.  
1.5.3 Control of stereochemistry 
In any glycosylation reaction, the product can either be 1,2-cis or 1,2-trans with regard to 
the oxygen at C-2 and the oxygen of the new anomeric linkage (Scheme 1.3).  
 
Scheme 1.3 Glycosylation to afford a) 1,2-cis or b) 1,2-trans mannosides 1.10 and 
1.11 
Chapter 1  Introduction 
36 
 
1,2-Trans glycosides can be synthesized using neighbouring group participation of acyl 
protecting groups. When an acyl group is present at the C-2 position (e.g. acetate, 
benzoate, phthalimide, or acetamide), it can trap the glycosyl oxocarbenium ion to form a 
more stable cyclic oxonium ion. With a protected glucose derivative, the 1,2-
acetoxonium ion blocks nucleophilic attack of the acceptor from the α-face and results in 
the formation of β-glucosides. For mannose, the β-face is blocked, and α-mannosides are 
produced (Scheme 1.4).  
 
Scheme 1.4 The formation of a 1,2-trans mannoside by Neighbouring group 
participation 
In contrast to 1,2-trans glycosides that can often be produced selectively by neighbouring 
group participation, the production of 1,2-cis glycosides requires non-participating 
functionalities at the C-2 position (e.g. azide, benzyl, nitrate or allyl). Even though these 
groups do not participate in the formation of a cyclic oxonium ion, the exclusive 
formation of a 1,2-cis glycoside is not guaranteed. One such example is the synthesis of 
β-mannosides, where the β face of the glycosyl donor is blocked by a neighbouring axial 
C-2 substituent, which disfavours attack by the acceptor from this direction. Furthermore, 
due to anomeric effect and intramolecular lone-pair repulsion, the α product is favored. 
57
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Other examples where neighbouring group participation cannot be used to form 
glycosidic linkages include β-rhamnosides and sialic acid derivatives. Recent 
developments in improved understandings of stereoelectronic and conformational effects 





The synthesis of oligosaccharides usually requires purification of multiple synthetic 
intermediates, in addition to the final product, which is a time consuming process. 
Therefore, various approaches have been tried to minimize the number of purification 
steps. One such approach is to perform multiple glycosylation reactions in one pot,
61,62
 in 
which several glycosidic bonds are made without isolation or purification of 
intermediates. Several methods have been reported which allow multiple one-pot 
glycosylations.
63
 Fraser-Reid’s ‘armed-disarmed’ approach allows for the selective 
activation of an armed donor (bearing electron donating benzyl ether protecting groups) 
over a disarmed donor (bearing electron withdrawing ester protecting groups ).
64
 
Treatment of a mixture of perbenzylated and per benzoylated pentenyl glycosides with 
iodonium di-sym-collidine perchlorate led to selective activation of the perbenzylated 
donor to yield a disaccharide which was then used directly in a subsequent glycosylation 
(Scheme 1.5).
65
 A second method involves pre-activation of donors before the addition of 
glycosyl acceptors (Scheme 1.6).
62
 Alternatively orthogonal anomeric leaving groups can 
be used which can be activated using different promoters. For example Hasty et al. have 
demonstrated the elegant usage of glycosyl thioimidates as versatile building blocks in 
oligosaccharide synthesis.
66
 They have demonstrated that glycosyl thioimidates (SBox, 
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STaz, SBaz) can be orthogonally activated, making this class of donors attractive for 
















































































Scheme 1.6 Preactivation based glycosylation 
 















































Scheme 1.7 Glycosylation involving orthogonal protection 
 
The reactivity of the donor can be modulated by a number of factors, including the 
leaving group, the promoter, the solvent, long-range participation effects, and steric 
hindrance. 
1.6 Methods of glycoprotein synthesis 
As discussed earlier in the chapter, the biosynthesis of glycans is not under direct genetic 
control, and so glycoproteins are produced intracellularly as inseparable heterogeneous 
mixtures of glycoforms, in which different oligosaccharide structures are linked to the 
same peptide chain. Therefore, the access to pure single glycoforms of glycoproteins has 
become an important scientific objective in order to prepare therapeutic glycoproteins. 
Glycoproteins can be synthesised by various methods including chemical protein 
glycosylations and glycoprotein remodelling.  
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Chemical protein glycosylation can be divided into separate categories of indiscriminate, 
chemoselective, site-specific, and site-selective glycosylation. 
1.6.1 Indiscriminate glycosylation  
The use of 2-iminomethoxymethyl thioglycosides (IME)
67,68
 and reductive amination 
methods are still, after many years, the most frequently used strategies for glycoprotein 
preparation, both of which rely upon the high abundance of surface lysine residues. The 
IME method was first developed by Lee in 1976, and involves conversion of the nitrile 
group of cyanomethyl thioglycosides into a methyl imidate group by treatment with 
either sodium methoxide or methanolic HCl. These imidates can be then easily reacted 
with amines or protein scaffolds containing lysine residues (Scheme 1.8). For example, 
work by Pearce et al. illustrated the low, medium, and high glycosylation of lysine 





Although these methods are useful to attach carbohydrates to proteins, due to their 
indiscriminate nature (all lysine residues can react), they may result in changes in protein 
properties and function. For example they alter the charge of the protein, which may 
affect its tertiary structure and activity.
69,70 
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1.6.2 Chemoselective and site-specific glycosylation 
Site-specific glycosylation is different from indiscriminate glycosylation in its ability to 
target a specific residue in the protein. Proteins like bovine serum albumin (BSA), which 
contain a single free Cys, are useful substrates, since Cys is much more reactive than 
other amino acid residues, and can so be reacted selectively. The selective attachment of 
carbohydrates to proteins containing a free Cys was first reported by Davis and Flitsh 




Scheme 1.9 Iodoacetamide protein glycosylation by Davis and Flitsch  
1.6.3 Site-selective glycosylation 
Site specific glycosylation has been extended by the use of site-directed mutagenesis to 
allow greater control of glycosylation. Site-selective glycosylation, as the name suggests, 
also allows selection of the site of glycosylation. This method involves a combination of 
site-directed mutagenesis and subsequent chemical modification.
72,73
 Such a strategy 
provides a flexible method that allows both regio- and glycan specific glycosylation of 
proteins. Common approaches involve the introduction of cysteine, via site-directed 
mutagenesis, as a chemoselective thiol tag to a preselected position within a given 
protein. The thiol can then be modified using thiol-specific carbohydrate reagents 
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(Scheme 1.10). For example Davis and co-workers introduced a cysteine residue into a 
protein and the free thiol was then modified chemoselectively using electrophilic thiol-
specific carbohydrate reagents, such as glycosylmethanethiosulfonates (Glyco-MTS),
73,74
 
or second generation glycosyl phenylthiosulfonates (Glyco-PTS).
75
 Another approach 
involved the selenenylsulfide (Glyco-SeS)
76,77
 mediated conjugation of sugars to cysteine 
residues of proteins, where pre-activation of either a cysteine mutant protein or the 
glycosyl thiol took place following exposure to PhSeBr. Using the glycosyl 
iodoacetamide approach
78,79
 Flitsch and co-workers successfully glycosylated mutants of 
human erythropoietin (EPO). Cysteine modification has also been exploited by Boons 
and co-workers
80
 for the production of homogeneous disulfide linked glycoproteins by 
disulfide exchange reactions. 
 
Scheme 1.10 Site selective glycosylation using A) glycosyl iodoacetamides; B 
disulfides C) Glyco-MTS, Glyco-PTS and Glyco- SeS reagents. 
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1.7 The total chemical synthesis of glycoproteins via Native Chemical 
Ligation 
The invention of native chemical ligation has revolutionized protein chemistry. Similarly, 
the application of NCL and its modified versions for ligation of peptides and 
glycopeptides provides a powerful tool for the total synthesis of large homogeneous 
glycoproteins.
81-84
 Application of peptide ligation approaches for assembling synthetic 
peptide fragments traces its beginnings to Kemp's prior thiol capture strategy. Later, in 
the 1990s Kent and co-workers have demonstrated peptide ligation using Native 
chemical ligation.
85
 NCL involves the chemoselective coupling of two protein fragments, 
one containing a C-terminal thioester and the other containing an N-terminal cysteine 
residue. The components combine to give a native peptide bond at the point of ligation 
(Scheme 1.11). Ligation proceeds via transthioesterification followed by a spontaneous 
and irreversible acyl shift to give a native peptide bond. The fact that this can be achieved 
in aqueous solution, in the absence of protecting groups, makes this a powerful 
technology for protein synthesis. 
 
Scheme 1.11 Mechanism of native chemical ligation 
Bertozzi and coworkers reported the first NCL-based total chemical synthesis of an 82-
amino acid glycoprotein carrying two O-GalNAc residues: a glycosylated form of the 
antimicrobial protein diptericin.
83
 Kajihara and co-workers synthesized a full size 
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glycoprotein carrying a complex type N-glycan, using two consecutive native chemical 
ligations of three peptide/ glycopeptide fragments followed by folding to provide the 
native glycoprotein.
86
 Danishefsky and co-workers, described incorporation of the core 
pentasaccharide
87
 and an epimer
88
 into the same 20-residue glycopeptide and synthesis of 










One drawback of NCL is the requirement for an N-terminal cysteine residue. Cysteine 
residues are not commonly found in natural peptide sequences and often have to be 
artificially incorporated. Several strategies have been investigated to overcome the need 
for a cysteine in the target at the proposed ligation site. One approach involves attaching 
an auxiliary thiol group to the N-terminal amino acid, and subsequent to ligation cleaving 
the auxiliary.
91
 Dawson and co-workers used a removable auxiliary to allow NCL 
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without Cys incorporation (Scheme 1.12).
92
 However, this method may not result in 
efficient ligation for sterically hindered amino acids. NCL was further improved by using 
sugar-assisted ligation (SAL),
93
 which has the advantage over Dawson’s NCL method 
that it is able to ligate even sterically hindered amino acids.  
 
Scheme 1.12 Modified NCL, developed by Dawson et al.
92
 
Various other auxillary-based strategies have been developed to mimic the cysteine- 
based NCL.
94
 Kajihara has demonstrated ligation at a serine site by post-ligational 
conversion of cysteine into serine.
95
 Danishefsky and co-workers have also demonstrated 
a mild, nonmetal-based reduction method for cysteine (Scheme 1.13), which tolerates all 
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thiol-containing groups, as well as oligosaccharide domains.
96
 Later they have also 









Scheme 1.14 Native chemical ligation at valine
97
 
An array of thiolated amino acids as latent residues for Ala, Leu, Lys, Phe, Pro, Val, and 
Thr has been demonstrated. After ligation the thiol group was removed by radical 
desulfurization.
94
 Recently even the synthesis of the full size erythropoietin (EPO) using 
alanine and cysteine based ligations has been reported by Danishefsky and co-workers.
98
 
EPO is a therapeutic glycoprotein that consists of 166 amino acid residues which 
improves the production of red blood cells, and is widely used for the treatment of 
anemia after chemotherapy. In their retrosynthetic design, Danishefsky’s group 
disconnected EPO into four glycopeptide fragments (I-IV), which allowed alanine and 
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cysteine based ligations to reconstitute the full-length EPO (Figure 1.5). Furthermore, 
they also synthesized a full length native EPO carrying full size natural glycans at all four 
conserved glycosylation sites.
99
 Although important glycoconjugates can be synthesized 
using NCL,
100
 it is an extremely arduous and logistically difficult process. 
Erythropeietin
 
Figure 1.5 Retrosynthetic analysis of EPO by Danishefsky et. al 
98*
 
                                                 
*
 Adapted from Danishefsky et. al  (98) Wang, P.; Dong, S.; Brailsford, J. A.; Iyer, K.; Townsend, S. 
D.; Zhang, Q.; Hendrickson, R. C.; Shieh, J.; Moore, M. A. S.; Danishefsky, S. J. Angew. Chem. Int. Ed. 
2012, 51, 11576. 
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1.8 Glycoprotein remodeling 
Most recombinant therapeutic glycoproteins are currently made by over-production in 
CHO cells. However production in engineered CHO cells is expensive, and results in the 
formation of heterogeneous mixtures of glycoforms.
101
 As explained above the total 
chemical synthesis of glycoproteins is not only very difficult but also a very time 
consuming process. Therefore an efficient method which is capable of providing 
homogeneous glycoproteins is still needed. A number of chemoenzymatic approaches to 
access glycoproteins, usually involving the chemical synthesis of the glycan have been 
developed. The approach in which the natural glycans of a glycoprotein or glycopeptide 
are first trimmed back to single GlcNAc residues, which are then elaborated 
enzymatically, has been termed “glycoprotein remodeling”. Enzymes such as Endo H or 
Endo M can be used to degrade heterogeneous glycoprotein glycoforms to a produce 
glycoforms possessing only a single N-linked GlcNAc residue at N-linked sites. 
Following this, the addition of other carbohydrates may be achieved by using either 
glycosyltransferases or ENGases (Scheme 1.15). ENGases are enzymes which 
specifically cleave the chitobiose core [GlcNAcβ(1-4)GlcNAc] of N-linked glycans 
between the two N-acetyl glucosamine residues. Glycosyltransferases can add one sugar 
at a time, whereas ENGases can deliver complete glycans in one step via either 
glycosylation or transglycosylation. Although glycosyltransferases have been used for 
the assembly of oligosaccharides
102-105
 and in some glycoprotein remodeling,
106-108
 their 
utility is limited by difficulty in accessing some of the enzymes. Furthermore, the use of 
glycosyltransferases is limited by their inherent specificity, their inability to attach more 
than one sugar at a time, and the need for complicated and expensive donors. Moreover 
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many of the glycosyltransferases that would be required to build N-glycan structures 
from a single GlcNAc are unavailable and /or would not operate in the required manner. 
Alternatively, the use of ENGases has allowed the conjugation of intact oligosaccharides 








                                                 
†
 Adapted from Rising, T. W. D. R., D. Phil. Thesis, Oxford University, 2007. 
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The first example of such endo-glycosidase-catalysed transglycosylation was reported by 
Takegawa and co-workers for the synthesis of a Man6GlcNAc2-modified glycoprotein.
109
 
Subsequent investigations revealed that the enzymes of the greatest synthetic value were 
Endo M and Endo A. Endo M was discovered by Yamamoto and co-workers in 1988 in 
the culture fluid of the fungus Mucor hiemalis from soil.
110,111
 It was found to be capable 
of hydrolyzing complex, hybrid, and high mannose N-glycans,
112
 and was also observed 
to possess transglycosylation activity.
111
 Although successful, the yields for these 
reactions were low (5-8%) for peptide and protein remodeling
113
 due to competing 
product hydrolysis. Endo A was discovered by Takegawa, from Arthrobacter 
protophormiae, and is specific for high mannose N-glycans.
114
 Yields for Endo A and 
Endo M were initially improved by the addition of an organic co-solvent,
115-118
 but 
product hydrolysis still limited the efficiency of the process. Nevertheless, Endo A and 
Endo M catalyzed transglycosylation allowed the addition of high mannose structures 
and complex N-glycans to a variety of peptide backbones.
111,117,119-124
 For example 
Haneda et al. demonstrated the synthesis of a di-glycosylated calcitonin derivative 




In 2001, Shoda reported that a disaccharide bearing a 1,2-oxazoline moiety at the 
reducing terminus could act as a transition state mimic for some endoglycosidases, 
specifically Endo A and Endo M,
126
 resulting in high yielding glycosylation (Scheme 
1.16). In this case, the product of the glycosylation was not recognized as a substrate by 
the enzyme, and therefore no enzyme catalyzed hydrolysis of the product was observed. 






























Yields from 44% - 77%
 
Scheme 1.16 ENGase catalyzed glycosylation with oxazoline donors. 
Later, both the Fairbanks
127-131
 and Wang group
121,132-139
 extensively investigated the 
application of ENGases and further developed this methodology. 
1.8.1 Work by Fairbanks et al 
Fairbanks et al initially focused on investigating the substrate specificity of enzymes with 
regard to the donors. They synthesized a series of oligosaccharide oxazoline donors 
(1.15-1.20), corresponding to the core components of N-linked high mannose glycans 
(Figure 1.6).
140
 Glycosylation reactions were performed with a GlcNAc-Asn glycosyl 
amino acid acceptor using the oxazolines as glycosyl donors catalysed by Endo M 
(Scheme 1.17). It was found that the minimum structural requirement was the 
Manβ(1→4)GlcNAc-oxazoline disaccharide, and the product of this glycosylation 
reaction was not recognized as a substrate by the enzyme, and therefore no enzyme 
catalysed hydrolysis was observed. However, as the oligosaccharide was increased in 
size, product hydrolysis was observed to become increasingly rapid. 













































Scheme 1.17 ENGase catalysed glycosylation reactions of amino acid acceptor A 
with oxazoline donors 
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To avoid this problem, non-natural donors were synthesized (1.21-1.26), which were 
epimers of the previously synthesized N-glycans in which a glucose residue was 
incorporated in place of the mannose attached to the GlcNAc (Figure 1.7).
141
 It was 
found that both Endo A and Endo M were able to process these donors. In the case of 
Endo M, the products were not recognized as substrates and no product hydrolysis was 
seen, whereas Endo A was able to slowly hydrolyze the reaction products.
127
 In 
subsequent studies they synthesized a truncated complex biantennary oxazoline
130
 1.26 
and performed enzyme catalyzed glycosylations. Both Endo A and Endo M could 
process this donor, though only a poor yield of product was obtained.  
 
Figure 1.7 Oxazoline donors 1.21-1.26 used by the Fairbanks group 
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In order to decrease the amount of product hydrolysis, and to increase the efficiency of 
the transglycosylation, mutant enzymes were developed. During the hydrolytic 
mechanism of both Endo A and Endo M, a key glutamate residue in the active site acts 
first as a general acid to promote cleavage of the glycosidic linkage, and then, in the 
second step, as a general base to facilitate nucleophilic attack of water onto the 
oxazolinium transition structure (Scheme 1.18). Removing the general acid was expected 
to decrease or completely remove the hydrolytic activity of the enzyme. Fairbanks and 
co-workers produced two mutants of Endo A in which the key catalytic acid residue, 
glutamic acid 173 was replaced by glutamine (E173Q) and histidine (E173H).
129
 The 
E173H mutant showed a slight decrease in the rate of glycosylation as compared to the 
wild type enzyme, together with a significantly reduced rate of product hydrolysis. The 
E173Q mutant showed a greater decrease in glycosylation activity, and was completely 
incapable of product hydrolysis. The utility of Endo A and these mutants for protein 
glycosylation was confirmed by carrying out the glycosylation of dRNase B using the 
tetrasaccharide oxazoline 1.19. In both cases of Endo A and E173H, the enzyme was able 
to effect production of a single glycoform of RNase B. It was also observed that WT 
Endo A catalyzed the hydrolysis of the product glycoprotein, and the best yield was 
obtained using the E173H mutant (Scheme 1.19). 
142
 







































































































Scheme 1.18 Mechanism of glycosylation using oxazoline donors catalyzed by WT 
Endo A, and the E173Q, E173H mutants 
 





Scheme 1.19: (i) Endo A or Endo E173H, phosphate buffer pH 6.5, H2O, 37 °C. 
More recently, Fairbanks and co-workers reported the first synthesis of glycosylated 
analogues of the diabetes drug pramlintide, by a combination of solid-phase peptide 
synthesis, and highly efficient enzymatic glycosylation using mutant enzymes.
143
 
1.8.2 Work by Wang et.al 
Similarly to the Fairbanks group, Wang et al. also investigated the donor requirements of 
enzymes. They synthesized various non-natural oxazolines, including a 
Gal2Man3GlcNAc-oxazoline,
134
 an octasaccharide bearing two lactose moieties, a 
pentasaccharide with a bisecting glucose, and a tetrasaccharide bearing azides on the 6-
positions of the non-reducing termini.
137
 All of these donors were found to be processed 
by Endo A. 
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Using Endo A, Wang and co-workers were also able to perform a double glycosylation of 
a 47-mer HIV-1 V3 domain peptide containing two GlcNAc residues,
121
 which 
demonstrated the potential application of these enzymes for N-glycosylation of multiple 
sites. This methodology was later applied in the glycoengineering of human IgG1-Fc, a 
monoclonal antibody with two  N-linked glycosylation sites.
144
 
In parallel to the work of Fairbanks, which produced mutants of Endo A, Wang and co-
workers generated a series of mutants of Endo M.
135
 Mutants Y217F and N175A showed 
particularly useful activity. The Y217F mutant demonstrated enhanced glycosylation 
activity and a decrease in hydrolytic activity, whilst the N175A mutant showed good 
glycosylation activity with complete loss of hydrolysis. Using these mutant enzymes, the 
Wang group transferred full length glycans, such as a high mannose Man9GlcNAc-
oxazoline 1.27, and a biantennary complex-type (SGP 1.28 from hen egg yolk), 
135
 to 
proteins (Figure 1.8). 
Wang has also synthesized an array of homogeneous IgG-Fc glycoforms using the Endo 
A catalyzed glycosylation remodeling approach.
145
 These results indicated that Endo A is 
remarkably efficient for introducing various modified N-glycan cores to the Fc domain 
by glycosylation with N-glycan core oxazolines. However, neither Endo A, nor the Endo 
M mutants (Endo M-N175A and Endo M-N175Q) was unable to efficiently transfer a 
full-length complex-type N-glycan to the Fc domain, indicating the limitations of both 
Endo-A and Endo-M for IgG-Fc glycosylation remodeling. Very recently, Wang and co-
workers have demonstrated the remodeling of monoclonal antibodies (mAb) using 
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mutants of Endo S,
146
 a member of the family GH18 hydrolases which is highly specific 
for the Fc region of IgGs. 
 
 
Figure 1.8 High mannose 1.27 and complex type SGP 1.28 oxazolines 
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1.9 Project objectives 
The ultimate objective of this research program was to develop a chemo-enzymatic 
method to synthesise bis-phosphorylated homogeneous glycoproteins and to use them for 
enzyme replacement therapy. 
This thesis describes the synthesis of bis-phosphorylated oligosaccharide oxazolines and 
investigations into their use as donors for ENGase catalysed glycosylations. 
Chapter 2 describes the synthesis of a tetrasaccharide oxazoline corresponding to the core 
portion of N-glycans, which was modified by the addition of phosphate groups at the 6-
positions of the two non-reducing mannose termini.  
Chapter 3 details the synthesis of a hexasaccharide oxazoline, the structure of which was 
chosen for its reported optimal binding to the M6PR. 
Chapter 4 describes a series of ENGase-catalysed glycosylation reactions that were 
carried out using the oxazoline donors synthesized in Chapters 2 and 3 using a GlcNAc-
Asn glycosyl amino acid acceptor. Investigations into glycoprotein remodeling using de-










Synthesis of a phosphorylated N-glycan tetrasaccharide 
oxazoline donor 
 




Phosphorylation of the glycan portion of glycoproteins is an important post-translational 
modification. Mannose-6-phosphate (M6P)-containing N-glycans belong to a class of 
high-mannose-type oligosaccharides with phosphorylation at the C6-OH group.
147,148
 
These M6P N-glycans play an essential role in the intracellular transport of hydrolases 
into the lysosomal compartments in eukaryotic cells. Mannose-6-phosphate receptors 
(MPRs), the cation-dependent (CD-MPRs) and the cation-independent (CI-MPRs), are 
responsible for recognizing M6P moieties of newly synthesized hydrolases, and 
facilitating their transport to the lysosome.
22,149,150
 Defects in the M6P and the MPR 
mediated sorting system are known to result in lysosomal storage diseases (LSD).
151,152
 
Understanding of the complex protein-transport system is incomplete, particularly with 
respect to the comprehensive structure-activity relationship of the M6P sugar-coding 
system at the molecular level. Not much information is available on how structure of the 
sugar and the position of phosphate groups on N-glycans affects their binding to 
MPRs.
153,154
 The heterogeneity of M6P-N-glycans and the difficulties in obtaining 
different, structurally well-defined M6P-N-glycans from natural sources impedes the 
ability to carry out detailed glycan receptor binding studies.
155
 Therefore, the total 
synthesis of M6P-N-glycans with defined glycoforms would provide an attractive 
solution. Furthermore, it would be interesting to see if endohexosaminidases could be 
used to acquire homogeneous phosphorylated glycoproteins. Previous studies have 
shown that endohexosaminidases can recognize and process sugar oxazoline 
donors,
127,128,130,132-134,136,140,156
 but no investigations have been conducted to determine 
whether they are able to process phosphorylated sugar oxazoline donors. Therefore, in 
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order to carry out such an investigation, we undertook the synthesis of N-glycan 
structures containing M6P residues, and studied the ability of ENGases to catalyse their 
transfer to peptides and proteins. An N-glycan tetrasaccharide, 2.1, was identified as a 
synthetic target containing two terminal mannose residues bearing phosphate groups at 
the 6-position. This tetrasaccharide corresponds to the core structure common in all N-
linked glycans with the modification of phosphate groups on the C-6 hydroxyl groups of 




2.2 Retrosynthetic analysis 
The phosphorylated tetrasaccharide oxazoline, 2.1, was the target of our investigation. 
Tetrasaccharide 2.1 could be constructed in a (2 + 1) + 1 approach from a core 
disaccharide along with a mannose donor bearing orthogonal protection at the C-6 
alcohol (Scheme 2.1). 
 





Formation of the β-mannoside linkage, incorporation of the phosphate moieties at the C-6 
position, and formation of the oxazoline were the major challenges for the synthesis of 
target 2.1. The β-mannoside linkage was to be formed by the same methodology as 
applied previously by the Fairbanks group,
130
 via triflation of the C-2 alcohol of a β-
glucoside followed by SN2 displacement of the triflate. Since, phosphate esters may be 
hydrolysed under both acidic and basic conditions,
157
 they were to be incorporated in a 
late stage of the synthesis. Once the phosphate groups were installed, global deprotection 
would be performed before formation of the oxazoline. The oxazoline ring was to be 
formed using known conditions
158
 to afford the target 2.1. 
Building block 2A (Scheme 2.1) included 4,6-benzylidene protection and a thioglycoside 
at the anomeric position, since it may act as a leaving group by activation under mild 
conditions.
159
 The free hydroxyls could be differentiated by regioselective alkylation at 





 using an allyl ether,  a versatile protecting group with multiple known 
methods of deprotection,
56
 and the C-2 position could be protected with an ester that 
would allow formation of a -glucoside. Levulinoyl esters were preferable as they could 
be selectively deprotected using hydrazine acetate in the presence of other ester 
protecting groups (e.g. acetate, benzoate) to allow selective access to C-2 and then 
subsequent epimerisation.  
Building block 2B required anomeric protection that would be stable towards a large 
number of reaction conditions, and yet which could be selectively removed in the latter 
stages of the synthesis. The Fairbanks group have previously employed the para-
methoxyphenol group with success,
127,140,141
 which can be removed selectively using 
ceric ammonium nitrate
161
 as a single-electron oxidant. The 2-amino group was protected 
using a phthalimide group. Previous studies have found that the presence of N-acetyl 
glucosamine units results in low efficiency of subsequent glycosylation reactions.
57,162
 
For example the acetamide could compete with the free alcohol of the acceptor and react 
with reactive donors, or attack the specific activator.
23,163
  
Building block 2C required orthogonal protection at the C-6 alcohol that could be 
selectively removed at a late stage of the synthesis to allow installation of a phosphate 
group. Tri-isopropylsilylchloride was selected for C-6 hydroxyl protection. The benzyl 
group was selected for the protection of the phosphate groups as well as for other 
alcohols. A thioglycoside was chosen as a donor for the same reasons as before. 
Hence, as shown in Scheme 2.2, the phosphorylated tetrasaccharide oxazoline donor 2.1 
was envisioned as being derived from precursor 2.2 bearing phosphate moieties at the C-
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6 position of mannose, and acetate or benzyl protection of all the other hydroxyl groups. 
Phosphodiester 2.2 could be formed from the fully protected tetrasaccharide precursor 
2.3 bearing TIPS protection at the C-6 alcohols of the terminal mannose residues. Silyl 
ether 2.3 could be derived from the orthogonally protected disaccharide 2.4 and the 
mannose donor 2.5. Disaccharide 2.4, with a β-mannosidic linkage could be synthesized 
from alcohol acceptor 2.7, and a thioglycoside donor 2.6.  
Since removal of the phthalamide requires the use of harsh basic conditions,
164
 this step 
would need to be completed prior to phosphorylation. Addtionally, cleavage of the 
acetate in this step would not be problematic, as it would be replaced during acetylation 
of the amine intermediate.  




Scheme 2.2. Detailed retrosynthetic analysis of tetrasaccharide 2.1 
2.3 Synthesis of building block 2.6 
-D-Glucose pentaacetate was treated with ethanethiol in the presence of BF3·OEt2 in 
DCM to give -thioglycoside 2.8 (Scheme 2.3). Deacetylation using Zemplen conditions, 
followed by incorporation of the 4,6-O-benzylidene gave diol 2.9. Thioglycoside 2.9 was 
regioselectively alkylated via the generation of a tin acetal in situ by treatment with 
dibutyl tin oxide followed by subsequent exposure to allyl bromide to yield alcohol 2.10. 
The C-2 alcohol was protected as a levulinate ester to give 2.6. The levulinate ester can 
be selectively cleaved using a non-basic reagent which does not affect the phthalimide 
group. 









































Scheme 2.3 (i) EtSH, BF3.OEt2, DCM, 4 h, 60%; (ii) a) NaOMe, MeOH, 1 h; b) PhCH(OMe)2, CSA,DMF, 
200 mbar, 60
o
C, 3.5 h, 65% over 2 steps; (iii) a) Bu2SnO, MeOH, reflux, 1 h; b) Allyl bromide, CsF, DMF, 
3 d, 63% over 2 steps; (iv) Levulinic acid, DCC, DMAP, DCM, 21 h, 84%. 
2.4 Synthesis of building block 2.7 
The known phthalimide protected glucosamine derivative, 2.7, was accessed following 



































Scheme 2.4 (i) a) NaOMe, MeOH, pthalic anhydride, Et3N, 3 d; b) py, acetic anhydride, 24 h, 50% over 2 
steps; (ii) p-MPOH, BF3⋅OEt2, DCM, 16 h, 70%; (ii) a) NaOMe, MeOH, 50 min; b) PhCH(OMe)2, CSA, 
DMF, 200 mbar, 60
o
C, 5 h, 54% over 2 steps; (iii) NaH, BnBr, DMF, 2 d, 83%; (iv) NaCNBH3, HCl (1M 
in Et2O), THF, 0 
o
C to rt, 14 h, 88%. 
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Commercially available glucosamine hydrochloride was converted to the free base with 
sodium methoxide in methanol, and protected with phthalic anhydride to afford 2.11. The 
hydroxyl groups were then acetylated to produce the fully protected glycoside 2.12, 
which was then treated with p-methoxyphenol in the presence of BF3∙OEt2 to afford the 
-glycoside 2.12. Zemplén deacetylation, followed by installation of a 4,6-benzylidene, 
gave alcohol 2.13. The free C-3 alcohol was then benzylated to afford the fully protected 
glucosamine derivative 2.14. Regioselective reductive opening of the benzylidene,
167
 
using sodium cyanoborohydride and hydrochloric acid, gave alcohol 2.7 in good yield. 
2.5 Synthesis of disaccharide 2.4 
Glycosylation of thioglycoside 2.6 with the glucosamine acceptor 2.7 by activation with 
methyl triflate
168
 and a hindered base (tri-tert-butyl pyrimidine) yielded the -gluco 
disaccharide 2.15 in an excellent 91% yield (Scheme 2.5). Glycosylation occurred with 
complete control of anomeric stereochemistry due to neighbouring group participation by 
the 2-O-levulinoyl ester. The levulinate ester was cleaved using hydrazine acetate
169
 to 
give 2.16. The free alcohol at C-2 was epimerized by triflation followed by SN2 
nucleophilic substitution by treatment with tetrabutylammonium acetate 
170
 in toluene 
under sonication (following the original sonication procedure of Fürstner)
171
 to yield the 
-manno disaccharide 2.4 (Scheme 2.5). 
























































Scheme 2.5 (i) MeOTf, 3Å mol. sieves, DCM, t-TBP, 0 °C to rt, 15 h, 81%; (ii) H2NNH2·AcOH, MeOH, 
DCM, 21 h, 87%; (iii) a) Tf2O, py, DCM, 0 °C to rt, 3 h; b) N-Bu4NOAc, toluene, sonication, 16 h, 77% 
over 2 steps; 
2.6 Synthesis of building block 2.5 
Commercially available D-mannose was treated with pyridine and acetic anhydride to 
obtain mannose pentaacetate 2.17 as a mixture of anomers (Scheme 2.6). Treatment of 
2.17 with ethanethiol and BF3·OEt2 gave thioglycoside 2.18.
172
 Deacetylation using the 
Zemplén method afforded tetra-ol 2.19, followed by regioselective silylation
173
 gave 
2.20. Silyl protected triol 2.20 was then treated with sodium hydride and benzyl bromide 
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Scheme 2.6 (i) py, acetic anhydride, 24 h, 98%; (ii) EtSH, BF3.OEt2, DCM, 21 h, 73%; (iii) NaOMe, 
MeOH, 16 h, quant.; (iv) TIPSCl, imidazole, THF, 0 °C to rt, 24 h, 89%; (v) NaH, BnBr, THF, 60 °C, 24 h, 
78%. 
2.7 Completion of synthesis 
The allyl ether of disaccharide 2.4 can be cleaved either directly, or via prior 
isomerisation of the prop-2-enyl (allyl) to the prop-1-enyl ether, which can be cleaved 
under mild conditions.
56
 Previous studies had found the use of palladium reagents for 
direct cleavage of the allyl ether to be unsuccessful.
23
 Catalytic palladium on carbon
174
 
produced no reaction, whilst the use of other palladium reagents resulted in cleavage of 
both the allyl and the 4,6-O benzylidene groups. 
Previous students of the Fairbanks group have performed extensive investigations to find 
optimal methods for isomerisation of allyl to the prop-1-enyl ethers.
23
 The first method 
investigated involved heating of the compound 2.4 with a basic catalyst,
175
 typically 
potassium tert-butoxide in DMSO
176,177
 in which the phthalimido group was observed to 
undergo some ring opening. Alternatively the use of Wilkinson’s catalyst, 
tris(triphenylphosphine) rhodium (I) chloride,
178
 proved too harsh, and resulted in 




 also resulted in a complex mixture of products. In the end, (1,5-
cyclooctadiene) bis(methyldiphenylphosphine) iridium(I) hexafluorophosphate catalyst 
activated with hydrogen,
180
 gave the desired enol ether product. Treatment of the enol 
ether with N-iodosuccinimide (NIS) and water resulted in the formation of the alcohol 
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2.21 in excellent yield (Scheme 2.7a). Glycosylation of acceptor 2.21, with thioglycoside 
donor 2.5, was performed stereoselectively with methyl trifluoromethanesulfonate 
(MeOTf) and tri-tert-butylpyrimidine (t-TBP) to afford trisaccharide 2.22 in 91% yield. 
Regioselective reductive ring opening of the benzylidine
181,182
 using Et3SiH and PhBCl2 
gave the free C-6 alcohol 2.23 in 94% yield. Glycosylation of 2.23 with thioglycoside 2.5 
gave the tetrasaccharide core 2.3 in 79% yield, which was then subjected to treatment 
with ethylene diamine and methanol at reflux to remove the phthalimide protecting 
group. The crude amine was acetylated to afford 2.24 in 91% yield. Initial attempts to 
remove silyl protection using TBAF
49
 as a source of fluoride proved difficult. Even after 
using a large excess of the reagent, only 30% product could be formed, and further 
increase in reagent resulted in the cleavage of the acetate group. Using BF3·OEt2, the 
TIPS group was selectively cleaved to afford 2.25 in 76% yield. Bis-phosphorylation was 
achieved using N,N-diisopropyl phosphoramidite in tetrazole (0.45 M solution in 
acetonitrile) followed by m-CPBA oxidation to give 2.26 in 58% yield (over two steps). 
Oxidative cleavage of the anomeric para-methoxyphenyl glycoside was achieved using 
ceric ammonium nitrate (CAN) to obtain 2.2 in 78% yield (Scheme 2.7b). Unfortunately 
hydrogenation reaction to remove the benzyl protecting groups of 2.2 proved to be 
laborious process. Due to the hindered nature of the 4-O-benzyl group of the central 
branching mannose unit cleavage of this benzyl ether by hydrogenation was extremely 
slow. Palladium on carbon and palladium(II) hydroxide were assayed as catalysts and 
were examined in both ethyl acetate and methanol as solvent. In all cases cleavage of 
benzyl groups required a very prolonged reaction time (15 days) and large quantities of 
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catalyst, which also resulted in simultaneous decomposition of the product 2.27 as well 
as the starting material 2.2.  
 
 
Scheme 2.7a (i) a) (1,5-cylclooctadiene) bis(methyldiphenylphosphine) iridium(I) hexafluorophosphate, 
THF, 14 h; b) NIS, H2O, 18 h, 86% over 2 steps; (ii) MeOTf, 3Å mol. sieves, DCM, t-TBP, 0 °C to rt, 18 h 
91%; iii) Et3SiH, PhBCl2, 3Å mol. sieves, DCM, -78 °C, 50 min, 94%; (iv) MeOTf, 3Å mol. sieves, DCM, 
t-TBP, 0 °C to rt, 18 h, 79%; v) (a) NH2CH2CH2NH2, MeOH, reflux, 18 h; (b) Ac2O, py, 18 h, 91%; vi) 
BF3.OEt2, DCM, 0 °C, 1 h, 76%; (vii) (BnO)2PNiPr2, tetrazole, DCM, rt, 18 h then m-CPBA, -78 °C, 2 h, 
58%; 





Scheme 2.7b (viii) CAN, MeCN, H2O, rt, 1 h, 78%; (ix) Pd/C, H2 , no reaction. 
Eventually, an alternative strategy involving a Birch reduction was attempted, which 
resulting in global deprotection, i.e. debenzylation and deacetylation of 2.2, to afford 
2.28 in 83% yield (Scheme 2.8). Deprotected phosphorylated tetrasaccharide 2.28 was 
then converted to the oxazoline 2.1 by treatment with DMC and triethylamine using the 









Scheme 2.8 i) Na, NH3(l), -33 °C, 83%; ii) DMC, Et3N, H2O, rt, 30 min, 95%. 
2.8 Conclusions 
The target tetrasaccharide 2.1 was synthesized in 7% overall yield in 32 steps based on 
the longest linear sequence. The main challenges faced were the selective deprotection of 
the two TIPS groups and the global deprotection of the benzyl and acetyl groups without 
decomposition of the formed tetrasaccharide. 
The two TIPS groups could be selectively removed in presence of other groups using 
BF3.OEt2 in DCM at 0 °C. Global deprotection could be achieved using Birch condition, 
in which, both benzyl and acetate protecting groups can be removed in a single step in 
excellent yield. Furthermore, the formation of the oxazoline could be achieved easily 
using Shoda’s method. 
Hence, with the success to synthesise a bis-phosphorylated tetrasaccharide oxazoline our 


















As discussed in the previous chapter, in eukaryotic cells, the mannose-6-phosphate 
receptors (MPRs) mediate the transfer of approximately 60 different newly-synthesized 
hydrolases to the lysosome by binding to mannose-6-phosphate (M6P) residues found on 
their N-linked oligosaccharides. Two distinct MPRs, the 46 kDa cation-dependent 
mannose-6-phosphate receptor (CD-MPR), and the 215-300 kDa cation-independent 
mannose-6-phosphate (CI-MPR), are the sole members of the P-type lectin family.
17
 
With the successful synthesis of the phosphorylated tetrasaccharide oxazoline 2.1, which 
was selected as the model for our studies, the next objective was to synthesize a full-
length phosphorylated oligosaccharide. The design of the synthetic N-glycan (Figure 3.1) 
was partially based on that of the natural Man9 structure found in the high mannose 
glycans of lysosomal enzymes.
183
 Oligosaccharides isolated from lysosomal hydrolases 
have been shown to be highly heterogeneous, containing typically up to 9 mannose  and 
1 or 2 mannose-6-phosphate residues. Inhibition studies using synthetic phosphorylated 
oligomannosides have shown that linear mannose sequences of a defined chain length 
terminated with an α-(1,2)-linked M6P residue exhibited the greatest affinity for the 
receptor binding sites.
15
 Furthermore, bis-phosphorylated oligosaccharides exhibited 
increased inhibition when compared to the mono-phosphorylated oligosaccharide. The 
latter observation is consistent with the fact that the CI-MPR has two M6P binding 
sites.
148
 On the basis of these studies, oligosaccharide 3.1 was selected as a synthetic 
target containing two terminal M6P residues linked via α-(1,2) linkage. A biantennary 
structure was selected for the ease of synthesis. 














Figure 3.1:  
 
3.2 Retrosynthetic analysis 
The target of our investigation, the phosphorylated hexasaccharide oxazoline 3.1, could 
be produced in a (2+2)+2 sense via two disaccharides that could be constructed from 4 
monosaccharide building blocks (Scheme 3.1). 





The use of the building blocks 2.6 (2A) and 2.7 (2B), which had already been employed 
during the synthesis of tetrasaccharide 2.1, would afford the disaccharide core 
incorporating the β-mannoside linkage (Scheme 3.1). 
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Building block 3C required orthogonal protection at the C-6 alcohol that could be de-
protected selectively at a late stage of the synthesis, to allow incorporation of a phosphate 
group. A triisopropylsilyl group was selected for C-6 alcohol protection. Benzyl groups 
were selected for the protection of the C-3 and C-4 alcohols. Acetate was selected as a 
protecting group for the anomeric position as it could be easily deprotected and replaced 
with a leaving group, and could be accessed from mannose pentaacetate on large scale. 
Acetate protection was also used at C-2 to allow for -mannoside formation via 
anchimeric assistance.  
Building block 3D was prepared by the formation of an orthoester with subsequent ring 
opening to introduce ethanethiol at the anomeric position.
184
 A thioglycoside was chosen 
as the anomeric leaving group because it could be activated under mild conditions. 
Thus, hexasaccharide 3.1 was visualised as being derived from precursor 3.2 bearing 
phosphate moieties at the C-6 positions of the two mannose units and acetyl and benzyl 
protection on all the other groups. Hexasaccharide 3.2 could be accessed from 
disaccharide donor 3.3 and the orthogonally protected disaccharide 2.4 (Scheme 3.2). 
Donor 3.3 could be synthesised from the imidate donore 3.4 (building block 3C) and the 
manno acceptor 3.5 (building block 3D). Finally it was envisaged that the disaccharide 
2.4 could be synthesised from the alcohol acceptor 2.7, and a thioglycoside donor 2.6. 




Scheme 3.2 Detailed retrosynthetic analysis of hexasaccharide 3.1 
3.3 Synthesis of building block 3.4 
Building block 3.4 was synthesized following Hendrickson’s method.
185
 Mannose was 
peracetylated to afford pentaacetate 3.6, which was then treated with 33% HBr in acetic 
acid to give the α-bromide. The glycosyl bromide was then treated with 2,6-lutidine in a 
mixture of methanol and DCM to afford the orthoester 3.7 in good yield (Scheme 3.3). 
Zémplen deacetylation afforded triol 3.8, which was followed by regioselective silylation 
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to give 3.9. The TIPS protected orthoester was then treated with benzyl bromide and 
sodium hydride to afford the benzylated orthoester 3.10. It was found that acid catalysed 
regioselective opening of orthoester 3.10 gave a mixture of C-1 and C-2 acetylated 
products. To overcome this problem, the orthoester was then exposed to acetic anhydride 
in pyridine to give 3.11 as the sole reaction product. The anomeric acetate was then 
selectively deprotected using hydrazinium acetate in DMF to afford hemiacetal 3.12. 
Trichloroacetimidate 3.4 was then prepared by reaction of alcohol 3.12 with 


































































3.11 3.12 3.4  
 
Scheme 3.3 (i) py, acetic anhydride, 24 h, 98 %; (ii) a) HBr, DCM, 2 h, 0 °C; b) 2,4,6-collidine, MeOH, 24 
h, 50 °C, 85% (over 2 steps); (iii) NaOMe, MeOH , quant; (iv) TIPSCl, imidazole, THF, 0 °C to rt, 24 h, 
48%; (v) BnBr, NaH, DMF, 24 h, 92% (vi) a) 80%, aq AcOH, 18 h, b) py, acetic anhydride, 24 h, 68%; 
(vii) hydrazinium acetate, DMF, 40 °C, 4 h, 95%; (viii) Cl3CCN , DBU, DCM, 0 °C, 30 min, 85%. 
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3.4 Synthesis of building block 3.5 
Building block 3.5 was synthesized using compound 3.8 as the starting material. The triol 
was first benzylated using benzyl bromide and sodium hydride to afford benzylated 
orthoester 3.13, which when exposed to mercuric bromide and ethanethiol in acetonitrile 
at 60 °C which resulted in the regioselective opening of orthoester 3.13 to obtain 
thioglycoside 3.14 (Scheme 3.4).
184
 Finally the Zémplen method was employed to 
































Scheme 3.4 (i) BnBr, NaH, DMF, 24 h, 88%; (ii) HgBr2, EtSH, CH3CN, 60 °C, 24 h, 78%; (iii) NaOMe, 
MeOH, 1 h, quant. 
3.5 Synthesis of disaccharide 3.3 
Glycosylation of the manno acceptor 3.5 with the imidate donor 3.4, in presence of 
TMSOTf as the activator in DCM at 0 °C, resulted in formation of disaccharide 3.3 with 





































Scheme 3.5 (i) TMSOTf, DCM, 0 °C, 30 min, 61%. 
3.6 Hexasaccharide synthesis 
With both disaccharides 2.4 and 3.3 in hand, attention turned to the synthesis of the 
hexasaccharide target 3.1. The allyl ether of the disaccharide 2.4 was catalytically 
isomerized to the enol ether using (1,5-cyclooctadiene) bis(methyldiphenylphosphine) 
iridium(I) hexafluorophosphate activated with hydrogen,
180
 followed by treatment with 
N-iodosuccinimide and water to afford the C-3 alcohol 2.21 (Scheme 3.6). Glycosylation 
of acceptor 2.21 with thioglycoside donor 3.3 was performed stereoselectively with 
methyl trifluoromethanesulfonate (MeOTf) and tri-tert-butylpyrimidine (t-TBP) to afford 
tetrasaccharide 3.15 in 55% yield (70% based on recovered acceptor). The 4,6-O-
benzylidine of 3.15 underwent reductive ring opening to afford tetrasaccharide acceptor 
3.16 in 83% yield in a highly regioselective manner following treatment  with 
triethylsilane and dichlorophenylborane. However glycosylation of the tetrasaccharide 
acceptor 3.16 with the disaccharide donor 3.3 proved to be troublesome.  
 




Scheme 3.6 (i) a) (1,5-cylclooctadiene) bis(methyldiphenylphosphine) iridium(I) hexafluorophosphate, 
THF, 14 h; b) NIS, H2O, 18 h, 86% over 2 steps; (ii) MeOTf, 3Å mol. sieves, DCM, t-TBP, 0 °C to rt, 18 h 
55%; iii) Et3SiH, PhBCl2, 3Å mol. sieves, DCM, -78 °C, 50 min, 83%; 
Initial attempts using methyl trifluoromethanesulfonate as activator in the presence tri-
tert-butylpyrimidine did not result in the formation of any product. The starting materials 
were recovered and re-subjected to the same reaction conditions but unfortunately again 
no formation of product was observed. Alternative activators for thioglycosides were 
therefore assayed. Reactions using N-iodosuccinimide (NIS) and silver 





 or NIS and trimethylsilyl trifluoromethanesulfonate were 
also unsuccessful, even after extended reaction times. Use of Crich’s activation 
method
58,186
 using 1-benzene sulphinyl piperidine (BSP) and triflic anhydride resulted in 
the formation of significant quantities of decomposition products and no desired product 
could be isolated. Glycosylation using NIS and a catalytic amount of triflic acid did not 
lead to reaction of the starting material, whilst increasing the amount of triflic acid led to 
slow decomposition of the starting materials (Table 3.1). 
Table 3.1 Summary of thioglycoside activation conditions used to attempt to 
synthesise the hexasaccharide 
Conditions Outcome 
MeOTf, t-TBP, DCM, 0 °C, 18 h. 
NIS, AgOTf, DCM, 0 °C, 1 h. 
NIS, TMSOTf, -20 °C, 30 min. 
NIS, TfOH, -78 °C, 15 min. 
BSP, Tf2O, -78 °C, 10 min. 
No reaction 
Slow decomposition of starting material. 




Since all efforts to glycosylate the thioglycoside were unsuccessful, it was decided to 
convert thioglycoside 3.3 to the trichloroacetimidate donor 3.17, as imidates are known 
to be active glycosyl donors. This was done in 2 steps, firstly by converting the 
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thioglycoside 3.3 to the corresponding hemiacetal using NBS in wet acetone, and then 































Scheme 3.7 (i) Cl3CCN, DBU, DCM, 0 °C, 30 min, 71% 
Glycosylation of the tetrasaccharide acceptor 3.16 with trichloroacetimidate 3.17 using 
TMSOTf in DCM was attempted.
188,189
 Surprisingly, this also resulted in decomposition 
of the starting materials and no formation of product. Despite numerous attempted 
reactions we were not able to obtain the hexasaccharide; furthermore we were unable for 
the rationalise the failure of the reactions (Scheme 3.8).  
 Scheme 3.8 (i) TMSOTf, DCM, 0 °C, 30 min, no reaction. 
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3.7 An alternate synthetic route to the hexasaccharide  
In light of these failed reactions our attention turned towards a publication by Chen et al. 
49
 wherein the acetate at the C-2 position of the thioglycoside donor 3.3 had been 
converted to a benzyl group before glycosylation was performed a similar 
oligosaccharide.  
Disaccharide 3.3 was deacetylated using the Zemplen method. The C-2 hydroxyl group 
was then protected as a benzyl ether by treatment with benzyl bromide and sodium 





























Scheme 3.9 (i) NaOMe, MeOH, 0 °C to rt, 18 h, 75%; ii) NaH, BnBr, DMF, 0 °C to rt, 18 h, 83%. 
Glycosylation of acceptor 2.21 with donor 3.18, using NIS and catalytic amount of TfOH 
as activator, afforded the tetrasaccharide 3.19 in 65% yield (Scheme 3.10a). 
Regioselective reductive benzylidene opening
181,182
 with Et3SiH and PhBCl2, gave the 
tetrasaccharide acceptor 3.20 in 78% yield. Pleasingly glycosylation of the 
tetrasaccharide acceptor 3.20 with thioglycoside 3.18 using NIS and triflic acid gave the 
desired hexasaccharide 3.2 in 72% yield. Hexasaccharide 3.2 was then treated with 
ethylene diamine and methanol at reflux to remove the phthalimide protecting group. The 
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crude amine was then acetylated to afford 3.21 in 71% yield over 2 steps. The TIPS 
groups were removed using BF3·OEt2 in 68% yield without any difficulty to obtain 3.22. 
Bisphosphorylation of 3.22 using N,N-diisopropyl phosphoramidite in tetrazole (0.45 M 
solution in acetonitrile) followed by m-CPBA oxidation then gave 3.23 in 94% yield over 
two steps (Scheme 3.10b).
50
 Oxidative cleavage of the anomeric para-methoxyphenyl 
glycoside was achieved using ceric ammonium nitrate (CAN) to obtain 3.24 in 80% 
yield.
130
 Global de-protection was performed using Birch reduction to obtain the fully de-
protected phosphorylated hexasaccharide 3.25 in 83% yield. The hexasaccharide was 
then converted to the desired oxazoline 3.1 by treatment with DMC and triethylamine 









Scheme 3.10a (i) 3.18, NIS, TfOH, 3Å mol. sieves, DCM, -20 °C, 30 min, 65%; ii) Et3SiH, PhBCl2, 3Å 
mol. sieves, DCM, -78 °C, 30 min, 78%; iii) 3.18, NIS, TfOH, 3Å mol. sieves, DCM, -20 °C, 30 min, 72%; 
iv) (a) NH2CH2CH2NH2, MeOH, reflux, 18 h; (b) Ac2O, py, 18 h, 71%; v) BF3.OEt2, DCM, 0 °C, 1 h, 68%. 





Scheme 3.10b (vi) (BnO)2PNiPr2, tetrazole, DCM, rt, 18 h then m-CPBA, -78 °C, 2 h, 94%; vii) CAN, 
MeCN, H2O, rt, 1 h, 80%; viii) Na, NH3(l), -33 °C, 83%; ix) DMC, Et3N, H2O, rt, 30 min, 95%. 
3.8 Conclusion 
Target hexasaccharide 3.1 was successfully synthesized in 6% overall yield in 40 steps 
based on the longest linear sequence. The main obstacle encountered was the 
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glycosylation reaction required to obtain the hexasaccharide 3.2. Different glycosylation 
conditions were tried, and, following a protecting group swap it was found that NIS and 
triflic acid activation of a thioglycoside donor gave a successful result. Global 
deprotection was performed without decomposition of the hexasaccharide. Furthermore, 
it was found that oxazoline formation was quite straightforward using Shoda’s method. It 
is clear that using this approach, various other biologically important phosphorylated 











Enzyme- catalyzed glycosylation reactions




In order to synthesize structurally defined oligosaccharides and glycoconjugates, a 
variety of elegant chemical and enzymatic methods have been developed.
39,190-192
 
Notably, in contrast to conventional chemical synthetic methods that usually require 
tedious protection and de-protection manipulations in order to achieve regio- and stereo-
selectivity, enzymatic glycosylation usually provides perfect control of anomeric 
configuration and high regioselectivity without the need for any protecting groups. Both 





Glycosyltransferases synthesize oligosaccharides, polysaccharides and glycoconjugates 
by transferring activated sugar-phosphate substrates (e.g. UDP-galactose) to acceptors. 
Generally they act in a stepwise manner and are highly specific with respect to their 
substrates.
102-104,106,107
 Glycosyltransferases that use sugar nucleoside phosphates as the 
donors are known as Leloir enzymes, named after Luis F. Leloir, the scientist who 
discovered the first sugar nucleotide and received the 1970 Nobel Prize in Chemistry for 
his work on carbohydrate metabolism. Glycosyltransferases that utilize non-nucleoside 
donors, e.g. sugar phosphates, are termed non-Leloir glycosyltransferases. 
Glycosyltransferases have proven to be extremely useful enzymes for building complex 
carbohydrates,
102,104,105
 but there are several drawbacks. Glycosyltransferases usually 
require complex sugar nucleoside phosphates as the donor, and have very stringent 
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substrate specificity. There is an additional complication in cases where the nucleoside 




Glycosidases play many important and varied roles in biological systems,
196
 ranging 
from processes such as degrading polysaccharide food sources to manipulation of 
glycoconjugate structures on the surfaces of proteins and cells. Glycosidases are of two 
types; 1) exoglycosidases, which cleave the glycosidic linkage to release the terminal 
monosaccharide residue of an oligosaccharide and, 2) endoglycosidases, which have the 
ability to cleave internal glycosidic bonds in an oligosaccharide chain or glycoconjugate. 
Under controlled conditions, glycosidases can be used to synthesize glycosidic bonds 
rather than to cleave them.
195




4.3.1 Mechanism of glycosidases: retaining and inverting mechanisms 
There are over 1000 different glycosyl hydrolases which are currently split into 133 
families.
201
 These are sub-divided in two main classes: retaining hydrolases and inverting 
hydrolases, a classification which is based on the stereochemical outcome of the 
hydrolysis reaction. The active site for both classes of enzymes usually contains two 
conserved carboxylic acid residues (Figure 4.1). The distance between the two carboxylic 
acids is usually indicator of whether a glycoside is mechanistically retaining or inverting. 
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Hydrolysis of a glycoside with net inversion of anomeric configuration is generally 
achieved via a one step, single-displacement mechanism involving an oxocarbenium -like 
transition state. Both carboxylic acids are positioned such that one carboxylic acid acts as 
a general acid to protonate the glycosidic oxygen and promote cleavage of the glycosidic 
bond. At the same, time the second carboxylic acid acts as a general base to promote 
attack of the nucleophilic water molecule (Figure 4.1). 
 
Figure 4.1 Mechanism of inverting glycosidases  
Hydrolysis with net retention of configuration is most commonly achieved via a two-step 
double-displacement mechanism involving a covalent glycosyl-enzyme intermediate that 
is subsequently hydrolysed (Figure 4.2). One carboxylic acid acts as a general acid to 
promote cleavage of the glycosidic bond in the same way as for inverting glycosidases. 
In this mechanism, however, the second carboxylic acid residue acts as a nucleophile to 
displace the glycosidic oxygen and form a covalent glycosyl-enzyme intermediate.
204
 The 
first acid residue then acts as a general base to promote nucleophilic attack by a water 
molecule onto this glycosyl-enzyme intermediate. 




















































Figure 4.2 Mechanism of retaining glycosidases  
4.3.2 Use of glycosidases for synthesis: thermodynamic vs kinetic 
approaches  
In the thermodynamic approach (reverse hydrolysis), synthesis can be favored over 
hydrolysis by using large excess of substrate,
195
 organic solvents, high salt 
concentrations,
205
 or high temperatures
193
. Unfortunately, the thermodynamic approach 
usually results in low yields and is generally not regioselective, and so often results in the 
formation of mixtures of products. Improved yields can often be achieved under 
conditions of kinetic control (Figure 4.3) .
141,195
 Thus, in order to obtain a good yield, the 
rate of hydrolysis must be slower than the rate of transglycosylation; one method of 
favouring transglycosylation over hydrolysis is to use high acceptor concentrations. 
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Furthermore, in order to achieve kinetic control the transglycosylation product must itself 
react more slowly than the activated donor used. Anomeric fluorides and p-nitrophenyl 
glycosides are two of the activated glycosides that are commonly used donors for 















Figure 4.3: Kinetic transglycosylation by interception of the covalent enzyme-bound 
intermediate using a retaining glycosidase  
4.4 Endoglycosidases 
Endoglycosidases cleave internal glycosidic bonds in an oligosaccharide chain or 
glycoconjugate. Some endoglycosidases, like chitinases and endo-β-N-
acetylglucosaminidases, can also catalyze transglycosylation reactions
117,206
 where they 
transfer intact oligosaccharide units. 
4.4.1 Chitinases 
Chitinases, which range in size from 20 kDa to about 90 kDa,
207
 catalyze the hydrolysis 
of chitin, a β(1→4)GlcNAc polysaccharide which is found as a structural components of 
many organisms. There are five known classes of chitinase which are further classified 
into two glycosyl hydrolase families.
208
 Family 18 chitinases are found in wide range of 
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organisms, including plants, bacteria, fungi and animals, whereas family 19 chitinases are 
found mainly in plants.
208,209
  
The hydrolytic mechanism is different for the two hydrolase families. Family 19 use an 
inverting mechanism similar to that described before, going via a single displacement 
mechanism.
208
 Family 18 uses a retaining mechanism via anchimeric assistance involving 
an oxazolinium intermediate (Figure 4.4).
209-211
 The oxygen atom of the glycosidic bond 
in first protonated by a carboxylic acid in the active site (general acid) and the 
oxazolinium ion intermediate is then formed by nucleophilic attack by the neighbouring 
acetamido group at the anomeric centre. The oxazolinium intermediate is then attacked 
by the incoming nucleophile; water in the case of a hydrolysis reaction and a sugar 
acceptor in the case of transglycosylation. 
 
Figure 4.4 Mechanism of glycosyl hydrolase family 18 enzymes 
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Various acceptors have been successfully glycosylated with GlcNAc using 
chitinases.
205,212
 The donors used include glycosides, phenylglycoside derivatives, and 
glycosyl fluorides. However, hydrolysis also takes place because the product of the 
reaction is a substrate for the enzyme. 
In 1996, Kobayashi et al. demonstrated the use of chitobiose oxazoline as a transition 
state mimic for glycosylation catalyzed by chitinase.
213
 At pH 7.8, the glycosylation 
reaction gave 40-50% yield of artificial chitin after six hours. When the glycosylation 
was performed at pH 10.6, a quantitative yield of product was obtained after 50 hours. 
Interestingly no hydrolysis took place because the pH required for enzymatic hydrolysis 
is pH 7.8. Later they also used this methodology to synthesise N, N'-Diacetylchitobiose 
(Scheme 4.1), the smallest repeating unit of chitin, by combining a sugar oxazoline 





























 are a group of endoglycoside hydrolases 
which catalyze the hydrolysis of the glycosidic bond between the two proximal N-
acetylglucosamines [GlcNAcβ(1→4)GlcNAc] (known as the chitobiose core),
216
 linked 
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to asparagine in N-linked glycans, leaving one N-acetylglucosamine residue attached to 
aspargine, whilst the other becomes the reducing end of the detached N-glycan.
217
 
Endohexosaminidases differ significantly from the chitinases in their specificity. 
Whereas chitinases can only cleave chitobiose, endohexosaminidases can cleave high 
mannose, hybrid, and even complex N-glycans depending on the individual specificity of 
particular enzymes. 
Members of this group of enzymes are found in both families 18 (GH18) and 85 (GH85) 
of the glycoside hydrolases.
201
 Four endo-β-N-acetylglucosaminidases that are members 
of family GH85, which are produced by both eukaryotes and prokaryotes, are Endo-M 
from Mucor hiemalis,
111
 Endo-CE from Caenorhabditis. elegans,
218
 Endo-A from 
Arthrobacter protophormiae
219
 and Endo-D from Streptococcus pneumonia.
220
 The 
family GH18 enzymes are related to chitin-degrading chitinases and contained, until 
recently, only endo-β-N-acetylglucosaminidases solely expressed by prokaryotes 
including Endo-H from Streptomyces plicatus,
221
 Endo-F1, F2, F3 from Elizabethkingia 
meningoseptica
222
 and Endo-S from Streptococcus pyogenes.
223
 Both family GH18 and 




In 2001, Shoda and co-workers found that oxazolines could be used as transition state 
mimics for some ENGases. Both Endo A and Endo M were capable of performing a 
glycosylation reaction using a disaccharide oxazoline donor substrate with p-nitrophenyl-
N-acetylglucosamine as an acceptor (Scheme 4.2).
126
 




Scheme 4.2 ENGase transglycosylation with oxazoline donors 
 
This report further stimulated interest in the potential synthetic applications of these 
enzymes by a number of research groups. The groups of Wang and Fairbanks have 
investigated various aspects of this reaction (see 1.8.1 and 1.8.2).
121,127,128,136,140,156
 
Mutants of Endo A and Endo M have also been used for this reaction to further improve 
the synthetic efficiency of the ENGase catalysed reactions.
129,135
 The donor and acceptor 
requirements for the enzymes have also been studied.
127,128,136,140
 Synthetic application of 
these enzymes has the potential to provide a generalized and high-yielding method for 




Glycosynthases are a type of engineered mutant glycosidases that can irreversibly 
catalyze the formation of a glycosidic bond from a glycosyl donor and an acceptor 
alcohol.
224
 In 1998, various research groups investigated mutagenesis of the catalytic 
active site residues and their use for the synthesis of oligosaccharides.
225,226
 Studies on β-
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glycosidases showed that changing the nucleophilic carboxylic acid residue in the active 
site of a retaining glycosidase to a non-nucleophilic amino acid (such as alanine) 
removed hydrolytic activity. In the absence of nucleophilic activity, the covalent 
glycosyl-enzyme intermediate could not be formed and so hydrolysis could not take 
place. However Planas and Withers found that activated α-glucosyl fluorides were still 
substrates for these enzymes. Furthermore the enzymes were capable of catalyzing the 
transfer of these glucose units to acceptor sugars, to give products with net inversion of 
configuration, but which were not hydrolyzed by the ezymes. Withers termed these 




Figure 4.5: Glycosynthases – general mechanism 
More recently, glycosynthases derived from inverting glycosidases have been developed. 
However, there is no ‘general strategy’ for their engineering.
228-230
 Glycosynthases have 






Glycosynthases, like glycosidases, can be divided in two classes; endo- or exo- 
glycosynthases, depending on the specificity of the glycosidase from which they were 
engineered.
235
 Endoglycosynthases catalyze the formation of specific glycosidic linkages 
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and they are highly regiospecific. The active site of endoglycosynthases can 
accommodate large oligosaccharide acceptors and large donor substrates, and can 
generate products with high degrees of polymerization. Exoglycosynthases have a more 
relaxed substrate specificity and regioselectivity, and their products are mostly short-
chain oligosaccharides. Further details about glycosynthases have been discussed in 
Chapter 1. 
4.6 Objectives 
 To investigate whether ENGases can process phosphorylated N-glycan oxazoline 
as donors and allow the production of the first synthetic N-linked glycoproteins 
that contains M6P residues in which the glycans are linked to the peptide by 
native linkages. 
 To apply this method to full-length N-glycan structures to obtain homogeneous 
phosphorylated N-glycan structures that are the natural ligands for M6P receptors. 
 To apply this method to produce recombinant lysosomal hydrolases, which may 
be used for the treatment of lysosomal storage diseases by Enzyme Replacement 
Therapy (ERT). 
4.7 ENGase catalysed glycosylation of amino acid acceptor using 
tetrasaccharide oxazoline 2.1 
ENGase-catalysed glycosylations were carried out using the phosphorylated 
tetrasaccharide oxazoline 2.1 as the donor and glycosyl amino acid 4.1 as the acceptor. 
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This acceptor has been previously used to investigate a variety of other ENGase 
catalysed glycosylations using non-phosphorylated N-glycan oxazolines as 
donors.
131,138,236
 The acceptor 4.1 bears a chromophore to facilitate HPLC analysis of the 
reaction efficiency via UV detection. 
It was found that WT Endo A, which does not normally operate hydrolytically on N-
glycans that bear a negative charge, was able to catalyze transfer of the oxazoline donor 
2.1 to the acceptor 4.1. Reaction of 2.1 and 4.1 and WT Endo A (1 µg) was conducted 
using three equivalents of the donor and one equivalent of the acceptor in a 100 mM 
sodium phosphate buffer at pH 6.5 at 37 ˚C and gave product 4.2 in 40% yield after 2 
hours (Scheme 4.3, Figure 4.8). The further addition of six equivalents of donor 2.1 
increased the yield to 73%. A full time course study of this particular reaction was 
undertaken (Figure 4.7), which revealed that, although the reaction product 4.2 was a 
hydrolytic substrate for WT Endo A, hydrolysis occurred only very slowly  
 
Scheme 4.3 (i) ENGase, phosphate buffer pH 6.5, H2O, 37 °C, 2 h. 
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Endo M has a broader hydrolytic capability than Endo A, as it has the ability to hydrolyse 
complex biantennary N-glycans as well as high mannose structures.
127,130
 However 
investigation under identical conditions that were used for Endo A revealed that Endo M 
was unable to catalyze the synthesis of 4.2. Glycosylation with the use of a commercially 
available glycosynthase mutant of Endo M, N175Q, was also performed. In this mutant, 
Asn175 which deprotonates the oxazolinium intermediate was mutated to glutamine. 
This effectively stops the hydrolytic activity of the enzyme, but it is still be able to 
perform the glycosylation reaction using an oxazoline as donor. However, reaction with 
the N175Q mutant did not result in glycosylation of 2.1 with 4.1 and only resulted in the 
hydrolysis of oxazoline 2.1. 
Surprisingly, Endo D, which has considerably more specific structural requirements with 
respect to the N-glycans it will hydrolyse as compared to both Endo A and Endo M,
237
 
was able to catalyse the production of 4.2, albeit in a very low yield (3%). 
 
 
Figure 4.7 Time course study of glycosylation of 4.1 with 2.1 catalyzed by Endo A 
 




Figure 4.8 HRMS data for glycosyl amino acid 4.2 
 
These results indicate that oxazoline 2.1 is a good donor substrate for Endo A but not for 
Endo M or its N175Q mutant. However the use of WT Endo A allowed the first 
successful synthesis of a phosphorylated N-glycan glycosyl amino acid using a chemo-
enzymatic approach. Furthermore, these results also showed that phosphorylated N-
glycan oligosaccharides can be processed by ENGases. 
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4.8 ENGase catalysed glycosylation of amino acid using 
hexasaccharide donor 3.1 
As the synthesis of 4.2 had been successfully achieved, the next aim was to use the same 
approach to couple to a GlcNAc-Asn amino acid to a larger phosphorylated 
oligosaccharide oxazoline donor, the structure of which better corresponded to a full 
length N-glycan structure bearing M6P residues, and which was also deemed optimal for 
binding the M6PRs. Besides providing glycoconjugates with optimal M6PR binding 
affinities, this would also help to develop a better understanding of the relationship 
between the synthetic and hydrolytic efficiencies of the ENGases and the chain length of 
the phosphorylated N-glycan oligosaccharide. ENGase catalysed glycosylations were 
therefore carried out using the phosphorylated hexasaccharide oxazoline 3.1 as the donor 
and glycosyl amino acid 4.1 as the acceptor, under the same standard reaction conditions 
(Scheme 4.4). 




Scheme 4.4 (i) ENGase, phosphate buffer pH 6.5, H2O, 37 °C, 2 h. 
 
WT Endo A was able to catalyze the transfer of the oxazoline donor 3.1 to acceptor 4.1, 
and the product 4.3 was produced, albeit in low yield (12%) after two hours. The use of 
extended reaction times did not improve the amount of product formed, and hydrolysis of 
the oxazoline 3.1 took place. A full time course study of this reaction (Figure 4.9) 
revealed that, although the reaction product 4.3 was a hydrolytic substrate for WT Endo 
A, hydrolysis occurred only very slowly. When the glycosylation reaction was performed 
using WT Endo M, the Endo M mutant N175Q, both were able to catalyze the reaction, 
and 4.3 was obtained in 6% and 8% yields respectively after four hours (Figure 4.10). 
The remaining oxazoline 3.1 was hydrolysed over this time. The ability of Endo M to 
catalyse the synthetic reaction using the hexasaccharide donor 3.1 as a substrate, which 
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contrasts with the failure of the analgous reaction using the tetrasaccharide 2.1, is a clear 
indicator of the effect of increased chain length. In the case of 3.1 the phosphate moieties 
are further from the reaction site, and so their presence has a smaller influence on the 
enzyme activity. 
 
Figure 4.9 Time course study of glycosylation of 4.1 with 3.1 catalyzed by Endo A 
 
Figure 4.10 Time course study of glycosylation of 4.1 with 3.1 catalyzed by Endo M 
and N175Q 




Figure 4.11 HRMS data for glycosyl amino acid 4.3 
 
4.9 Glycosylation of 2.1 and 3.1 with dRNase B 
With the synthesis of phosphorylated glycosyl-amino acids successfully achieved, 
attention turned to the potential application of this approach for the production of 
phosphorylated glycoproteins. RNase B, which is commercially available as a mixture of 
high mannose glycoforms, was trimmed back by treatment with Endo H to produce 
dRNase B, a glycoprotein possessesing a single GlcNAc residue at the sole glycosylation 
site. Partially glycosylated ribonuclease B (dRNase B) has previously been used as a 
model acceptor for enzyme catalyzed glycosylations using Endo A.
134,137
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Firstly, WT Endo A mediated glycosylation of dRNase B 4.4 was performed using 3 
equivalents of the tetrasaccharide donor 2.1 in a 100 mM sodium phosphate buffer at pH 
6.5 at 37 ˚C, to obtain phosphorylated glycoprotein 4.5 (Scheme 4.5). Product formation 
was confirmed by HRMS (Figure 4.12). As no peak separation could be seen by using 
reverse phase HPLC, the reaction was monitored using SDS-PAGE (see Appendix); 
where the yield appeared to be approximately 20%. Different MeCN/H2O gradient 
systems were tried in order to separate the starting material and product peaks using C-
18, C-8 and C-5 reverse phase columns, but unfortunately all attempts were unsuccessful 
and purification of the product 4.5 could not be achieved. 
Next, we tried to use a Concanavalin A column (Con A) to purify the product. Con A is 
known to bind to high-mannose type glycans, N-linked hybrid type glycans, and some N-
linked biantennary complex type glycans.
238,239
 However, when the mixture of 
deglycosylated and glycosylated proteins were passed through a Con A column, no 
distinct peaks were seen. While carrying out this work, Wang and co-workers published 
their work on the chemoenzymatic synthesis and lectin recognition of a fluorinated 
glycoprotein.
236
 They reported that the difluoro-Man3GlcNAc2 glycoform (Scheme 4.6) 
showed only a very weak affinity for Con A. These results indicate that the C-6 hydroxyl 
group is important for the binding of the mannose residues to Con A and the presence of 
fluorine or a phosphate group likely blocks Con A binding. 
Finally, hydroxyapatite (HAP) affinity chromatography was used to try and purify the 
glycoprotein. HAP is a crystalline form of calcium phosphate with the chemical formula, 
Ca10(PO4)6(OH)2. Several studies have demonstrated that phosphorylated proteins bind 
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more strongly to HAP matrices than their unphosphorylated counterparts. Therefore, it 
was expected that phosphorylated glycoproteins should selectively bind to HAP. 
However, on passing the protein mixture through a HAP column, a broad peak was seen, 
which, when analysed by MS, showed both deglycosylated and glycosylated proteins. 
Purification might be achieved, by changing the solvents and gradients and this remains 
one of the main objectives for the future. 
 
Scheme 4.5 (i) ENGase, phosphate buffer pH 6.5, H2O, 37 °C, 2 h. 
 




Figure 4.12 HRMS data for 4.5 
 
 




Next WT Endo A mediated glycosylation of dRNase B 4.4 with hexasaccharide 
oxazoline was undertaken under standard reaction conditions: 6 equivalents of the 
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hexasaccharide donor 3.1 in a 100 mM sodium phosphate buffer at pH 6.5 at 37 ˚C the 
phosphorylated glycoprotein 4.6 was obtained (Scheme 4.7). The formation of the 
product was confirmed by HRMS. It was expected that the purification of the 
phosphorylated glycoprotein may be achieved easily, but, to our surprise again both the 
dRNase and the glycosylated protein merged together as a broad peak using HPLC and 
proved difficult to purify. 
Nevertheless, these investigations indicated the potential of WT Endo A to catalyze the 
synthesis of glycoforms of glycoproteins which bear M6P-terminated N-glycans. With 
these results in hand, attention turned to the application of this approach to produce a 
phosphorylated version of a recombinant lysosomal hydrolase that has current 
therapeutic application. In principle the production of such glycoproteins, which bear 
phosphorylated N-glycans with optimal binding affinities for the M6PRs, should improve 
the efficacy of treatment of several lysosomal storage diseases by enzyme replacement 
therapy. 




Scheme 4.7 (i) ENGase, phosphate buffer pH 6.5, H2O, 37 °C, 1 h. 
4.10 Glycosylation of de-glycosylated fabrazyme with 2.1 and 3.1 
Fabrazyme was sourced from the laboratory of Prof Fran Platt (Department of 
Pharmacology, University of Oxford). Fabrazyme contains three N-glysosylation sites: 
N108, N161 and N184. Complex oligosaccharides are known to be present at Asn 108, 
whereas oligomannose (predominantly phosphorylated) structures were present at Asn 
161 and 184. 
Fabrazyme was deglycosylated with WT Endo A in sodium phosphate buffer (100 mM, 
pH 6.5) at 37 °C for 10 h (Scheme 4.7) in order to cleave the oligomannoses present at 
sites 161 and 184 without cleaving the complex structure at Asn 108. The reaction was 
monitored by RP-HPLC. Before deglycosylation HPLC trace showed two merged peaks 
at tR = 20.5 min. After Endo A mediated hydrolysis a single peak at tR = 22 min was 
observed (Figure 4.13 and 4.14). The de-glycosylated Fabrazyme (dFab 4.7) was then 
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purified using RP-HPLC and analysed by MS which showed successful cleavage of the 
oligomannoses from sites 161 and 184. The phosphorylated tetrasaccharide oxazoline 
donor (50 equivalents) 2.1 and dFab 4.7 (1 equivalent) were then incubated with WT 
Endo A under standard reaction conditions for two hours. Double glycosylation of dFab 
was observed; the addition of two tetrasaccharide units, gave glycoprotein 4.8, which 
possesses two M6P-terminated N-glycans each containing two M6P residues, was 
confirmed by HRMS. Glycosylation of 4.7 with 3.1 was also performed using 50 
equivalents the phosphorylated hexasaccharide donor 3.1 to obtain the phosphorylated 
glycoprotein 4.9, the formation of which was confirmed by MS. 
 
Figure 4.13 HPLC trace of Fabrazyme 




Figure 4.14 HPLC trace of deglycosylated Fabrazyme 
 





















Scheme 4.7 Glycoprotein remodeling of Fabrazyme (i) WT Endo A, phosphate buffer 
pH 6.5, H2O, 37 °C, 1 h. 
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Figure 4.15: HRMS data for 4.8 
 
4.11 Evaluation of binding of 4.5 to the cation-independent mannose-6-
phosphate receptor (CI-MPR)  
The binding of phosphorylated glycoprotein 4.5 to cation-independent mannose-6-
phosphate receptor (CI-MPR) was evaluated using immunocytochemistry and 
immunoprecipitation methods by Dr Antonia Miller.
‡
 
Immunocytochemistry is a technique that is used to anatomically localize the presence of 
a specific protein or antigen in the cells by use of a specific primary antibody that binds 
to it. The primary antibody is then bound by a secondary antibody that has a conjugated 
                                                 
‡
 This work was performed by Dr Antonia Miller, Callaghan Innovation Research Ltd. 
Chapter 4  Enzyme catalyzed glycosylation reactions 
120 
 
fluorophore, which allows the visualization of the protein under a fluorescence 
microscope.  
In order to perform the CI-MPR binding studies with glycoprotein 4.5, liver carcinoma 
cells (HepG2) were cultured on chamber slides in the presence or absence of 1 µM 
(M6P)2RNase for 2 hours under standard cell culture conditions (37 °C, 5% CO2, 
minimal essential media, 1.5% BSA, 100 units/ml penicillin, 100 µg/ml streptomycin, 
250 ng/ml amphotericin). HepG2 cells were also incubated in parallel with 1 µM 
deglycosylated RNase B to provide a control for MPR-independent RNase binding. After 
incubation, the cells were fixed (4% paraformaldehyde in 1 x phosphate buffered saline, 
PBS) and permeabilized (80% methanol in 1x PBS). The cells were then blocked with 
3% non-fat dried milk/1% BSA in 1x PBS, and two primary antibodies were then applied 
to label the CI-MPR (mouse anti-cation independent mannose-6-phosphate receptor) and 
RNase (rabbit anti-RNase A). Cells were then incubated with fluorophore-conjugated 
secondary antibodies which allow for visualization of CI-MPR and RNase (goat anti-
mouse IgG-Alexa Fluor 488 and goat anti-rabbit IgG-Alexa Fluor 568 respectively) 
through their interaction with previously applied primary antibodies. The cells were then 
stained with a nuclear stain (4',6-diamidino-2-phenylindole, DAPI) and mounted with 
coverslips. The Images were captured on a Leica TCS SP5 confocal microscope using a 
63x objective lens (Figures 4.16). Appropriate controls were included which did not 
receive either primary or secondary antibody or both to control for non-specific binding/ 
background fluorescence. It depicts the co-localization of (M6P)2RNase with CI-MPR in 
HepG2 cells following 2 hours of incubation with 1 µM (M6P)2RNase. Staining of 
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HEPG2 cells post incubation for A, the nuclear stain DAPI, B, the CI-MPR, C, RNase , 
D, Merged image of A-C, indicate co-localization of CI-MPR with RNase. 
The co-localization of the CI-MPR and RNase signals on HepG2 cells demonstrates that 
a phosphorylated glycoprotein or glycopeptide can be specifically targeted to cells 
expressing cation independent mannose-6-phosphase receptors. 
 
Figure 4.16 Co-localization of the CI-MPR and RNase 
Immunoprecipitation is a technique used to isolate or detect a particular protein from a 
sample containing a mixture of proteins. In this technique, the particular protein of 
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interest is precipitated out using an antibody that specifically binds to that protein. This 
method requires the antibody to be coupled to a solid substrate. 
HepG2 cells were treated with either 4.5 or deglycosylated RNase as above and cell 
lysates prepared. The cell lysates were then incubated with mouse anti-CI-MPR 
antibody-conjugated Protein A sepharose overnight at 4 °C to capture (M6P)2RNase (4.5) 
bound to the CI-MPR. The protein A sepharose was washed extensively and the bound 
sample containing (M6P)2RNase-CI-MPR was then eluted with reducing buffer 
containing sodium dodecyl sulphate and dithiothreitol. The eluate was subjected to 
Western blotting for detection of RNase captured by CI-MPR (Figure 4.17). 
 
Figure 4.17 Western blotting (RNase capture by CI-MPR) 
 
4.12 Conclusions 
This chapter described the ability of endohexosaminidases to utilise phosphorylated N-
glycan oxazolines 2.1 and 3.1 as donor substrates for a series of enzyme catalyzed 
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glycosylation reactions. It was shown that, although Endo A could process the 
tetrasaccharide 2.1, Endo M only resulted in hydrolysis of the oxazoline 2.1. It was also 
interesting to observe that the hydrolysis of the pentasaccharide product formed using 
WT Endo A was very slow, indicating a significant kinetic window for the synthetic 
reaction. Both Endo A and Endo M were able to process the phosphorylated 
hexasaccharide oxazoline 3.1, albeit giving products in a lower overall yield. From the 
literature it is known that, N-glycans up to a tetrasaccharide in size are only cleaved 




We have also demonstrated the glycosylation of dRNase B with a phosphorylated 
tetrasaccharide oxazoline 2.1 to obtain a neoglycoprotein in modest yield. Furthermore, 
the same approach was successfully employed for the glycosylation of dRNase with a 
full length phosphorylated N-glycan hexasaccharide 3.1 to obtain a glycoprotein, the 
glycan of which has been optimized for binding to M6PRs. 
The ultimate objective of this work was to develop methodology to access homogeneous 
phosphorylated glycoenzymes to optimize the treatment of lysosomal storage diseases by 
ERT. In the case reported here, we successfully deglycosylated a commercially available 
drug, Fabrazyme, which is clinically used for the treatment of Fabry disease, and 
glycosylated it with both tetrasaccharide 2.1 and hexasaccharide 3.1, respectively, to 
obtain two different phosphorylated glycoenzymes. 
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4.13 Future work 
This work has demonstrated the ability of ENGases to process phosphorylated N-glycan 
oxazolines, and the use of a chemo-enzymatic method to access homogeneous 
phosphorylated glycoproteins. At this point of time, the successful purification of the 
glycoproteins has yet not been achieved. Further work must be carried to develop a 
purification method for these glycoenzymes. 
Furthermore, additional work must be carried out to synthesize various different sized 
phosphorylated oxazoline donors both to elucidate the substrate specificity of the 
ENGases and to synthesize optimal homogeneous glycoprotein products. These 
homogeneous glycoproteins may then be used to optimise the treatment of a variety of 
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5.1 General chemical procedures 
Unless otherwise stated, reagents were obtained from commercial sources and used as 
received. Water was purified by reverse osmosis in–house. HPLC–grade solvents were 
used for reactions and in case of moisture–sensitive reactions; solvents were dried by 
literature procedures and freshly distilled as required. Melting points were recorded on 
an Electrothermal melting point apparatus. Elemental analysis was done by the Campbell 
Microanalytical Laboratory, University of Otago. Thin Layer Chromatography (t.l.c.) 
was carried out on Merck Kieselgel 60F254 pre-coated glass-backed plates. Visualisation 
of the plates was achieved using a UV lamp (max = 254 or 365 nm), and/or ammonium 
molybdate (5% in 2 M sulfuric acid), or sulfuric acid (5% in ethanol). Flash column 
chromatography was carried out using Sorbsil C60 40/60 silica.  




C NMR spectra were recorded on Agilent 400–MR and Varian 500 INOVA 
instruments operating for 
1
H NMR at  400 and 500 MHz, respectively and at 100 and 125 
MHz, respectively, for 
13
C NMR. All the 
1
H NMR spectra recorded in deuterated 
solvents were referenced to the solvent peak and/or TMS: CDCl3, 7.26 ppm; CD3CN, 2.0 
ppm; CD3OD, 3.3 ppm; DMSO, 2.6 ppm. 
13
C NMR were all referenced to their solvent 
peaks: chloroform, 77.0 ppm; acetonitrile, 36.8 ppm; methanol, 49.3 ppm; DMSO, 39.6 
ppm. When required, gCOSY, 1–D TOCSY, HSQC, HSQC “non-decoupled”and HMBC 
experiments were performed using standard pulse sequences.  
Mass Spectrometry 
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Mass spectra were recorded by Dr. Marie Squire and Dr. Alexander on either a DIONEX 
Ultimate 3000 or Bruker MaXis 4G spectrometer, operated in high resolution positive ion 
electrospray mode. Samples were prepared by dissolving in an appropriate solvent at the 
required concentration.  
Infrared Spectroscopy 
Infrared spectra were recorded on a Perkin–Elmer Spectrum One FTIR instrument 
operating in diffuse reflectance mode with samples prepared as KBr pellets (KBr) or on a 
Bruker FTIR spectrometer with Alpha’s Platinum ATR single reflection diamond where 
the neat samples were recorded. 
Carbohydrates and derivatives have been named in accordance with IUPAC 
recommendations and numbered according to the carbohydrate convention. The two 
protons on C-6 are labelled H-6 and H-6′.  
5.2 Experimental for chapter 2 








D-Glucose pentaacetate (5.0 g, 12.8 mmol) and ethanethiol (1.39 mL, 19.2 mmol) were 
dissolved in anhydrous DCM (20 mL). Boron trifluoride diethyl etherate (2.40 mL, 19.2 
mmol) was added to the solution and the mixture stirred at rt under an atmosphere of 
nitrogen. After 4 h t.l.c. (petrol:ethyl acetate 1:1) indicated formation of a single product 
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(Rf 0.55) and complete consumption of the starting material (Rf 0.45). The reaction 
mixture was quenched with triethylamine (2.5 mL), poured onto water (40 mL) and 
extracted into DCM (3 x 50 mL). The combined organics were washed with sodium 
hydroxide (2 x 50 mL of a 1 M solution) and brine (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The residue was crystallised using petroleum ether to afford ethyl 
2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside 2.8 (3.0 g, 60%) as a white crystalline 






 –30 (c, 1.0 in CHCl3) [Lit. [α]D 
20
 – 26 (c, 1.0 in 
CHCl3)];
141
 δH (500 MHz, CDCl3) 1.28 (1H, t, J 7.5 Hz, CH2CH3), 2.02, 2.03, 2.07, 2.08 
(12H, 4 x s, 4 x CH3), 2.69-2.73 (2H, m, CH2CH3), 3.72 (1H, m, H-5), 4.14 (1H, dd, J6,6’ 
12.3 Hz, H-6), 4.25 (1H, dd, H-6’), 4.50 (1H, d, J1,2 10.2 Hz, H-1), 5.04 (1H, at, J 9.6 Hz, 
H-2), 5.09 (1H, at, J 10.2 Hz, H-4), 5.23 (1H, at, J 9.4 Hz, H-3). 










Sodium methoxide (0.01 g, 0.13 mmol) was dissolved in methanol (6 mL) and the 
solution cooled to rt. Ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside 2.8 (0.50 g, 
1.27 mmol) was added in portions and the mixture stirred at rt under an atmosphere of 
nitrogen. After 1 h t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a single product 
(Rf 0.0) and complete consumption of starting material (Rf 0.55). The mixture was 
concentrated in vacuo. DMF (6 mL), benzaldehyde dimethyl acetal (0.38 mL, 2.54 
mmol) and DL-camphor-10-sulfonic acid (0.058 g, 0.25 mmol) were added and the 
mixture rotated in a round bottom flask on a rotary evaporator at 60 
o
C under a pressure 
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of 240 mbar. After 4 h t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major 
product (Rf 0.25). The reaction mixture was quenched with triethylamine and 
concentrated in vacuo.  The residue was dissolved in ethyl acetate (10 mL), washed with 
water (2 x 10 mL) and brine (2 x 10 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The residue was crystallised (petrol/ethyl acetate) to afford ethyl 4,6-O-
benzylidene-1-thio-β-D-glucopyranoside 2.9 (0.24 g, 65% over two steps) as a white 






 –58 (c, 1.0 in CHCl3) [lit. [α]D 
22
 – 63 (c, 1.05 in CHCl3)];
141
 δH (500 MHz, CDCl3) 1.34 (3H, t, J 7.5 Hz, CH2CH3), 
2.74-2.81 (2H, m, CH2CH3), 3.49-3.54 (2H, m, H-2, H-5), 3.59 (1H, at, J 8.8 Hz, H-3), 
3.77 (1H, at, J 10.1 Hz, H-6), 3.85 (1H, at, J 8.9 Hz, H-4), 4.36 (1H, dd, J5,6’ 4.8 Hz, J6,6’ 
10.6 Hz, H-6’), 4.48 (1H, d, J1,2 9.6 Hz, H-1), 5.55 (1H, s, PhCH(O)), 7.37-7.51 (5H, m, 
5 x Ar-H). 










Ethyl 4,6-O-benzylidene-1-thio-β-D-glucopyranoside 2.9 (10.0 g, 32 mmol) was 
dissolved in methanol (200 mL) and dibutyltin oxide (9.56 g, 38.4 mmol) added. The 
slurry was stirred at reflux under an nitrogen atmosphere for 3 h and the resulting 
solution concentrated in vacuo. DMF (100 mL), allyl bromide (4.97 mL, 57.6 mmol) and 
cesium fluoride (6.31 g, 41.6 mmol) were added to the residue and the mixture stirred at 
rt under an atmosphere of nitrogen. After 3 days t.l.c. (petrol:ethyl acetate, 1:1) indicated 
formation of a major product (Rf 0.70) and a trace of remaining starting material (Rf 
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0.25). The reaction mixture was concentrated in vacuo, the residue dissolved in DCM 
(100 mL), washed with 1N HCl solution (100 mL).Washed the organics with DI water 
(100 mL) and brine (100 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (petrol:ethyl acetate, 2:1) to afford 
ethyl 3-O-allyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 2.10 (7.0 g, 63% over two 








 –47 (c, 
1.0 in CHCl3) [lit. [α]D 
19
 – 53 (c, 1.1 in CHCl3)];
 141
 δH (500 MHz, CDCl3) 1.33 (3H, t, J 
7.5 Hz, CH2CH3), 2.5 (1H, d, J 2.0 Hz, OH), 2.77 (2H, m, CH2CH3), 3.47-3.66 (4H, m, 
H-2, H-3, H-4. H-5), 3.76 (1H, at, J 10.3 Hz, H-6), 4.30 (1H, dd, Jvic 6.1 Hz, Jgem 12.6 
Hz, OCHH’CH=CH2), 4.36 (1H, dd, J5,6’ 4.8 Hz, J6,6’ 10.6 Hz, H-6’), 4.45 (1H, m, 
OCHH’CH=CH2), 4.49 (1H, d, J1,2 9.5 Hz, H-1), 5.20 (1H, dd, Jvic 10.2 Hz, CH=CHHZ), 
5.32 (1H, dd, Jvic 17.1 Hz, Jgem 1.7 Hz, CH=CHHE), 5.55 (1H, s, PhCH(O)), 5.97 (1H, m, 
OCH2CH=CH2), 7.26-7.49 (5H, m, 5 x Ar-H). 










Ethyl 3-O-allyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 2.10 (6.0 g, 17 mmol) 
was dissolved in DCM (240 mL). Levulinic acid (3.46 mL, 34 mmol), 
dicyclohexylcarbodiimide (7.0 g, 34 mmol) and DMAP (0.21 g, 1.7 mmol) were added 
and the mixture was stirred at rt under an atmosphere of nitrogen. After 21 h t.l.c. 
(petrol:ethyl acetate, 2:1) indicated formation of a single product (Rf 0.60) and complete 
consumption of 2.1 (Rf 0.55). Filtered the reaction mixture and washed the residue with 
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DCM. The filtrate was diluted with DCM (300 mL), washed with water (2 x 500 mL), 
sodium hydrogen carbonate (2 x 500 mL of a saturated aqueous solution) and brine (500 
mL), dried (MgSO4), filtered, concentrated in vacuo and the residue purified by flash 
column chromatography (petrol:ethyl acetate, 2:1) to afford ethyl 3-O-allyl-4,6-O-
benzylidene-2-O-levulinoyl-1-thio-β-D-glucopyranoside 2.6 (6.44 g, 84%) as an 
amorphous white solid, m.p. 97.5-98.5 
o




 m.p. [α]D 
20
 – 60.4 (c, 1.0 in 
CHCl3); [lit. [α]D 
18
 – 51 (c, 0.5 in CHCl3) ];
141
 δH (500 MHz, CDCl3) 1.26 (3H, t, J 7.5 
Hz, CH2CH3), 2.17 (3H, s, CH3), 2.64-2.84 (6H, m, 3 x CH2), 3.47-3.51 (1H, m, H-5), 
3.67-3.71 (2H, m, H-3, H-4), 3.78 (1H, at, J 10.3 Hz, H-6), 4.17 (1H, dd, Jvic 6.0 Hz, Jgem 
13.0 Hz, OCHH’CH=CH2), 4.34-4.48 (2H, m, H-6’, OCHH’CH=CH2), 4.50 (1H, d, J1,2 
9.1 Hz, H-1), 5.02 (1H, at, J 9.9 Hz, H-2), 5.16 (1H, d, Jvic 10.4 Hz, CH=CHHZ), 5.25 
(1H, dd, Jgem 1.7 Hz, Jvic 17.2 Hz, CH=CHHE), 5.56 (1H, s, PhCH(O)), 5.88 (1H, m, 









Sodium methoxide (13.8 g, 254.9 mmol) was added to a stirred mixture of D–
Glucosamine hydrochloride (50 g, 231.8 mmol) in MeOH (1.25 L) and stirred under an 
atmosphere of nitrogen for 1 h. Phthalic anhydride (34.33 g, 231.8 mmol) and 
triethylamine (64.6 mL, 464 mmol) were added and the mixture stirred under an 
atmosphere of nitrogen. After 3 days the reaction mixture was concentrated in vacuo, the 
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residue dissolved in pyridine (700 mL) and cooled to 0 
o
C. Acetic anhydride (650 mL) 
was added portionwise, the reaction mixture allowed to warm to rt and stirred for 22 h. 
After this time t.l.c. (petrol:ethyl acetate, 1:2) indicated complete consumption of starting 
material (Rf 0.0) and formation of a major product (Rf 0.30). The reaction mixture was 
poured onto ice/water (1 L) and extracted with DCM (4 x 500 mL). The organics were 
washed with HCl (4 x 500 mL of a 1 M solution), sodium hydrogen carbonate (2 x 500 
mL of a saturated solution), dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (petrol:ethyl acetate, 2:1) and 
crystallisation (petrol/diethyl ether) to afford 1,3,4,6-tetra-O-acetyl-2-deoxy-2-







 + 110 (c, 1.0 in CHCl3) [lit. [α]D 
22
 + 64 (c, 1.0 in 
CHCl3)];
141
 δH (500 MHz, CDCl3) 1.88, 2.00, 2.05, 2.10 (12H, 4 x s, 4 x CH3), 4.00 (1H, 
ddd, J4,5 10.2 Hz, J5,6 2.2 Hz, J5,6’ 4.5 Hz, H-5), 4.15 (1H, dd, J6,6’ 12.5 Hz, H-6), 4.38 
(1H, dd, H-6’), 4.51 (1H, dd, J1,2 8.9 Hz, J2,3 10.5 Hz, H-2), 5.22 (1H, dd, J3,4 9.2 Hz, H-










1,3,4,6-Tetra-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 2.11 (2.0 g, 2.10 
mmol) was dissolved in DCM (12 mL) and para-methoxyphenol (0.78 g, 3.15 mmol) 
added. The mixture was stirred at rt under an atmosphere of nitrogen for 5 min; after this 
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time boron trifluoride diethyl etherate (0.76 mL, 3.15 mmol) was added portionwise. 
After 21 h t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major product (Rf 
0.60) and complete consumption of starting material (Rf 0.55). The reaction mixture was 
poured onto sodium hydrogen carbonate (12 mL of a saturated aqueous solution), 
extracted into DCM (3 x 12 mL), washed with sodium hydrogen carbonate (15 mL of a 
saturated aqueous solution), dried (MgSO4), filtered and concentrated in vacuo. The 
residue was crystallised (petrol/ethyl acetate) to afford p-methoxyphenyl 3,4,6-tri-O-
acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 2.3 (1.6 g, 71%) as a white 






 + 53.2 (c, 1.0 in CHCl3) [lit. 
[α]D 
25
 + 51 (c, 1.0 in CHCl3)];
141
 δH (500 MHz, CDCl3) 1.89, 2.05, 2.11 (9H, 3 x s, 3 x 
CH3), 3.73 (3H, s, OCH3), 3.95-3.99 (1H, m, H-5), 4.19 (1H, dd, J5,6 2.3 Hz, J6,6’ 12.2 Hz, 
H-6), 4.34 (1H, dd, J5,6’ 5.1 Hz, H-6’), 4.59 (1H, dd, J1,2 8.5 Hz, J2,3 10.5 Hz, H-2), 5.24 
(at, J 9.8 Hz, H-4), 5.86 (1H, dd, J3,4 9.9 Hz, H-3), 5.86 (1H, d, H-1), 6.73-6.86 (4H, m, 4 









To a solution of p-methoxyphenyl 3,4,6-tri-O-acetyl-2-deoxy-2- phthalimido-β-D-
glucopyranoside 2.3 (1.3 g, 2.4 mmol) in MeOH (17 mL) was added NaOMe (0.013 g. 
0.24 mmol) in portions and the mixture stirred at rt under an atmosphere of nitrogen. 
After 17 h t.l.c. (Petrol:ethyl acetate, 1:1) indicated formation of a single product (Rf 0.0) 
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and complete consumption of starting material (Rf 0.60). The mixture was concentrated 
in vacuo. DMF (13 mL), benzaldehyde dimethyl acetal (0.71 mL, 4.8 mmol) and 
DLcamphor-10-sulfonic acid (0.12 g, 0.48 mmol) were added to the residue and the 
mixture rotated in a round bottom flask on a rotary evaporator at 60 
o
C under a pressure 
of 240 mbar. After 5 h t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major 
product (Rf 0.65). The reaction mixture was concentrated in vacuo, the residue dissolved 
in ethyl acetate (20 mL), washed with water (2 x 20 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was crystallised (petrol/ethyl 
acetate) to afford p-methoxyphenyl 4,6-O-benzylidene- 2-deoxy-2-phthalimido-β-D-







 + 11 (c, 1.0 in CHCl3) [lit. [α]D 
25
 + 9.7 (c, 0.8 in 
CHCl3)];
141
 δH (500 MHz, CDCl3) 2.47 (1H, br s, OH), 3.70-3.79 (2H, m, H-4, H-5), 3.73 
(3H, s, OCH3), 3.86 (1H, at, J 9.6 Hz, H-6), 4.40 (1H, dd, J5,6’ 4.1 Hz, J6,6’ 10.5 Hz, H-
6’), 4.51 (1H, dd, J1,2 8.8 Hz, J2,3 10.5 Hz, H-2), 4.73 (1H, at, J 8.9 Hz, H-3), 5.60 (1H, s, 
PhCH(O)), 5.82 (1H, d, H-1), 6.73- 6.86 (4H, m, 4 x Ar-H), 7.38-7.51 (5H, m, 5 x Ar-H), 









A solution of p-methoxyphenyl 4,6-O-benzylidene-2-deoxy-2-phthalimido-β D-
glucopyranoside 2.13 (0.50 g, 0.99 mmol) in DMF (10 mL) was cooled to 0 
o
C. Sodium 
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hydride (50% dispersion in mineral oil, 0.07 g, 1.5 mmol) was added in portions to the 
cooled solution. Once addition was complete the slurry was left to stir for 30 min at 0 
o
C 
under an atmosphere of nitrogen, before the dropwise addition of benzyl bromide (0.18 
mL, 1.5 mmol). The reaction mixture was allowed to warm gradually to rt. After 17 h 
t.l.c. (petrol:ethyl acetate, 2:1) indicated formation of product (Rf 0.50) and complete 
consumption of starting material (Rf 0.25). The reaction was quenched with methanol (2 
mL), concentrated in vacuo and diluted with ethyl acetate (10 mL). The solution was 
washed with water (2 x 10 mL), the washings re-extracted with ethyl acetate (2 x 10 mL) 
and the combined organics dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified twice by flash column chromatography (petrol:ethyl acetate, 2:1 and 
toluene:ethyl acetate, 9:1) to afford p-methoxyphenyl 3-O-benzyl-4,6-O-benzylidene-2-







 + 81 (c, 1.0 in CHCl3) [lit. [α]D 
25
 + 72 (c, 0.8 in 
CHCl3)];
141
 δH (500 MHz, CDCl3) 3.72-3.77 (1H, m, H-5), 3.71 (3H, s, OCH3), 3.87-3.93 
(2H, m, H-4, H-6), 4.42 (1H, dd, J5,6’ 4.8 Hz, J6,6’ 10.6 Hz, H-6’), 4.47-4.50 (2H, m, H-2, 
H-3), 4.54, 4.83 (2H, m, PhCH2), 5.66 (1H, s, PhCH(O)), 5.74 (1H, d, J1,2 8.2 Hz, H-1), 
6.71-6.82 (4H, m, 4 x Ar-H), 6.82-7.03 (5H, m, 5 x Ar-H), 7.40-7.72 (5H, m, 5 x Ar- H), 
7.74-7.90 (4H, m, 4 x Ar-H). 
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To a dry round bottom flask containing activated 4 Å molecular sieves (200 mg), 
p-methoxyphenyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido--D-
glucopyranoside 2.14 (200 mg, 340 mol), THF (10 mL) and sodium cyanoborohydride 
(265 mg, 4.20 mmol) were added. The reaction mixture was cooled down to 0 C and 
hydrochloric acid (1 M in diethyl ether) added dropwise until gas ceased to evolve. The 
reaction mixture was stirred at 0 C. After 2.5 h, t.l.c. (petrol:ethyl acetate, 3:1) indicated 
formation of a major product (Rf 0.2) and complete consumption of starting material (Rf 
0.35). Water (20 mL) and DCM (20 mL) were added, and the organic layer washed with 
sodium bicarbonate (2 x 50 mL) and brine (2 x 50 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petrol:ethyl acetate, 3:1) to give p-methoxyphenyl 3,6-di-O-benzyl-2-deoxy-2-
phthalimido--D-glucopyranoside 3.8 (141 mg, 70%) as a clear oil. []D
20
 +63 (c, 1.0 in 
CDCl3) [lit. []D +56.1 (c, 0.8)];
23
 H (400 MHz, CDCl3) 2.91 (1H, d, J3,OH 2.2 Hz, OH), 
3.71 (3H, s, OCH3), 3.72-3.77 (1H, m, H-5), 3.80-3.88 (2H, m, H-6, H-6′), 3.91 (1H, m, 
H-4), 4.31 (1H, dd, J2,3 10.8 Hz, J3,4 8.3 Hz, H-3), 4.41 (1H, dd, J1,2 8.3 Hz, H-2), 4.57, 
4.78 (2H, m, J 12.2 Hz, PhCH2), 4.59, 4.65 (2H, m, J 11.9 Hz, PhCH2), 5.67 (1H, d, H-
1), 6.68-6.83 (4H, m, 4 x Ar-H), 6.95-7.09 (5H, m, 5 x Ar-H), 7.30-7.39 (5H, m, 5 x Ar-
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p-Methoxyphenyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 2.7 
(2.21 g, 3.70 mmol), ethyl 3-O-allyl-4,6-O-benzylidene-2-O-levulinoyl-1-thio-β-D-
glucopyranoside 2.6 (2.20 g, 4.82 mmol) and tri-tert-butylpyrimidine (3.76 g, 15.2 
mmol) were dissolved in anhydrous DCM (22 mL) and transferred to a flame-dried 
round-bottom flask containing activated 3Å molecular sieves (8.0 g). The mixture was 
cooled to 0 oC under an atmosphere of nitrogen and methyl trifluoromethanesulfonate 
(1.70 mL, 15.2 mmol) added. After 14 h t.l.c. (petrol:ethyl acetate, 2:1) indicated 
complete consumption of 2.7 (Rf 0.40) and formation of a major product (Rf 0.10). 
Triethylamine was added and the reaction mixture stirred for 10 min before being filtered 
through celite and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol:ethyl acetate, 2:1) to afford pmethoxyphenyl 3-O-allyl-4,6-O-
benzylidene-2-O-levulinoyl-β-D-glucopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-





 +36 (c, 1.0 in CDCl3) [lit. []D +31 (c, 0.6 in CHCl3)];
23
 δH (400 MHz, 
CDCl3) 2.23 (3H, s, CH3), 2.55-2.88 (4H, m, 2 x CH2), 3.25 (1H, m, H-5b), 3.45-3.52 
(2H, m, H-3b, H-6b), 3.58 (1H, at, J 9.6 Hz, H-4b), 3.69 (1H, m, H-5a), 3.71 (3H, s, 
OCH3), 3.84 (1H, dd, J5,6 1.3 Hz, J6,6’ 11.1 Hz, H-6a), 3.93 (1H, dd, J5,6’ 3.3 Hz, H-6’a), 
4.10 (1H, dd, Jvic 5.7 Hz, Jgem 13.0 Hz, OCHH’CH=CH2), 4.16 (1H, at, J 9.2 Hz, H-4a), 
4.28 (1H, dd, J5,6’ 4.9 Hz, J6,6’ 10.4 Hz, H-6’b), 4.31-4.36 (2H, m, H-3a, 
OCHH’CH=CH2), 4.40 (1H, dd, J1,2 8.5 Hz, J2,3 10.7 Hz, H-2a), 4.44, 4.81 (2H, m, 
PhCH2), 4.52, 4.79 (2H, m, PhCH2), 4.65 (1H, d, J1,2 8.0 Hz, H-1b), 4.96 (1H, dd, J2,3 8.8 
Hz, H-2b), 5.16 (1H, dd, Jvic 10.4 Hz, Jgem 1.5 Hz, CH=CHHZ), 5.24 (1H, dd, Jvic 17.3 Hz, 
CH=CHHE), 5.46 (1H, s, PhCH(O)), 5.63 (1H, d, H-1a), 5.86 (1H, m, CH=CH2), 6.69-
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6.72 (2H, m, 2 x Ar-H), 6.81-6.83 (2H, m, 2 x Ar-H), 6.87-6.93 (3H, m, 3 x Ar-H), 7.02-
7.04 (2H, m, 2 x Ar-H), 7.32-7.41 (8H, m, 8 x Ar-H), 7.46-7.48 (2H, m, 2 x Ar-H), 7.68-
















(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 2.15 (0.50 g, 0.5 
mmol) was dissolved in DCM (2.5 mL) and methanol (6 mL). Hydrazine acetate (0.115 
g, 1.25 mmol) was added and the mixture stirred under an atmosphere of nitrogen. After 
14 h t.l.c. (petrol:ethyl acetate, 3:2) indicated complete consumption of starting material 
(Rf 0.70) and formation of a single product (Rf 0.50). The reaction mixture was 
concentrated in vacuo and the residue purified by flash column chromatography (2:1 
petrol:ethyl acetate) to afford p-methoxyphenyl 3-O-allyl-4,6-O-benzylidene- β-D-
glucopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 






 + 55 (c, 1.0 in 
CHCl3) [lit. [α]D 
19
 + 33 (c, 0.3 in CHCl3)];
23
 δH (500 MHz, CDCl3) 3.24 (1H, m, H-5b), 
3.45-3.57 (4H, m, H-2b, H-3b, H-4b, H-6b), 3.72 (3H, s, OCH3), 3.74-3.77 (1H, m, H-
5a), 3.88 (1H, dd, J5,6 1.7 Hz, J6,6’ 11.3 Hz, H-6a), 4.06 (1H, dd, J5,6’ 3.6 Hz, H-6’a), 4.17-
4.22 (2H, m, H-4a, H-6’b), 4.26 (1H, dd, Jvic 6.1 Hz, Jgem 12.8 Hz, OCHH’CH=CH2), 
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4.42- 4.46 (3H, m, H-2a, H-3a, OCHH’CH=CH2), 4.45, 4.82 (2H, m, PhCH2), 4.61, 4.75 
(2H, m, PhCH2), 4.69 (1H, d, J1,2 7.0 Hz, H-1b), 5.21 (1H, dd, Jvic 10.4 Hz, Jgem 1.5 Hz, 
CH=CHHZ), 5.32 (1H, dd, Jvic 17.3 Hz, CH=CHHE), 5.47 (1H, s, PhCH(O)), 5.61 (1H, d, 
H-1a), 5.96 (1H, m, CH=CH2), 6.69-6.72 (2H, m, 2 x Ar-H), 6.80-6.83 (2H, m, 2 x Ar-
H), 6.88-6.95 (3H, m, 3 x Ar-H), 7.03-7.05 (2H, m, 2 x Ar-H), 7.36-7.40 (8H, m, 8 x Ar-
















benzyl- 2-deoxy-2-phthalimido-β-D-glucopyranoside 3.2 (0.50 g, 0.56 mmol) was 
dissolved in DCM (20 mL) and the solution cooled to 0 
o
C. Pyridine (0.81 mL, 10.1 
mmol) was added and the mixture stirred for 5 min under an atmosphere of nitrogen; 
after this time trifluoromethane sulfonic anhydride (0.74 mL, 4.48 mmol) was added and 
the mixture allowed to warm to room temperature. After 3 h t.l.c. (petrol:ethyl acetate, 
2:1) indicated formation of a single product (Rf 0.35) and complete consumption of 
starting material (Rf 0.10). The reaction mixture was diluted with DCM (15 mL), washed 
with sodium hydrogen carbonate (2 x 10 mL of a saturated aqueous solution), dried 
(MgSO4) and concentrated in vacuo. The residue was dissolved in toluene (20 mL) and 
tetrabutylammonium acetate (1.2 g, mmol) added. The reaction mixture was subjected to 
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sonication under an atmosphere of nitrogen. After 16 h t.l.c. (petrol:ethyl acetate, 3:2) 
indicated formation of a single product (Rf 0.45) and complete consumption of the 
intermediate triflate (Rf 0.55). The mixture was concentrated in vacuo and the residue 
purified by flash column chromatography (3:2 petrol:ethyl acetate) to afford p-
methoxyphenyl 2-O-acetyl-3-O-allyl- 4,6-O-benzylidene-β-D-mannopyranosyl-(1→4)-
3,6-di-O-benzyl-2-deoxy-2- phthalimido-β-D-glucopyranoside 2.4 (0.40 g, 77% over two 






 + 36 (c, 1.0 in CHCl3) 
[lit. [α]D 
19
 + 28.1 (c, 0.7 in CHCl3) ];
23
 δH (500 MHz, CDCl3) 2.17 (3H, s, CH3), 3.21 
(1H, m, H-5b), 3.43 (1H, dd, J2,3 2.4 Hz, J3,4 8.9 Hz, H-3b), 3.59 (1H, at, J 10.3 Hz, H-
6b), 3.67 (1H, br d, J 9.9 Hz, H-5a), 3.72 (3H, s, OCH3), 3.77-3.88 (3H, m, H-4b, H-6a, 
H-6’a), 4.04-4.07 (2H, m, OCHH’CH=CH2, OCHH’CH=CH2), 4.18-4.23 (2H, m, H-4a, 
H-6’b), 4.32 (1H, at, J 9.0 Hz, H-3a), 4.39-4.45 (2H, m, H-2a, PhCH2), 4.54, 4.80 (2H, 
m, PhCH2), 4.74 (1H, br s, H-1b), 4.86 (1H, d, J 12.3 Hz, PhCH2), 5.18 (1H, dd, Jvic 10.3 
Hz, Jgem 1.3 Hz, CH=CHHZ), 5.30 (1H, dd, Jvic 17.4 Hz, CH=CHHE), 5.41 (1H, d, J 3.4 
Hz, H-2b), 5.51 (1H, s, PhCH(O)), 5.61 (1H, d, J1,2 8.2 Hz, H-1a), 5.85 (1H, m, 
CH=CH2), 6.69-6.72 (2H, m, 2 x Ar-H), 6.80-6.82 (2H, m, 2 x Ar-H), 6.89-6.95 (3H, m, 
3 x Ar- H), 7.01-7.04 (2H, m, 2 x Ar-H), 7.32-7.39 (8H, m, 8 x Ar-H), 7.46-7.48 (2H, m, 
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D (+)-Mannose (15.0 g, 83.2 mmol) was dissolved in pyridine (300 mL), the reaction 
mixture cooled to 0 C and acetic anhydride (191 mL) was added slowly. The reaction 
mixture was stirred and allowed to warm to room temperature. After 20 h, t.l.c. (ethyl 
acetate) indicated formation of a major product (Rf 0.7) and complete consumption of 
starting material (Rf 0). The reaction mixture was diluted with DCM (50 mL) and 
quenched by addition of sodium thiosulphate (100 mL) 10% in aqueous solution. The 
reaction mixture was diluted with Separated the organic layer and aqueous layer 
extracted with DCM (2 x 50 mL). The organic layers were combined and washed with 
NaHCO3 (2 x 100 mL of a satd solution), brine (2 x 100 mL), dried (Na2SO4), filtered 
and concentrated in vacuo to give 1,2,3,4,6-penta-O-acetyl-D-mannopyranoside 2.17 
(32.0 g, 98.5%) as a pale oil and mixture of anomers (7:1, :). δH (500 MHz, CDCl3)
23
 
 anomer: 2.01, 2.05, 2.09, 2.17, 2.18 (15H, 5 x s, 5 x CH3), 4.05-4.07 (1H, m, H-5), 
4.08-4.11 (1H, m, H-6), 4.28 (1H, dd, J5,6′ 4.8 Hz, J6,6′ 12.4 Hz, H-6′), 4.33 (1H, m, H-2), 
5.32-5.38 (2H, m, H-3, H-4), 6.08 (1H, br. s, H-1);  anomer: 2.01, 2.05, 2.09, 2.17, 2.18 
(15H, 5 x s, 5 x CH3), 3.81 (1H, m, H-5), 4.11-4.15 (1H, m, H-6), 4.29-4.33 (1H, m, H-
6′), 5.13 (1H, dd, J2,3 3.2 Hz, J3,4 9.4 Hz, H-3) , 5.32 (1H, m, H-4) , 5.48-5.49 (1H, m, H-
2), 5.86 (1H, br. s, H-1).  
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1,2,3,4,6-penta-O-acetyl-D-mannopyranoside 2.17 (30.0 g, 76.8 mmol) and ethanethiol 
(8.33 mL, 115.3 mmol) were dissolved in anhydrous DCM (300 mL). Boron trifluoride 
diethyl etherate (14.2 mL, 115.3 mmol) was added and the mixture stirred at rt under an 
atmosphere of nitrogen. After 16 h t.l.c. (petrol:ethyl acetate 1:1) indicated formation of a 
major product (Rf 0.75) and consumption of starting material (Rf 0.6). The reaction 
mixture was quenched by addition of sodium hydrogen carbonate (300 mL of a saturated 
solution), stirred for a further 2 h, separated and the organic layer dried (Na2SO4), filtered 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(petrol:ethyl acetate 2:1) to afford ethyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-









 + 87.1 (c, 1.0 in CHCl3) [Lit. [α]D 
20
 + 104 (c, 0.88 in CHCl3)];
23
 
δH (500 MHz, CDCl3) 1.29 (3H, t, J 7.5 Hz, SCH2CH3), 1.99, 2.04, 2.10, 2.17 (12H, 4 x 
s, 4 x CH3), 2.60-2.66 (2H, m, SCH2CH3), 4.10 (1H, dd, J5,6 2.0 Hz, J6,6’ 12.0.Hz, H-6), 
4.32 (1H, dd, J5,6’ 5.0 Hz, H-6’), 4.40 (1H, m, H-5), 5.25-5.33 (4H, m, H-1, H-2, H-3, H-
4). 








To a solution of Ethyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranoside 2.18 (5.00 g, 
12.7 mmol) in MeOH (250 mL) NaOMe (3.44 g, 63.7 mmol) was added in portions and 
the mixture stirred at rt under an atmosphere of nitrogen. After 16 h t.l.c. (methanol:ethyl 
acetate, 1:9) indicated formation of a single product (Rf 0.20) and complete consumption 
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of starting material (Rf 0.70). Dowex was added and stirred until the solution became 
neutral. The solution was filtered and concentrated in vacuo to afford ethyl 1-thio-α-D-
mannopyranoside 4.3 (2.89 g, 100%) as a golden foam [α]D 
20
 + 199 (c, 1.0 in MeOH); 
[lit.[α]D 
18
 + 228 (c, 0.6 in CHCl3)]
23
. δH (500 MHz, CD3OD) 1.12 (3H, t, J 10 Hz, 
SCH2CH3), 2.40-2.46 (2H, m, SCH2CH3), 3.45-3.47 (2H, m, H-3, H-4), 3.55 (1H, dd, J5,6 
5.6 Hz, J6,6’ 11.6.Hz, H-6), 3.64 (1H, dd, J5,6’ 2.3 Hz, H-6’), 3.69-3.71 (2H, m, H-2, H-5), 
5.08 (1H, s, H-1). 








Ethyl 1-thio-α-D-mannopyranoside 2.19 (2.0 g, 8.90 mmol) and imidazole (1.52 g, 22.3 
mmol) were dissolved in THF (20 mL). The mixture was cooled to 0 
o
C and chloro-tri-
iso-propylsilane (3.8 mL, 17.8 mmol) added. The reaction mixture was warmed to rt and 
stirred under an atmosphere of nitrogen. After 24 h t.l.c. (petrol:ethylacetate, 1:1) 
indicated formation of a major product (Rf 0.5) and consumption of starting material (Rf 
0). The reaction mixture was diluted with ethyl acetate (50 mL), washed with ammonium 
chloride (2 x 25 mL of a saturated aqueous solution), dried (Na2SO4) and concentrated in 
vacuo. The residue was purified by flash column chromatography (ethyl acetate:petrol, 
2:1) to afford ethyl 6-O-tri-iso-propylsilyl-1- thio-α-D-mannopyranoside 2.20 (3.0 g, 
88.5%) as a white foam. [α]D
20
 + 136 (c, 1.0 in CHCl3); [lit. [α]D 
22
 + 126 (c, 0.6 in 
CHCl3)]
23
; δH (500 MHz, CDCl3) 1.07-1.14 (21H, m, CH(CH3)2), 1.26 (3H, t, J 7.5 Hz, 
SCH2CH3), 2.51- 2.59 (2H, m, SCH2CH3), 2.88 (1H, d, J 4.0 Hz, OH), 3.13 (1H, br s, 
Chapter 5  Experimental 
144 
 
OH), 3.66 (1H, br s, OH), 3.82-3.88 (2H, m, H-3, H-4), 3.94-3.97 (2H, m, H-6, H-6’), 
4.02-4.06 (2H, H-2, H-5), 5.29 (1H, s, H-1). 







Ethyl 6-O-tri-iso-propylsilyl-1-thio-α-D-mannopyranoside 2.20 (3.0 g, 7.88 mmol) was 
dissolved in THF (30 mL) and sodium hydride (1.89 g, 39.4 mmol of a 50% dispersion in 
mineral oil) added in portions. The mixture was stirred under an atmosphere of nitrogen 
for 10 min and then benzyl bromide (5.66 mL, 47.3 mmol) added in portions. The 
reaction mixture was heated to 60 
o
C and stirred for a further 20 h, after which time t.l.c. 
(petrol:ethyl acetate, 9:1) indicated formation of a major product (Rf 0.6) and 
consumption of starting material (Rf 0.0). Methanol (30 mL) was added and the solution 
stirred for 15 min then concentrated in vacuo. The residue was dissolved in ethylacetate 
(50 mL) and washed with water (2 x 30 mL). The aqueous washings were re-extracted 
with DCM (2 x 30 mL), the organics combined, dried (Na2SO4) and concentrated in 
vacuo. The residue was purified by flash column chromatography (petrol:ethyl acetate, 
19:1) to afford ethyl 2,3,4-tri-O-benzyl-6-O-triiso- propylsilyl-1-thio-α-D-
mannopyranoside 2.5 (4.0 g, 78%) as a pale yellow oil, [α]D 
20
 + 71 (c, 1.0 in CHCl3); 
[lit. [α]D 
22
 + 66 (c, 1.0 in CHCl3)]
23
; δH (500 MHz, CDCl3) 1.0-1.17 (21H, m, 
CH(CH3)2), 1.23 (3H, t, J 7.4 Hz, SCH2CH3), 2.51-2.64 (2H, m, SCH2CH3), 3.81 (1H, 
brs., H-2), 3.87 (1H, dd, J3,4 8.65, 2.66 Hz, H-3), 3.91-4.02 (4H, m, H-4, H-5, H-6, H-6’), 
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4.57 , 4.62 (2H, m, PhCH2), 4.63, 4.93 (1H, d, J 10.88 Hz  PhCH2), 4.67 (2H, br s, 















Freshly distilled THF (15 mL) was added to a flame-dried flask containing (1,5- 
cyclooctadiene)bis(methyldiphenylphosphine) iridium(I) hexafluorophosphate (28 mg, 
0.03 mmol). The mixture was degassed and subjected to an atmosphere of hydrogen for 
15 min until the catalyst lost its pink colour and had fully dissolved. p- Methoxyphenyl 
2-O-acetyl-3-O-allyl-4,6-O-benzylidene-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-
deoxy-2 phthalimido-β-D-glucopyranoside 2.4 (0.39 g, 0.42 mmol) was dissolved in 
freshly distilled THF (25 mL) in a second flame-dried flask. The solution of the activated 
Iridium catalyst was added and the mixture was stirred for 14 h under an atmosphere of 
nitrogen. After this time water (2.1 mL) and N-iodosuccinimide (0.281 g, 2.10 mmol) 
were added. After 18 h t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major 
product (Rf 0.20) and consumption of starting material (Rf 0.55). The reaction mixture 
was diluted with DCM (25 mL), washed with sodium thiosulfate (2 x 15 mL of a 10% 
solution), sodium hydrogen carbonate (2 x 15 mL of a saturated solution), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (1:1 petrol:ethyl acetate) to afford p-methoxyphenyl 2-O-acetyl-4,6-O-











 + 40 (c, 1.0 in CHCl3) [lit. [α]D 
20
 + 34.3 (c, 0.75 in CHCl3);
23
 δH (500 
MHz, CDCl3) 2.19 (3H, s, CH3), 2.23 (1H, d, JOH,3 3.6 Hz, OH), 3.20 (1H, m, H-5b), 
3.59 (1H, at, J 9.8 Hz, H-6b), 3.65-3.71 (2H, m, H-3b, H-5a), 3.72 (3H, s, OCH3), 3.74-
3.76 (1H, m, H-4b), 3.78 (1H, dd, J5,6 1.7 Hz, J6,6’ 11.3 Hz, H-6a), 3.87 (1H, dd, J5,6’ 3.1 
Hz, H-6’a), 4.18-4.22 (2H, m, H-4a, H-6’b), 4.30-4.34 (1H, m, H-3a), 4.40-4.45 (2H, m, 
H-2a, PhCH2), 4.51, 4.79 (2H, m, PhCH2), 4.76 (1H, d, J1,2 0.6 Hz, H-1b), 4.85 (1H, d, J 
12.2 Hz, PhCH2), 5.30 (1H, dd, J2,3 3.5 Hz, H-2b), 5.50 (1H, s, PhCH(O)), 5.61 (1H, d, 
J1,2 8.4 Hz, H-1a), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-H), 6.88-6.95 
(3H, m, 3 x Ar-H), 7.02- 7.04 (2H, m, 2 x Ar H), 7.33-7.40 (8H, m, 8 x Ar-H), 7.46-7.48 





A solution of disaccharide 2.21 (1.00 g, 1.13 mmol), thioglycoside 2.5 (1.10 g, 1.69 
mmol) and tri-tert-butylpyrimidine (1.26 g, 5.07 mmol) in DCM (40 mL) was added to a 
flame-dried round-bottom flask containing activated 3Å molecular sieves (3.0 g). The 
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solution was cooled to 0 
o
C under an atmosphere of nitrogen, stirred for 20 min and 
methyl trifluoromethanesulfonate (0.574 mL, 5.07 mmol) added. After 16 h t.l.c. 
(petrol:ethyl acetate, 1:1) indicated formation of a major product (Rf 0.65) and complete 
consumption of the alcohol starting material 2.21 (Rf 0.25). Triethylamine (0.706 mL, 
5.07 mmol) was added and the reaction mixture stirred for 10 min before being filtered 
through Celite
®
 and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol:ethyl acetate, 2:1) to afford trisaccharide 2.22 (1.52 g, 91%) as a 
white foam, []D
25
 + 11.0 (c, 0.5 in CHCl3); max (KBr disk) 1751, 1716 (s, C=O) cm
-1
; 
δH (500 MHz, CDCl3) 1.06 (3H, s, CH(CH3)2), 1.07 (18H, s, CH(CH3)2), 2.03 (3H, s, 
CH3), 3.11-3.15 (1H, m, H-5b), 3.56 (1H, at, J 10.4 Hz, H-6b), 3.64-3.70 (3H, m, H-2c, 
H-5a, H-5c), 3.71 (3H, s, OCH3), 3.73 (1H, dd, J2,3 2.6 Hz, J3,4 9.9 Hz, H-3c), 3.77-3.81 
(3H, m, H-4b, H-6a, H-6’a), 3.87 (1H, dd, J2,3 3.5 Hz, J3,4 9.9 Hz, H-3b), 3.93 (1H, d, J 
9.9 Hz, H-6c), 3.98 (1H, dd, J5,6’ 4.4 Hz, J6,6’ 11.1 Hz, H-6’c), 4.04 (1H, at, J 9.5 Hz, H-
4c), 4.15-4.19 (2H, m, H-4a, H-6’b), 4.31 (1H, dd, J2,3 10.6 Hz, J3,4 8.5 Hz, H-3a), 4.37-
4.46 (4H, m, H-2a, 3 x PhCH2), 4.53, 4.74 (2H, m, PhCH2), 4.55, 4.61 (2H, m, PhCH2), 
4.68, 4.91 (2H, m, PhCH2), 4.76 (1H, s, H-1b), 4.84 (1H, d, J 12.2 Hz, PhCH2), 5.24 (1H, 
s, H-1c), 5.40 (1H, d, J 3.5 Hz, H-2b), 5.46 (1H, s, PhCH(O)), 5.59 (1H, d, J1,2 8.4 Hz, 
H-1a), 6.68-6.70 (2H, m, 2 x Ar-H), 6.80-6.81 (2H, m, 2 x Ar-H), 6.90-6.96 (3H, m, 3 x 
Ar-H), 7.01-7.02 (2H, m, 2 x Ar-H), 7.09-7.11 (2H, m, 2 x Ar-H), 7.14-7.19 (3H, m, 3 x 
Ar-H), 7.25-7.38 (18H, m, 18 x Ar-H), 7.43-7.45 (2H, m, 2 x Ar-H), 7.67-7.73 (4H, m, 4 
x Ar-H); δC (125.8 MHz, CDCl3) 12.2 (d, CH(CH3)2), 18.2 (q, CH(CH3)2), 21.0 (s, CH3), 
55.7 (q, OCH3), 55.8 (d, C-2a), 63.2 (t, C-6c), 66.6 (d, C-5b), 68.3 (t, C-6a), 68.7 (t, C-
6b), 71.1 (d, C-2b), 71.9, 72.2, 73.6, 74.7, 74.9 (5 x t, 5 x PhCH2), 73.2 (d, C-3b), 74.1 
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(d, C-5c), 74.5 (d, C-4c), 74.9 (d, C-5a), 75.4 (d, C-2c), 77.2 (d, C-3a), 78.6 (d, C-4a), 
79.1 (d, C-4b), 79.4 (d, C-3c), 97.8 (d, C-1a), 98.7 (d, C-1c), 99.3 (d, C-1b), 101.9 (d, 
PhCH(O)), 114.5, 118.8, 126.2, 127.3, 127.4, 127.4, 127.5, 127.7, 127.8, 127.9, 128.0, 
128.0, 128.0, 128.1, 128.2, 128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 128.7, 129.4, 134.0, 
(24 x d, 38 x Ar-C), 137.4, 138.1, 138.6, 138.6, 138.9, 139.2, 151.0, 155.5 (10 x s, 10 x 
Ar-C), 169.6 (s, C=O); HRMS (ES
+















A solution of p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-
mannopyranosyl-(13)-2-O-acetyl-4,6-O-benzylidene--D-mannopyranosyl-(14)-3,6-
di-O-benzyl-2-deoxy-2-phthalimido--D-glucopyranoside 2.22 (0.150 g, 0.102 mmol) in 
DCM (5 mL) was added to a flame-dried round-bottom flask containing activated 3Å 
molecular sieves (0.30 g). The solution was stirred at rt under an atmosphere of nitrogen 
for 30 min then cooled to -78 
o
C. Triethylsilane (49 L, 0.31 mmol) and 
dichlorophenylborane (45 L, 0.35 mmol) were added and the reaction mixture stirred at 





C. After 45 min t.l.c. (petrol:ethyl acetate, 3:2) indicated formation of a single 
product (Rf 0.30) and consumption of starting material (Rf 0.50). Triethylamine (0.75 
mL) and methanol (0.75 mL) were added, the reaction mixture diluted with DCM (10.0 
mL), washed with sodium hydrogen carbonate (2 x 5 mL of a saturated solution), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was co-distilled with methanol 
five times at 50 
o
C before being purified by flash column chromatography (3:2 
petrol:ethyl acetate) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-
propylsilyl--D-mannopyranosyl-(13)-2-O-acetyl-4-O-benzyl--D-mannopyranosyl-
(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido--D-glucopyranoside 2.23 (0.143 g, 94%) 
as a white foam, []D
25
 + 27 (c, 0.5 in CHCl3); max (KBr disk) 3445 (s, O-H), 1749, 
1716, 1636 (s, C=O) cm
-1
; δH (500 MHz, CDCl3) 1.07 (3H, s, CH(CH3)2), 1.08 (18H, s, 
CH(CH3)2), 2.07 (3H, s, CH3), 3.07-3.09 (1H, m, H-5b), 3.42-3.44 (1H, m, H-6b), 3.58-
3.62 (3H, m, H-3b, H-4b, H-5c), 3.65-3.68 (3H, m, H-2c, H-5a, H-6’b), 3.71 (3H, s, 
OCH3), 3.77 (1H, dd, J5,6 2.9 Hz, J6,6’ 9.5 Hz, H-6a), 3.80-3.82 (2H, m, H-3c, H-6’a), 
3.92 (1H, dd, J5,6 1.1 Hz, J6,6’ 11.3 Hz, H-6c), 4.03 (1H, dd, J5,6’ 3.2 Hz, H-6’c), 4.15 
(1H, at, J 9.4 Hz, H-4a), 4.19 (1H, at, J 9.6 Hz, H-4c), 4.29 (1H, dd, J2,3 10.6 Hz, J3,4 9.7 
Hz, H-3a), 4.37-4.42 (3H, m, H-2a, 2 x PhCH2), 4.48-4.57 (5H, m, 5 x PhCH2), 4.64 (1H, 
d, J 12.0 Hz, PhCH2), 4.68 (1H, s, H-1b), 4.72-4.75 (2H, m, 2 x PhCH2), 4.88 (2H, at, J 
10.9 Hz, 2 x PhCH2), 5.07 (1H, d, J1,2 1.7 Hz, H-1c), 5.35 (1H, d, J 2.4 Hz, H-2b), 5.60 
(1H, d, J1,2 8.5 Hz, H-1a), 6.69-6.71 (2H, m, 2 x Ar-H), 6.79-6.81 (2H, m, 2 x Ar-H), 
6.92-6.98 (3H, m, 3 x Ar-H), 7.01-7.03 (2H, m, 2 x Ar-H), 7.20-7.34 (25H, m, 25 x Ar-
H), 7.67-7.79 (4H, m, 4 x Ar-H); δC (125.8 MHz, CDCl3) 12.2 (d, CH(CH3)2), 18.2 (q, 
CH(CH3)2), 21.2 (s, CH3), 55.7 (m, C-2a, OCH3), 61.8 (t, C-6b), 62.6 (t, C-6c), 68.3 (t, 
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C-6a), 71.3 (d, C-2b), 72.4, 72.5, 73.7, 74.6, 74.7, 74.9 (6 x t, 6 x PhCH2), 74.2 (d, C-5c), 
74.3 (d, C-4c), 74.7 (d, C-4b), 74.9 (d, C-5a), 75.4 (d, C-5b), 76.5 (d, C-2c), 77.0 (d, C-
3a), 78.3 (d, C-4a), 78.3 (d, C-3b), 79.6 (d, C-3c), 97.7 (d, C-1b), 98.6 (d, C-1c), 100.7 
(d, C-1a), 114.5, 118.8, 127.3, 127.3, 127.4, 127.5, 127.5, 127.5, 127.6, 127.7, 128.0, 
128.0, 128.2, 128.2, 128.4, 128.4, 128.4, 128.6, 128.7, 133.7, (20 x d, 38 x Ar-C), 138.0, 
138.1, 138.4, 138.7, 138.9, 139.2, 150.9, 155.5 (8 x s, 10 x Ar-C), 169.7 (s, C=O); 
HRMS (ES
+
) Calculated For C86H99NNaO19Si (MNa
+









A solution of p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-
mannopyranosyl-(13)-2-O-acetyl-4-O-benzyl--D-mannopyranosyl-(14)-3,6-di-O-
benzyl-2-deoxy-2-phthalimido--D-glucopyranoside 2.23 (0.179 g, 0.121 mmol), 
thioglycoside 2.5 (0.118 g, 0.182 mmol) and tri-tert-butylpyrimidine (0.135 g, 0.545 
mmol) in DCM (8 mL) was added to a flame-dried round-bottom flask containing 
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activated 3Å molecular sieves (0.3 g). The solution was cooled to 0 
o
C under an 
atmosphere of nitrogen, stirred for 20 min and methyl trifluoromethanesulfonate (62 L, 
0.55 mmol) added. After 16 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated formation of a 
major product (Rf 0.55) and complete consumption of the alcohol starting material 2.23 
(Rf 0.20). Triethylamine (76 L, 0.55 mmol) was added and the reaction mixture stirred 
for 10 min before being filtered through celite and concentrated in vacuo. The residue 




glucopyranoside 2.3 (0.198 g, 79%) as a white foam,[]D
25
 + 24 (c, 0.25 in CHCl3);max 
(KBr disk) 1717, 1630 (s, C=O) cm
-1
; δH (500 MHz, CDCl3) 1.00, 1.03 (6H, 2 x s, 2 x 
CH(CH3)2), 1.11, 1.12 (36H, 2 x s, 2 x CH(CH3)2), 2.06 (3H, s, CH3), 3.11-3.22 (1H, m, 
H-5b), 3.59-3.76 (6H, m, H-3b, H-5c, H-5d, H-6a, H-6’a, H-6b), 3.72 (3H, s, OCH3), 
3.78-3.89 (6H, m, H-2c, H-2d, H-4b, H-5a, H-6’b, H-6c), 3.94-4.00 (3H, m, H-3a, H-3d, 
H-6’c), 4.03-4.09 (2H, m, H-3c, H-6d), 4.14-4.29 (4H, m, H-4a, H-4c, H-4d, H-6’d), 
4.35-4.70 (14H, m, H-2a, 13 x PhCH2), 4.73-4.78 (3H, m, H-1b, 2 x PhCH2), 4.83-4.95 
(4H, m, H-1d, 3 x PhCH2), 5.08 (1H, s, H-1c), 5.39 (1H, s, H-2b), 5.58 (1H, d, J1,2 8.4 
Hz, H-1a), 6.68-6.76 (4H, m, 4 x Ar-H), 6.78-6.82 (4H, m, 4 x Ar-H), 6.93-6.98 (2H, m, 
2 x Ar-H), 7.17-7.37 (39H, m, 39 x Ar-H), 7.62-7.67 (4H, m, 4 x Ar-H); δC (125.8 MHz, 
CDCl3) 12.1, 12.2 (2 x d, 2 x CH(CH3)2), 18.0, 18.2 (2 x q, 2 x CH(CH3)2), 21.2 (s, CH3), 
55.7 (m, C-2a, OCH3), 62.7 (t, C-6c), 62.9 (t, C-6d), 66.2 (t, C-6b), 68.3 (t, C-6a), 71.6 
(d, C-2b), 71.6, 72.4, 72.5, 72.8, 74.4, 74.4, 74.5, 74.8, 74.9 (9 x t, 9 x PhCH2), 73.4 (d, 
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C-5c), 73.6 (d, C-4d), 73.9 (d, C-5b), 74.2 (d, C-4a), 74.4 (d, C-4c), 74.6 (d, C-5d), 74.9 
(d, C-4b), 75.3 (d, C-5a), 75.5 (d, C-2d), 76.3 (d, C-2c), 77.2 (d, C-3a), 78.4 (d, C-3b), 
79.2 (d, C-3d), 79.8 (d, C-3c), 97.8 (d, C-1a), 98.6 (d, C-1d), 99.6 (d, C-1b), 100.6 (d, C-
1c), 114.4, 118.6, 126.6, 127.0, 127.1, 127.2, 127.4, 127.5, 127.6, 127.7, 127.7, 127.8, 
127.9, 127.9, 127.9, 128.0, 128.1, 128.1, 128.2, 128.2, 128.3, 128.4, 128.5, 128.6, 128.6, 
129.6, 129.6, 132.8, 133.4, 135.8, 135.8, 136.1 (32 x d, 53 x Ar-C), 133.7, 133.7, 134.0, 
134.1, 138.0, 138.1, 138.6, 138.6, 138.8, 138.9, 139.2, 151.2, 155.5 (13 x s, 13 x Ar-C), 
169.5, 169.6, 171.0 (3 x s, 3 x C=O); HRMS (ES
+
) Calculated For C122H147NNaO24Si2 
(MNa
+
) 2089.9783. Found (MNa
+
):2089.9838. 





coupling constants from C-coupled HSQC experiments. They were as follows: C(1a)- 












-D-glucopyranoside 2.3 (0.120 g, 0.0580 mmol) was dissolved in methanol (6 mL) and 
ethylene diamine (3 mL) and the solution heated to reflux under an atmosphere of 
nitrogen. After 16 h,t.l.c. (petrol:ethyl acetate, 2:1) indicated formation of a single 
product (Rf 0.25) and complete consumption of starting material (Rf 0.40). The reaction 
mixture was concentrated in vacuo and co-distilled five times with toluene. The residue 
was dissolved in pyridine (3 mL), cooled to 0 
o
C and acetic anhydride (1 mL) added. The 
reaction mixture was stirred at rt under an atmosphere of argon. After 20 h t.l.c. 
(petrol:ethyl acetate, 2:1) indicated formation of a single product (Rf 0.40) and complete 
consumption of amine intermediate (Rf 0.25). The reaction mixture was concentrated in 
vacuo, the residue dissolved in DCM (10 mL), washed with water (10 mL), sodium 
hydrogen carbonate (2 x 10 mL of a saturated aqueous solution), dried (MgSO4) and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petrol:ethyl acetate, 3:2) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-
propylsilyl--D-mannopyranosyl -(13)-[2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-
mannopyranosyl-(16)]-2-O-acetyl-4-O-benzyl--D-mannopyranosyl-(14)-2-
acetamido-3,6-di-O-benzyl-2-deoxy--D-glucopyranoside 2.24 (0.104 g, 91%) as a pale 
yellow foam, []D
25
 + 35 (c, 0.18 in CHCl3);max (KBr disk) 3441 (s, N-H stretch), 1751, 
1635 (s, C=O) cm
-1
; δH (500 MHz, CDCl3) 1.02 (6H, m, 2 x CH(CH3)2), 1.05, 1.06 (36H, 
2 x s, CH(CH3)2), 1.61, 1.94 (6H, 2 x s, 2 x CH3), 3.29-3.30 (1H, m, H-5b), 3.40-3.46 
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(2H, m, H-6b, H-6c), 3.56-3.79 (13H, m, H-2a, H-2c, H-2d, H-3b, H-3d, H-4b, H-5a, H-
5c, H-5d, H-6a, H-6’a, H-6’b, H-6’c), 3.76 (3H, s, OCH3), 3.86-3.90 (2H, m, H-3c, H-
6d), 3.94 (1H, dd, J5,6’ 3.6 Hz, J6,6’ 11.0 Hz, H-6’d), 4.04 (1H, at, J 7.9 Hz, H-3a), 4.07-
4.16 (3H, m, H-4a, H-4c, H-4d), 4.37 (1H, d, J 12.4 Hz, PhCH2), 4.40 (1H, d, J 11.7 Hz, 
PhCH2), 4.42 (1H, d, J 11.9 Hz, PhCH2), 4.46-4.59 (10H, m, 10 x PhCH2), 4.61 (1H, d, J 
11.7 Hz, PhCH2), 4.66 (1H, d, J 12.0 Hz, PhCH2), 4.70 (1H, s, H-1b), 4.76 (1H, d, J 11.6 
Hz, PhCH2), 4.81 (1H, s, H-1d), 4.87 (1H, d, J 11.2 Hz, PhCH2), 4.88 (1H, d, J 10.9 Hz, 
PhCH2), 5.09 (1H, d, J1,2 1.3 Hz, H-1c), 5.27 (1H, d, J2,NH 7.5 Hz, NH), 5.33 (1H, d, J1,2 
6.9 Hz, H-1a), 5.37 (1H, d, J 3.0 Hz, H-2b), 6.76-6.79 (2H, m, 2 x Ar-H), 6.88-6.90 (2H, 
m, 2 x Ar-H), 7.16-7.32 (45H, m, 45 x Ar-H); δC (125.8 MHz, CDCl3) 12.2, 12.2 (2 x d, 
2 x CH(CH3)2), 18.1, 18.2 (2 x q, 2 x CH(CH3)2), 21.0, 23.3 (2 x s, 2 x CH3), 55.4 (d, C-
2a), 55.8 (q, OCH3), 62.5 (t, C-6c), 62.8 (t, C-6d), 65.9 (t, C-6b), 69.3 (t, C-6a), 71.4 (d, 
C-2b), 72.3, 72.4, 72.4, 72.6, 73.5, 74.3, 74.7, 74.8, 75.6 (9 x t, 9 x PhCH2), 73.3 (d, C-
5c), 73.9 (d, C-5a), 74.1 (d, C-5d), 74.3 (d, C-4d), 74.6 (d, C-5b), 75.1 (d, C-4a), 75.2 (d, 
C-4c), 75.4 (d, C-4b), 75.8 (d, C-2d), 76.1 (d, C-2c), 77.3 (d, C-3a), 79.0 (d, C-3b), 79.6 
(d, C-3d), 80.6 (d, C-3c), 97.4 (d, C-1b), 98.1 (d, C-1d), 98.8 (d, C-1a), 100.4 (d, C-1c), 
114.4, 118.6, 126.6, 127.0, 127.1, 127.2, 127.4, 127.5, 127.6, 127.7, 127.7, 127.8, 127.9, 
127.9, 127.9, 128.0, 128.1, 128.1, 128.2, 128.2, 128.3, 128.4, 128.5, 128.6, 128.6, 129.6, 
129.6, 132.8, 133.4 (29 x d, 49 x Ar-C), 138.0, 138.3, 138.6, 138.7, 138.8, 138.9, 139.1, 
139.1, 139.4, 151.6, 155.2 (11 x s, 11 x Ar-C), 169.8, 170.5 (2 x s, 2 x C=O); HRMS 
(ES
+
) Calculated For C116H148NO23Si2 (MH
+
) 1980.0014. Found (MH
+
):1980.0041. 










D-glucopyranoside 2.24 (140 mg, 0.07 mmol) was dissolved in anhydrous DCM (5 mL) 
under an atmosphere of nitrogen in a flame-dried flask. The solution was cooled to 0 
o
C 
and boron trifluoride diethyl etherate (43 μL, 0.35 mmol) was added dropwise. The 
reaction was stirred at 0 
o
C for 1 h after which time t.l.c. (petrol: ethyl acetate, 1:1) 
indicated complete consumption of starting material (Rf 0.55) and formation of a single 
product (Rf 0.2). The reaction mixture was diluted with DCM (10 mL), washed with 
sodium hydrogen carbonate (10 mL of a saturated aqueous solution), dried (Na2SO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol: ethyl acetate, 1:1) to afford p-Methoxyphenyl 2,3,4-tri-O-
benzyl-α-D-mannopyranosyl-(1→3)-[2,3,4-tri-O-benzyl-6-α-D-mannopyranosyl-(1→6)]-
2-O-acetyl-4-O-benzyl-β-D-mannopyranosyl (1→4)-2-acetamido-3,6-di-O-benzyl-2-
deoxy-β-D-glucopyranoside 2.25 (88 mg, 76%) as a white foam. [α]D
20
 +32 (c, 1.0 in 
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CHCl3); νmax (KBr disk) 3428 (s, N-H stretch),1746, 1739 (s, C=O) cm
-1
; δH (500 MHz, 
CDCl3) 1.58, 1.97 (6H, 2 x s, 2 x CH3), 3.32-3.38 (1H, m, H-5b), 3.40-3.48 (2H, m, H-
6b, H-6c), 3.56-3.79 (13H, m, H-2a, H-2c, H-2d, H-3b, H-3d, H-4b, H-5a, H-5c, H-5d, 
H-6a, H-6’a, H-6’b, H-6’c), 3.76 (3H, s, OCH3), 3.82-4.0 (4H, m, H-3c, H-6d ,H-6’d, H-
3a), 4.13-4.20 (3H, m, H-4a, H-4c, H-4d), 4.43-4.51 (3H, m, PhCH2) 4.52-4.61 (10H, m, 
10 x PhCH2), 4.63-4.64 (2H, m, PhCH2), 4.70 (1H, s, H-1b), 4.95 (1H, s, H-1d), 5.10 
(1H, s, H-1c), 5.33 (1H, d, J1,2 6.4 Hz, H-1a), 5.37 (1H, d, J2,3 3.0 Hz, H-2b), 6.77-6.79 
(2H,m, 2 x Ar-H), 6.88-6.90 (2H, m, 2 x Ar-H), 7.19-7.32 (45H, m, 45 x Ar-H); δC (125 
MHz, CDCl3) 21.0, 23.3 (2 x s, 2 x CH3), 55.64 (q, OCH3), 56.62 (d, C-2a), 61.9 (t, C-
6c), 62.3 (t, C-6d), 66.4 (t, C-6b), 68.7 (t, C-6a), 71.2 (d, C-2b), 72.2, 72.3, 72.6, 72.7, 
73.5, 74.2, 74.6, 74.7, 75.4 (9 x t, 9 x PhCH2), 73.4 (d, C-5c), 74.1 (d, C-5a), 74.5 (d, C-
5d), 75.0 (d, C-4d), 75.2 (d, C-5b), 75.4 (d, C-4a), 75.5 (d, 4b), 75.6 (d, C-4c), 75.8 (d, C-
2d), 76.0 (d, C-2c), 77.3 (d, C-3a), 79.6 (d, C-3b), 79.7 (d, C-3d), 80.3 (d, C-3c), 97.5 (d, 
C-1b), 98.1 (d, C-1d), 98.7(d, C-1a), 100.9 (d, C-1c), 114.4, 118.6, 126.6, 127.0, 127.1, 
127.2, 127.4, 127.5, 127.6, 127.7, 127.7, 127.8, 127.9, 127.9, 127.9, 128.0, 128.1, 128.1, 
128.2, 128.2, 128.3, 128.4, 128.5, 128.6, 128.6, 129.6, 129.6, 132.8, 133.4 (29 x d, 49 x 
Ar-C), 138.0, 138.3, 138.6, 138.7, 138.8, 138.9, 139.1, 139.1, 139.4, 151.6, 155.2 (11 x s, 
11 x Ar-C),170.0, 170.4 (2 x s, 2 x C=O); HRMS (ES
+
) Calculated For C98H108NO23 
(M+H) 1667.7346. Found (M+H): 1667.7350. 
p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-dibenzyloxyphosphoryl-α-D-
mannopyranosyl-(1→3)-[2,3,4-tri-O-benzyl-6-O-dibenzyloxyphosphoryl-α-D 






Dibenzyl N,N-diisopripyl phosphoramidate (0.053 mL, 0.16 mmol) and 1H-tetrazole 
(0.48 mL of a 0.45 M solution in acetonitrile) were added to a flame-dried flask and 
dissolved in DCM (0.45 mL). The solution was stirred at rt 10 min under nitrogen 
atmosphere. p-Methoxyphenyl 2,3,4-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[2,3,4-tri-
O-benzyl-6--α-D-mannopyranosyl-(1→6)]-2-O-acetyl-4-O-benzyl-β-D-mannopyranosyl 
(1→4)-2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside 2.25 (0.04 mg, 0.02 
mmol) in DCM (0.45 mL) was added, and the reaction stirred for 18 h. After this time 
t.l.c. (petrol:ethyl acetate, 1:1) indicated complete consumption of alcohol starting 
material (Rf 0.30) and formation of a major product (Rf 0.60). The reaction mixture was 
cooled to -78
o
C and m-chloroperbenzoic acid (0.035 g, 0.2 mmol) was added. The 
mixture was stirred for 2 h and then warmed to rt, after which time t.l.c. (petrol:ethyl 
acetate, 1:1) indicated complete consumption of the phosphine intermediate (Rf 0.60) and 
formation of a major product (Rf 0.25). The reaction was quenched by addition of sodium 
bisulfite (5 mL of a 10% w/v aqueous solution), stirred for 10 min, and extracted with 
DCM (10 mL). The organic extracts were washed with sodium hydrogen carbonate (5 
mL of a saturated aqueous solution) and brine (5 mL), dried (Na2SO4), filtered and 
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concentrated in vacuo. The residue was purified by flash column chromatography 




2.26 (0.25 g, 58% over two steps) as a white foam.[α]D
20
 +41 (c, 1.0 in CHCl3); δH (400 
MHz, CDCl3) 1.61, 1.89 (6H, 2 x s, 2 x CH3), 3.29-3.30 (1H, m, H-5b), 3.42-3.48 (2H, 
m, H-6b, H-6c), 3.56-3.79 (13H, m, H-2a, H-2c, H-2d, H-3b, H-3d, H-4b, H-5a, H-5c, H-
5d, H-6a, H-6’a, H-6’b, H-6’c), 3.76 (3H, s, OCH3), 3.86-3.94 (3H, m, H-3c, H-6d ,H-
6’d), 4.04-4.16 (4H, m, H-3a, H-4a, H-4c, H-4d), 4.37-4.42 (3H, m, PhCH2), 4.46-4.59 
(10H, m, 10 x PhCH2), 4.61-4.66 (2H, m, PhCH2), 4.70 (1H, s, H-1b), 4.76 (1H, d, 10.6 
Hz, PhCH2), 4.81 (1H, s, H-1d), 4.87 (1H, d, 8 Hz, PhCH2), 4.88 (1H, d, 10.2 Hz, 
PhCH2), 5.10 (1H, s, H-1c), 5.21 (2H, m, PhCH2), 5.33 (1H, d, J1,2 6.4 Hz, H-1a), 5.37 
(1H, d, J2,3 3.0 Hz, H-2b), 6.76-6.79 (2H,m, 2 x Ar-H), 6.88-6.90 (2H, m, 2 x Ar-H), 
7.16-7.45 (65H, m, 65 x Ar-H); δC (100 MHz, CDCl3) 21.0, 23.3 (2 x CH3), 55.64 ( 
OCH3), 56.62 (C-2a), 66.0 (C-6c), 66.8 (C-6d), 67.1 (C-6b), 67.8 (C-6a), 71.2 (C-2b), 
72.2, 72.3, 72.4, 72.5, 72.6, 72.7, 73.5, 74.0, 74.3, 74.6, 74.7, 75.0, 75.6 (13 x PhCH2), 
73.2 (C-5c), 74.1 (C-5a), 74.5 (C-5d), 75.1 (C-4d), 75.2 (C-5b), 75.4 (C-4a), 75.5 (4b), 
75.7 (C-4c), 75.8 (C-2d), 76.2 (C-2c), 77.3 (C-3a), 78.1 (C-3b), 79.7 (C-3d), 80.7 (C-3c), 
96.9 (C-1b), 97.9 (C-1d), 98.4(C-1a), 100.2 (C-1c), 114.4, 118.4, 126.6, 126.9, 127.1, 
127.3, 127.3, 127.4, 127.4, 127.4, 127.5, 127.5, 127.6, 127.6, 127.7, 127.7, 127.8, 127.8, 
127.8, 127.9, 127.9, 128.0, 128.1 128.2, 128.2, 128.3, 128.3, 128.3, 128.3, 128.3, 128.4, 
128.4, 128.5, 128.5, 128.5, 128.6, 128.8, 129.7, 130.1, 133.1, 136.0 (41 x d, 69 x Ar-C) 
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135.8, 135.9, 136.0, 136.2, 137.7, 138.0, 138.1, 138.3, 138.4, 138.4, 138.5, 138.7, 139.0, 
151.4, 155.1 (15 x Ar-C), 170.0, 170.5 (2 x s, 2 x C=O); δP (162 MHz, CDCl3) – 1.02, – 
1.20; HRMS (ES
+
) Calculated For C126H134NO29P2 (MH
+












deoxy-β-D-glucopyranoside 2.26 (15 mg, 0.01 mmol) was suspended in a mixture of 
acetonitrile (0.8 mL) and water (0.21 mL). Ceric ammonium nitrate (27 mg, 0.05 mmol) 
was added, and the reaction mixture stirred at rt. After 1 h, t.l.c. (ethyl acetate) indicated 
complete consumption of starting material (Rf 0.25) and formation of a single product (Rf 
0.15). The reaction mixture was diluted with DCM (10 mL) and washed with sodium 
hydrogen carbonate (2 x 5 mL of a saturated aqueous solution), sodium thiosulfate (2 x 5 
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mL of a 5% w/v aqueous solution), EDTA (2 x 5 mL of a 0.1 M aqueous solution) and 
water (5 mL). The organic extracts were dried (Na2SO4), filtered, concentrated in vacuo, 




glucopyranose 2.2 (11mg, 78%) as a pale yellow foam. δH (400 MHz, CDCl3) 1.61, 1.89 
(6H, 2 x s, 2 x CH3), 3.29-3.30 (1H, m, H-5b), 3.42-3.48 (2H, m, H-6b, H-6c), 3.56-3.79 
(13H, m, H-2a, H-2c, H-2d, H-3b, H-3d, H-4b, H-5a, H-5c, H-5d, H-6a, H-6’a, H-6’b, H-
6’c), 3.76 (3H, s, OCH3), 3.86-3.94 (3H, m, H-3c, H-6d ,H-6’d), 4.04-4.16 (4H, m, H-3a, 
H-4a, H-4c, H-4d), 4.37-4.42 (3H, m, PhCH2) 4.46-4.59 (10H, m, 10 x PhCH2), 4.61-
4.66 (2H, m, PhCH2), 4.70 (1H, s, H-1b), 4.76 (1H, d, 10.4 Hz, PhCH2), 4.81 (1H, s, H-
1d), 4.87 (1H, d, 11 Hz, PhCH2), 4.88 (1H, d, 10.2 Hz, PhCH2), 5.10 (1H, s, H-1c), 5.21 
(2H, m, PhCH2) 5.33 (1H, d, J1,2 6.4 Hz, H-1a), 5.37 (1H, d, J2,3 3.0 Hz, H-2b), 7.16-7.45 
(65H, m, 65 x Ar-H); δC (100 MHz, CDCl3) 21.0, 23.3 (2 x CH3), 56.62 (C-2a), 66.0 (C-
6c), 66.8 (C-6d), 67.1 (C-6b), 67.8 (C-6a), 71.2 (C-2b), 72.2, 72.3, 72.4, 72.5, 72.6, 72.7, 
73.5, 74.0, 74.3, 74.6, 74.7, 75.0, 75.6 (13 x PhCH2), 73.2 (C-5c), 74.1 (C-5a), 74.5 (C-
5d), 75.1 (C-4d), 75.2 (C-5b), 75.4 (C-4a), 75.5 (4b), 75.7 (C-4c), 75.8 (C-2d), 76.2 (C-
2c), 77.3 (C-3a), 78.1 (C-3b), 79.7 (C-3d), 80.7 (C-3c), 96.9 (C-1b), 97.9 (C-1d), 98.4(C-
1a), 100.2 (C-1c), 126.6, 126.9, 127.1, 127.3, 127.3, 127.4, 127.4, 127.4, 127.5, 127.5, 
127.6, 127.6, 127.7, 127.7, 127.8, 127.8, 127.8, 127.9, 127.9, 128.0, 128.1 128.2, 128.2, 
128.3, 128.3, 128.3, 128.3, 128.3, 128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 128.8, 129.7, 
130.1, 133.1, 136.0 (39 x d, 65 x Ar-C) 135.8, 135.9, 136.0, 136.2, 137.7, 138.0, 138.1, 
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138.3, 138.4, 138.4, 138.5, 138.7, 139.0 (13 x s, 13 x Ar-C), 170.0, 170.5 (2 x s, 2 x 
C=O); δP (162 MHz, CDCl3) – 1.04, – 1.10; HRMS (ES
+
) Calculated For C119H128NO28P2 
(MH
+









glucopyranose 2.2 (12 mg, 0.01 mmol) in THF (3 mL) was added to NH3(l) (20 mL) at -
33° C. The minimum amount of sodium for the mixture to turn deep blue was added to 
the stirred mixture. After 30 min MeOH (4 mL) was added, and reaction mixture was 
stirred for a futher 1 h., warmed to rt, and the solvent was removed in vacuo. Gel 
filtration of the crude residue on a Sephadex G-10 column (eluting with 0.01% NH3) 
afforded 6-O-Phosphate-α-D-mannopyranosyl-(1→3)-[6-O-phosphate-α-D-
mannopyranosyl-(1→6)]-β-D-mannopyranosyl-(1→4)-2-acetamido-2-deoxy-D-
glucopyranose 2.27 (4.9mg, 98%), as a white foam. δH (400 MHz, D2O) 1.89 (3H, s, 
CH3), 3.46-3.55 (1H, m, H-5b), 3.61-3.95 (16H, m, H-6b, H-6c, H-2a, H-2c, H-2d, H-3b, 
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H-3d, H-4b, H-5a, H-5c, H-5d, H-6a, H-6’a, H-6’b, H-6’c, H-3c, H-2b), 3.94-4.11 (2H, 
m, H-6d ,H-6’d), 4.7-4.9 (4H, m, H-3a, H-4a, H-4c, H-4d), 5.0 (2H, m, H-1b, H-1c), 5.1 
(1H, s, H-1a); δC (100 MHz, D2O) 21.9 (CH3), 46.6 (C-2a), 60.0 (C-6c), 62.8 (C-6d), 
63.0 (C-6b), 63.4 (C-6a), 65.1 (C-2b), 65.5 (C-5c), 65.7 (C-5a), 66.0 (C-5d), 66.3 (C-4d), 
68.0 (C-5b), 68.9 (C-4a), 71.7 (4b), 71.9 (C-4c), 72.6 (C-2d), 73.8 (C-2c), 74.5 (C-3a), 
79.8 (C-3b), 80.2 (C-3d), 80.5 (C-3c), 99.5 (C-1b), 99.7 (C-1d), 100.2 (C-1a), 102.5 (C-
1c), 174.5 (s, C=O); δP (162 MHz, D2O) 4.70, 4.76; HRMS (ES
+
) Calculated For 
C26H48NO27P2 (MH
+








(1→6)]-β-D-mannopyranosyl-(1→4)-2-acetamido-2-deoxy-D-glucopyranose 2.27 (2 mg, 
0.0023 mmol) and triethylamine (3 µL, 0.021 mmol) were dissolved in D2O (18.4 µL) 
and the resulting solution was cooled to 0°C. DMC (12 mg, 0.007 mmol) was added to 
the solution and the mixture was stirred for 15 min at the same temperature. Gel filtration 
of the residue on a Sephadex G-10 column eluted with 0.01% NH3 afforded 2-Methyl [6-





oxazoline 2.1 (1.8 mg, 95%) as a white foam. δH (400 MHz, D2O) 1.89 (3H, s, CH3), 2.8-
2.95 (1H, m, H-5b), 3.26-3.95 (16H, m, H-6b, H-6c, H-2a, H-2c, H-2d, H-3b, H-3d, H-
4b, H-5a, H-5c, H-5d, H-6a, H-6’a, H-6’b, H-6’c, H-3c, H-2b), 3.96-4.11 (2H, m, H-6d 
,H-6’d), 4.7-4.9 (6H, m, H-3a, H-4a, H-4c, H-4d, H-1b, H-1c), 5.95 (1H, d, J 7.3 Hz H-
1a). δP (162 MHz, CDCl3) 4.38; HRMS (ES
+















D(+)-Mannose (15.0 g, 83.3 mmol) was dissolved in pyridine (300 mL), the reaction 
mixture cooled to 0 C and acetic anhydride (190 mL) added slowly. The reaction 
mixture was stirred and allowed to warm to room temperature. After 20 h, t.l.c. 
(petrol:ethyl acetate, 1:1) indicated formation of a major product (Rf 0.7) and complete 
consumption of starting material (Rf 0). The reaction mixture was poured onto ice-water 
(500 mL) and extracted with DCM (3 x 200 mL). The organic layers were combined and 
washed with hydrochloric acid (3 x 500 mL of a 1 M solution), sodium hydrogen 
carbonate (3 x 500 mL of a saturated solution), brine (2 x 500 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give 1,2,3,4,6-penta-O-acetyl-D- mannopyranoside 
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3.6 (32.0 g, 99 %) as a pale oil and mixture of anomers (7:1, :). δH (500 MHz, 
CDCl3)
23
  anomer: 2.01, 2.05, 2.09, 2.17, 2.18 (15H, 5 x s, 5 x CH3), 4.05-4.07 (1H, m, 
H-5), 4.08-4.11 (1H, m, H-6), 4.28 (1H, dd, J5,6′ 4.8 Hz, J6,6′ 12.4 Hz, H-6′), 4.33 (1H, m, 
H-2), 5.32-5.38 (2H, m, H-3, H-4), 6.08 (1H, s, H-1);  anomer: 2.01, 2.05, 2.09, 2.17, 
2.18 (15H, 5 x s, 5 x CH3), 3.81 (1H, m, H-5), 4.11-4.15 (1H, m, H-6), 4.29-4.33 (1H, m, 
H-6′), 5.13 (1H, dd, J2,3 3.2 Hz, J3,4 9.4 Hz, H-3) , 5.32 (1H, m, H-4) , 5.48-5.49 (1H, m, 










1,2,3,4,6-Penta-O-acetyl-D-mannopyranoside 3.6 (10.0 g, 24.4 mmol) was dissolved in 
DCM (20 mL) and the solution cooled to 0 C. Hydrogen bromide (20 mL of a 33% in 
acetic acid solution) was added and the reaction mixture stirred at room temperature. 
After 2 h, t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major product (Rf 0.75) 
and complete consumption of starting material (Rf 0.7). Ice water (100 mL) was added 
and the reaction mixture extracted with DCM (2 x 100 mL). The organic extracts were 
combined and washed with sodium hydrogen carbonate (2 x 100 mL of a saturated 
solution), dried (MgSO4), filtered and concentrated in vacuo to give 2,3,4,6-tetra-O-
acetyl--D-mannopyranosyl bromide 5.2 (9.30 g, 93%) as a light yellow oil.Compound 
5.2 (9.30 g, 22.6 mmol), methanol (1.83 mL, 45.2 mmol) and 2,4,6-collidine (3.9 mL, 
29.4 mmol) were dissolved in DCM (60 mL) and the reaction mixture refluxed at 50 C. 
Chapter 5  Experimental 
165 
 
After 17 h, t.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a major product (Rf 0.6) 
and complete consumption of starting material (Rf  0.75). The reaction mixture was 
cooled to room temperature, water (100 mL) added and the reaction mixture extracted 
with DCM (100 mL). The combined organic layers were washed with sodium hydrogen 
carbonate (100 mL of a saturated solution) and brine (100 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The residue was crystallised (diethyl ether) to give 3,4,6-tri-
O-acetyl-1,2-O-(1-exo-methoxyethylidene)--D-mannopyranoside 3.7 (7.0 g, 85%) as 




–21 (c, 1.0 in CHCl3) [lit. 
[α]D
25
 -22.2 (c, 2.5 in CHCl3)];
4
 δH (500 MHz, CDCl3)
241
 1.60 (3H, s, CCH3), 1.91, 1.92, 
1.97 (9H, 3 x s, 3 x OC(O)CH3), 3.14 (3H, s, OC(CH3)OCH3), 3.53 (1H, m, H-5), 4.00 
(1H, m, H-6), 4.10 (1H, m, H-6′), 4.47 (1H, m, H-2), 5.01 (1H, m, , H-3), 5.15 (1H, at, J 










3,4,6-Tri-O-acetyl-1,2-O-(1-exo-methoxyethylidene)--D-mannopyranoside 3.7 (2.00 g, 
5.3 mmol) was dissolved in methanol (20 mL). Sodium (86.0 mg, 1.6 mmol) was added 
and the solution was stirred. After 35 min, t.l.c. (petrol:ethyl acetate, 1:1) indicated 
formation of a major product (Rf 0.2) and complete consumption of starting material (Rf 
0.6). The reaction mixture was concentrated in vacuo.  The dried residue was taken up in 
dry THF (15 mL), stirred, imidazole (0.54 g, 8.0 mmol) was added. The mixture was 
Chapter 5  Experimental 
166 
 
cooled to 0 
o
C and chloro-tri-iso-propylsilane (1.4 mL, 6.0 mmol) added. The reaction 
mixture was warmed to rt and stirred under an atmosphere of nitrogen. After 24 h t.l.c. 
(petrol:ethylacetate, 1:1) indicated formation of a major product (Rf 0.4) and 
consumption of starting material (Rf 0). The reaction mixture was diluted with ethyl 
acetate (20 mL), washed with ammonium chloride (2 x 15 mL of a saturated aqueous 
solution), dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash 
column chromatography (ethyl acetate:petrol, 1:1) to afford 1,2-O-(1-





–15 (c, 1.0 in CHCl3);.δH (500 MHz, CDCl3)
185
1.00 - 1.16 (m, 21 H), 
1.60 (3H, s, CCH3), 2.55 (d, J 6.85 Hz, 1 H), 3.14 (3H, s, OC(CH3)OCH3), 3.27 - 3.35 
(m, 1 H), 3.53 - 3.65 (m, 3 H), 3.75 - 3.82 (m, 1 H), 3.88 (t, J=8.68 Hz, 2 H), 4.06 (dd, 











1,2-O-(1-methoxyethylidene)-6-O-triisopropylsilyl-β-D-mannopyranose 3.9 (1.0 g, 2.5 
mmol) was dissolved in DMF (10 mL) and sodium hydride (0.24 g, 10.0 mmol of a 50% 
dispersion in mineral oil) added in portions. The mixture was stirred under an atmosphere 
of nitrogen for 10 min and then benzyl bromide (1.2 mL, 10.0 mmol) added in portions. 
The reaction mixture was stirred for 18 h, after which time t.l.c. (petrol:ethyl acetate, 1:1) 
indicated formation of a major product (Rf 0.8) and consumption of starting material (Rf 
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0.4). Methanol (10 mL) was added and the solution stirred for 15 min then concentrated 
in vacuo. The residue was dissolved in ethylacetate (20 mL) and washed with water (2 x 
15 mL). The aqueous washings were re-extracted with DCM (2 x 10 mL), the organics 
combined, dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash 
column chromatography (petrol:ethyl acetate, 1:1) to afford 1,2-O-(1-
methoxyethylidene)-3,4-di-O-benzyl-6-O-triisopropylsilyl-β-D-mannopyranose 3.10 (1.3 
g, 92%) as a pale yellow oil. [α]D 
20
 + 53 (c, 1.0 in CHCl3)
185
; δH (400 MHz, CDCl3)
185
 
0.9-1.09 (m, 21H), 1.71 (s, 3H,CH3), 3.14 (s, 3H OCH3), 3.87-3.97 (m, 3H), 4.01 (m, 1H, 









To a mixture of acetic acid (94mL), water (48 mL), and acetone (70 mL) 1,2-O-(1-
methoxyethylidene)-3,4-di-O-benzyl-6-O-triisopropylsilyl-β-D-mannopyranose 3.10 (4.2 
g, 7.3 mmol) was added and stirred for 18 hr at room temperature. The clear solution was 
concentrated in vacuo and co-evaporated with toluene (50 mL) two times. The residue 
was dissolved in anhydrous pyridine/acetic anhydride (1:1, 25 mL) and stirred for 7 h at 
room temperature. Concentrated in vacuo and purified by flash column chromatography 
with (petrol:ethyl acetate, 4:1) gave 1,2-di-O-acetyl-3,4-di-O-benzyl-6-O-
triisopropylsilyl-α/β-D-mannopyranose 3.11 ( 3.0 g, 68%) as an anomeric mixture. Rf 0.7 
(petrol:ethyl acetate, 4:1). δH (400 MHz, CDCl3)
185
 1.08-1.09 (m, 21H), 2.05 (s, 3H, 
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COCH3), 2.13 (s, 3H, COCH3), 3.68-3.71 (m, 1H, 5-H), 3.91-4.13 (m, 4H), 4.57-4.59 
(m, 1H), 4.68-4.76 (m, 2H), 4.90-4.93 (m, 1H), 5.32 (dd, 1H, J = 2.4 Hz, 3.2 Hz, H-2), 










A solution of 1,2-di-O-acetyl-3,4-di-O-benzyl-6-O-triisopropylsilyl-α/β-D-
mannopyranose 3.11 (3.0g, 5.0 mmol) and hydrazinium acetate (0.60 g, 5.9 mmol) in dry 
N,N-dimethylformamide (60 mL) was heated for 4 h at 50 °C under nitrogen 
atmosphere. After cooling to room temp, water (500 mL) was added and the mixture was 
extracted with ethyl acetate (3 × 150 mL). The combined organic extracts were washed 
with water (2 × 150 mL), dried with Na2SO4, and concentrated in vacuo. Purification of 
the residue by flash chromatography (hexane/ethyl acetate, 4:1) gave 2-O-acetyl-3,4-di-
O-benzyl-6-O-tri-isopropylsilyl-α/β-D-mannopyranose 3.12 (2.6 g, 95%, colorless syrup) 
as an anomeric mixture. Rf = 0.69 (petrol:ethyl acetate, 4:1). δH (400 MHz, CDCl3)
185
 
1.08-1.07 (m, 21H), 2.12 (s, 3H, COCH3), 3.88- 4.05 (m, 5H), 4.56-4.59 (m, 1H), 4.65-
4.73 (m, 2H), 4.90-4.92 (m, 1H), 5.18 (s., 1H), 5.34 (d, 1H, J = 2.0 Hz, 1-H), 7.32-7.31 
(m, 10H, Ar). 
2-O-acetyl-3,4-di-O-benzyl-6-O-triisopropylsilyl-α-D-mannopyranose 
trichloroacetimidate 3.4 













2-O-acetyl-3,4-di-O-benzyl-6-O-tri-isopropylsilyl-α/β-D-mannopyranose 3.12 (0.17 g, 
0.3 mmol) was dissolved in DCM (1.5 mL). 1,1,1-Trichloroacetonitrile (1.6 mL) was 
added and the reaction mixture cooled to 0 C. DBU (14 l, 0.09 mol) was added and 
the solution was stirred and allowed to warm to room temperature under nitrogen 
atmosphere. After 1h, t.l.c (petrol:ethyl acetate, 4:1) indicated formation of a major 
product (Rf 0.5) and complete consumption of starting material (Rf 0.3). The reaction 
mixture was filtered through Celite
®
 and concentrated in vacuo. The residue was purified 
by flash column chromatography (petrol:ethyl acetate, 4:1) to give 2-O-acetyl-3,4-di-O-
benzyl-6-O-triisopropylsilyl-α-D-mannopyranose trichloroacetimidate 3.4 (0.18 g, 85%) 
as a colorless foam, [α]D 
20
 + 48 (c, 1.0 in CHCl3); [lit. [α]D 
22
 + 43.4 (c, 2.2 in 
CH2CI2)
185
; δH (400 MHz, CDCl3)
 3
 1.08-1.14 (m, 21H), 2.15 (s, 3H, COCH3), 3.85 (dd, J 
1.5, 9.8 Hz, 1H), 3.95 (d, J 11.3 Hz, 1H), 4.09-4.05 (m, 2 H), 4.17 (t, J 9.8 Hz, 1H), 4.62-
4.57 (m, 1H), 4.71 (d, J 10.7 Hz, 1H), 4.75 (d, J 11.3 Hz, 1H), 4.93 (d, J 10.4 Hz, 1H), 
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3,4,6-Tri-O-acetyl-1,2-O-(1-exo-methoxyethylidene)--D-mannopyranoside 3.7 (6.00 g, 
16.9 mmol) was dissolved in methanol (60 mL). Sodium methoxide (27.0 mg, 5.0 mmol) 
was added and the solution stirred. After 35 min, t.l.c. (petrol:ethyl acetate, 1:1) indicated 
formation of a major product (Rf 0) and complete consumption of starting material (Rf 
0.6). The reaction mixture was concentrated in vacuo.  The dried residue was taken up in 
dry DMF (60 mL), stirred and the solution cooled to 0 C. Benzyl bromide (8.90 mL, 
75.0 mmol) was added followed by slow addition of sodium hydride (4.70 g of a 60% 
mineral oil dispersion, 99.4 mmol). After 17 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated 
formation of a major product (Rf 0.45) and complete consumption of starting material (Rf 
0). Methanol (20 mL) was added slowly until bubbling ceased. The reaction mixture was 
extracted with DCM (2 x 200 mL), washed with water (2 x 100 mL), brine (100 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (petrol:ethyl acetate, 3:1) to yield 3,4,6-tri-O-benzyl-1,2-O-(1-
exo-methoxyethylidene)--D-mannopyranoside 3.13 as a white solid (7.10 g, 88%.), m.p. 
73-74 C [lit. 71-72 °C]; [α]D
20
 +31 (c, 1.0 in CHCl3) [lit. [α]D
20
 +34 (c, 1.35 in CHCl3)]; 
δH (500 MHz, CDCl3)
 184,241-243 184,241-243 184,241-243 183,240-242
 1.76 (3H, s, CCH3), 3.31 (3H, 
s, OCH3), 3.41-3.47 (1H, m, H-5), 3.70-3.78 (3H, m, H-3, H-6, H-6′), 3.93 (1H, at, H-4), 
4.40 (1H, m, H-2), 4.55, 4.61 (2H, m, PhCH2), 4.61, 4.90 (2H, m, PhCH2), 4.80 (2H, m, 
PhCH2), 5.36 (1H, d, H-1), 7.24-7.41 (15H, m, 15 x Ar-H).  
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3,4,6-tri-O-benzyl-1,2-O-(1-exo-methoxyethylidene)--D-mannopyranoside 3.13 (6.00 g, 
12.2 mmol) was dissolved in dry MeCN (40 mL). The mixture was stirred for 60 min 
before ethanethiol (2.91 mL, 40.4 mmol) and HgBr2 (220 mg, 60 mmol) were added. The 
suspension was stirred at 60 °C. After 24 h, t.l.c. (petrol:ethyl acetate, 3:1) indicated 
formation of a major product (Rf 0.75) and complete consumption of starting material (Rf 
6).  Diluted with DCM (50 mL), washed with 5%NaOH (50 mL), dried (MgSO4) and 
concentrated. The residue was purified by column chromatography (petrol:ethyl acetate, 
3:1) to give Ethyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 3.14 as a 
colourless oil (5.10 g, 78%). δH (500 MHz, CDCl3)
184
 1.28 (3H,t, J.10 Hz, CH2CH3), 
2.17 (3H, s, OC(O)CH3), 2.55 - 2.70 (2H, m, CH2CH3), 3.68 (1H, m, H-6), 3.84 (1H, m, 
H-6’), 3.90 - 3.98 (2H, m, H-3, H-4), 4.14 - 4.20 (1H, m, H-5), 4.45 - 4.56 (3H, m, 
CH2Ph), 4.68-4.72 (2H, m, CH2Ph), 4.85 (1H, d, J.10 Hz, CH2Ph), 5.32 (1H, s, H-1), 
5.44 (1H, d, J.1.5 Hz, H-2), 7.12 - 7.38 (15H, m, Ar-H); 
13
C NMR (125 MHz, 
CDCl3):14.9 (CH2CH3), 21.2 (OC(O)CH3), 25.5 (CH2CH3), 68.9 (C-6), 70.6, 71.8, 74.6 
(C-3, C-4, C-5), 71.9, 73.4, 75.2 (CH2Ph), 78.6 (C-2), 82.5 (C-1), 127.6, 127.7, 127.8, 
127.9, 128.2, 128.3, 128.5, 137.7, 138.2, 138.4, (Ar-C), 170.5 (C=O). 








Ethyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 3.14 (3.2 g, 1.90 
mmol) was dissolved in MeOH (30 mL) and NaOMe (0.03g, 0.6 mmol) was added. After 
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1 h, t.l.c. (petrol:ethyl acetate, 3:1) indicated formation of a major product (Rf 0.50) and 
complete consumption of starting material (Rf 0.75). The reaction mixture was filtered, 
concentrated and purified by column chromatography (petrol:ethyl acetate, 3:1) to give 
Ethyl 3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 3.5 as a colourless oil (2.95 g, 
100%). δH (500 MHz, CDCl3)
184
 1.28 (3H, t, J.10 Hz, CH2CH3), 2.53 - 2.71 (3H, m, 
CH2CH3 , OH), 3.67 (1H, dd, J.1.9, 10 Hz, H-6), 3.79 (1H, m, H-6’), 3.84 (1H, m, H-3), 
3.90 (1H, t, J. 10 Hz, H-4), 4.09-4.12 (1H, m, H-2), 4.16-4.20 (1H, m, H-5), 4.50 (2H, d, 
J.10Hz CH2Ph), 4.65-4.72 (3H, m, CH2Ph), 4.82 (1H, d, J. 10.9 Hz, CH2Ph), 5.39 (1H, s, 
H-1), 7.16 - 7.39 (15H, m, Ar-H); 
13
C NMR (125 MHz, CDCl3): 14.8 (CH2CH3), 24.9 
(CH2CH3), 68.9 (C- 6), 69.9, 71.5, 74.6 (C-3, C-4, C-5), 72.1, 73.4, 75.1 (CH2Ph), 80.5 
(C-2), 83.4 (C-1), 127.6, 127.7, 127.8, 127.9, 128.0, 128.3, 128.4, 128.6, 137.7, 138.3, 
138.4 (Ar-C). 
Ethyl 2-O-acetyl-3,4-di-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- 












Ethyl 3,4,6-tri-O-benzyl-1-thio-α-D-mannopyranoside 3.5 (1.0 g, 2.0 mmol) and 2-O-
acetyl-3,4-di-O-benzyl-1-O-trichloroacetimidyl-6-O-triisopropylsilyl-α/β-D- 
mannopyranosyl 3.4 (2.1 g, 3.0 mmol) were dissolved in dry DCM (20 mL) and 
transferred to a flame-dried round-bottomed flask containing activated 4Å molecular 
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sieves (2.00 g). The solution was cooled to -10 C and stirred under an atmosphere of 
nitrogen. TMSOTf (13.0 l, 0.08 mmol) was added and the temperature was allowed to 
rise to 0 C. After 25 min, t.l.c. (petrol:ethyl acetate, 9:1) indicated formation of a major 
product (Rf 0.7) and complete consumption of Ethyl 3,4,6-tri-O-benzyl-1-thio-α-D-
mannopyranoside 3.5. (Rf 0.2). Triethylamine was added and the solution was stirred for 
a further 10 min. The reaction mixture was filtered through Celite
®
, washed with sodium 
hydrogen carbonate (10 mL of a saturated solution), dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petrol: ethyl acetate, 20:1) to afford compound 3.3 (1.6 g, 61%) as yellow oil. [α]D 
20
 
+8.3 (c, 1.0 in CHCl3); [lit. [α]D 
20




H NMR δH (400 MHz, 
CDCl3)
5
 0.98 - 1.18 (21H, m), 1.25 (t, J 7.43 Hz, 3 H), 2.08 (s, 3 H), 2.58 (m, 2 H), 3.64 
- 3.71 (m, 1 H), 3.71 - 3.81 (m, 2 H), 3.81 - 4.07 (m, 7 H), 4.11 (br. s., 2 H), 4.39 - 4.58 
(m, 3 H), 4.59 - 4.69 (m, 5 H), 4.86 (m, 2H), 5.10 (s, 1 H), 5.30 (s, 1 H), 5.47 (br. s., 1 









A solution of p-methoxyphenyl 2-O-acetyl-4,6-O-benzylidene-β-D-mannopyranosyl-
(1→4)-3,6 di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 2.21 (0.07 g, 0.08 
mmol), 3.3 (0.10 g, 0.1 mmol) and tri-tert-butylpyrimidine (0.11 g, 0.45 mmol) in DCM 
(2 mL) was added to a flame-dried round bottom flask containing 3Å molecular sieves 
(0.2 g). The solution was cooled to 0 °C under an atmosphere of nitrogen, stirred for 30 
min and methyl trifluoromethanesulfonate (0.05 mL, 0.45 mmol) was added. After 18 h 
t.l.c. (petrol: ethyl acetate, 3:2) indicated formation of a major product (Rf 0.4) and 
complete consumption of alcohol starting material 2.21 (Rf 0.20). Triethylamine (0.10 
mL) was added and the reaction mixture stirred for 10 min before being filtered through 
Celite® and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol: ethyl acetate, 3:2) to afford compound p-Methoxyphenyl 2-O-
acetyl-3,4-di-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6-tri-O-
benzyl-α-D-mannopyranosyl-(13)-2-O-acetyl-4,6-O-benzylidene--D mannopyranosyl-
(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido--D-glucopyranoside 3.15 (80 mg, 55%) 
as a yellow foam. [α]D 
20
 -2.1 (c, 1.0 in CHCl3);
 
δH (400 MHz, CDCl3) 0.94 - 1.06 (m, 21 
H), 2.07 (s, 3 H), 2.04 (s, 3 H), 3.04 (m, 2 H), 3.45 - 3.54 (m, 3 H), 3.54 - 3.64 (m, 3 H), 
3.65 - 3.74 (m, 7 H), 3.74 - 3.92 (m, 6 H), 3.92 - 4.03 (m, 4 H), 4.03 - 4.17 (m, 4 H), 4.26 
- 4.53 (m, 8 H), 4.53 - 4.74 (m, 10 H), 4.78 - 4.91 (m, 4 H), 5.16 (m, 3 H), 5.43 (d, 
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J=5.87 Hz, 3 H), 5.57 (d, J=8.61 Hz, 1 H), 6.70 (d, J=9.00 Hz, 2 H), 6.80 (m, 3 H), 6.88 - 
6.97 (m, 3 H), 7.02 (m,3 H), 7.14 - 7.41 (m, 35 H), 7.68 (br. s., 4 H); 
13
C NMR (125 
MHz, CDCl3) 12.1, 18.0, 18.1, 20.9, 21.0, 29.7, 55.6, 62.0, 66.6, 68.1, 68.4, 68.7, 69.2, 
69.4, 71.0, 71.8, 72.0, 72.2, 72.6, 73.2, 73.3, 73.6, 74.4, 74.5, 74.7, 75.2, 76.7, 77.0, 77.2, 
77.3, 78.0 , 78.5 , 78.5 , 97.6, 98.0, 99.2, 99.7, 101.3 , 114.4, 118.6, 123.3, 125.7, 127.2, 
127.4, 127.5, 127.6, 127.7, 127.8, 127.9, 127.96, 127.98, 128. 0, 128.1, 128.2, 128.2, 
128.3, 128.3, 128.4, 128.5, 128.9, 131.5, 133.8, 137.1, 137.9, 138.3, 138.3, 138.5, 138.5, 
138.5, 139.0, 150.8, 155.4, 169.6, 170.0.; HRMS (ES
+
) Calculated For 
C108H121NSiNaO25 (MNa
+









A solution of p-Methoxyphenyl 2-O-acetyl-3,4-di-O-benzyl-6-O-tri-iso-propylsilyl--D-
manno pyranosyl- (12)- 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(13)-2-O-acetyl-
4,6-O-benzylidene--D mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-
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-D-glucopyranoside 3.15 (0.06 g, 0.03 mmol) in DCM (2.5 mL) was added to a flame-
dried round bottom flask containing 3Å molecular sieves (0.12 g). The solution was 
stirred for 30 min under an atmosphere of nitrogen then cooled to -78 °C. Triethylsilane 
(14 µL, 0.09 mmol) and dichlorophenyl borane (14 µL, 0.11 mmol) were added and 
stirred the reaction mixture at -78 °C. After 30 min t.l.c. (petrol:ethyl acetate, 7:3) 
showed formation of a single product (Rf 0.3) and consumption of starting material (Rf 
0.5). Triethylamine (0.1 mL) and methanol (0.1 mL) were added, the reaction mixture 
diluted with DCM (4 mL), washed with sodium hydrogen carbonate (2 x 5 mL of a 
saturated solution), dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
evaporated with methanol five times at 50 
o
C before being purified by flash column 
chromatography (7:3 petrol: ethyl acetate) to obtain p-Methoxyphenyl 2-O-acetyl-3,4-di-
O-benzyl-6-O-tri-iso-propylsilyl--D-mannopyranosyl-(12)- 3,4,6-tri-O-benzyl-α-D-
mannopyranosyl-(13)-2-O-acetyl-4-O-benzyl--D mannopyranosyl-(14)-3,6-di-O-
benzyl-2-deoxy-2-phthalimido--D-glucopyranoside 3.16 (0.05 g, 83%) as a yellow 
foam. [α]D 
20
 +1.5 (c, 1.0 in CHCl3);
 
δH (400 MHz, CDCl3) 0.91 - 1.05 (m, 21 H), 2.01 - 
2.14 (m, 6 H), 2.98 - 3.08 (m, 1 H), 3.31 (m, 1 H), 3.51 - 3.64 (m, 4 H), 3.64 - 3.82 (m, 
11 H), 3.82 - 3.96 (m, 5 H), 3.99 (dd, J=9.59, 2.54 Hz, 2 H), 4.09 (m, 3 H), 4.20 - 4.32 
(m, 2 H), 4.32 - 4.53 (m, 7 H), 4.56 - 4.71 (m, 8 H), 4.76 - 4.92 (m, 4 H), 5.03 (s, 2 H), 
5.12 (s, 1 H), 5.36 - 5.48 (m, 3 H), 5.58 (d, J=8.61 Hz, 2 H), 6.69 (d, J=9.00 Hz, 2 H), 
6.79 (d, J=8.61 Hz, 3 H), 6.94 (m,3 H), 7.01 (m, 3 H), 7.17 - 7.39 (m, 32 H), 7.67 (br. s., 
4 H); δC (125 MHz, CDCl3) 12.0, 17.9, 18.0, 21.0, 21.0, 24.6, 55.6, 61.6, 62.1, 67.9, 68.8, 
69.3, 71.3, 71.8, 72.0, 72.8, 73.2, 73.4, 73.5, 74.1, 74.4, 74.5, 74.6, 74.8, 75.2, 75.4, 76.7, 
77.0, 77.3, 77.8, 77.9, 78.7, 97.6, 98.2, 100.2, 101.2, 114.4, 115.3, 118.6, 123.4, 127.4, 
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127.5, 127.5, 127.8, 127.9, 128.0, 128.1, 128.2, 128.2, 128.2, 128.3, 128.5, 133.6, 133.8, 
137.8, 137.8, 138.2, 138.3, 138.5, 138.6, 138.9, 150.8,169.6, 170.1. 






A solution of A solution of p-methoxyphenyl 2-O-acetyl-4,6-O-benzylidene-β-D-
mannopyranosyl-(1→4)-3,6 di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
2.21 (0.22 g, 0.25 mmol), and 3.18 (0.32 g, 0.29 mmol) in DCM (10 mL) was added to a 
flame-dried round bottom flask containing 3Å molecular sieves (0.5 g). The solution was 
cooled to -20 °C under an atmosphere of nitrogen, stirred for 30 min and NIS (0.07 g, 
0.30 mmol) was added. After 10 min, triflic acid (2.6 µL, 0.03 mmol) was added. After a 
further 30 min t.l.c. (petrol:ethyl acetate, 2:1) indicated the formation of a major product 
(Rf 0.5) and the complete consumption of alcohol starting material 2.21 (Rf 0.3). 
Triethylamine (0.1 mL) was added and the reaction mixture stirred for 10 min before 
being filtered through Celite
®
. The filtrate was diluted with DCM (10 mL) and washed 
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with sat.aqueous NaHCO3 (10 mL), brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (petrol: 
ethyl acetate, 2:1) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl-
-D-manno pyranosyl- (12)- 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(13)-2-O-
acetyl-4,6-O-benzylidene--D-mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido--D-glucopyranoside 3.19 (0.31 g, 65%) as a white foam. [α]D
20
 +2 (c, 1.0 in 
CHCl3); max (KBr disk) 1753, 1712 (s, C=O) cm
-1
; δH (400 MHz, CDCl3) 1.02-1.26 
(21H, m, 3 x CH(CH3)2), 2.09 (3H, s, CH3), 3.03-3.08 (1H, m, H-5b), 3.43-3.46 (1H, b, 
H-6b), 3.65-3.71 (5H, m, H-3b, H-5a, H-6c, H-6’c), 3.72 (3H, s, OCH3), 3.72-3.89 (13H, 
m, H-4b, H-6a, H-6’a, H-3c, H-4c, H-5c, H-3d, H-4d, H-5d, H-6d, H-6’d), 3.97- 4.17 
(5H, m, H-4a, H-6’b, H-2c, H-2d, H-3d), 4.28-4.34 (1H, m, H-3a), 4.40-4.68 (15H, m, H-
2a, 14 x PhCH2), 4.71 (1H, s, H-1c), 4.80-4.92 (4H, m, 4 x PhCH2), 5.17 (1H, s, H-1b), 
5.40 (1H, s, H-1d), 4.42-4.45( 1H, m, H-2b), 5.50 (1H, s, PhCH(O)), 5.61 (1H, d, J1,2 8.2 
Hz, H-1a), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-H), 6.88-6.95 (3H, m, 
3 x Ar-H), 7.02-7.04 (2H, m, 2 x Ar-H), 7.33-7.40 (40H, m, 40 x Ar-H), 7.68-7.80 (4H, 
m, 4 x Ar-H); δC (100 MHz, CDCl3) 12.0 (d, CH(CH3)2), 18.0 (q, CH(CH3)2), 21.1 (s, 
CH3), 55.6 (q, OCH3), 55.7 (d, C-2a), 62.5 (t, C-6c), 66.3 (d, C-5a), 66.5 (d, C-5b), 68.1 
(t, C-6a), 68.4 (t, C-6b), 69.5 (t, C-6d), 71.0 (d, C-2b), 71.4, 71.5, 72.0, 72.3, 73.0, 73.7, 
74.4 (8 x t, 8 x PhCH2), 72.8 (d, C-5d), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.4 (d, C-4d), 
74.5 (d, C-2c), 74.7 (d, C-4c), 75.1 (d, C-2d), 76.9 (d, C-3a), 78.5 (d, C-4a), 79.2 (d, C-
4b), 79.6 (d, C-2c), 80.2 (d, C-3d), 97.4 (d, C-1a), 97.7 (d, C-1d), 99.2 (d, C-1c), 99.7 (d, 
C-1b), 101.3 (d, PhCH(O)), 114.3, 118.6, 123.4, 127.2, 125.63, 127.2, 127.3, 127.4, 
127.4, 127.5, 127.5, 127.6, 127.7, 127.7, 127.8, 127.9, 128.0, 128.1, 128.1, 128.2, 128.3, 
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128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 128.8, 129.4, 129.6, 131.6, 133.8 (32 x d, 54 x 
Ar-C), 136.9, 137.1, 137.9, 138.0, 138.1, 138.4, 138.5, 138.6, 138.6, 138.8, 139.1 (11 x s, 
12 x Ar-C), 151.0, 155.5, 169.6 (3 x s, 3 x C=O); HRMS (ES
+
) Calculated For 
C113H125NO24Si (MH
+








A solution of p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno 
pyranosyl- (12)- 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(13)-2-O-acetyl-4,6-O-
benzylidene--D-mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido--D-
glucopyranoside 3.19 (0.37 g, 0.20 mmol) in DCM (5 mL) was added to a flame-dried 
round bottom flask containing 3Å molecular sieves (1.0 g). The solution was stirred for 
30 min under an atmosphere of nitrogen, and then cooled to -78 °C. Triethylsilane (0.14 
mL, 0.86 mmol) and dichlorophenyl borane (90 µL, 0.67 mmol) were added and the 
reaction mixture was stirred at -78 °C. After 30 min, t.l.c. (petrol: ethyl acetate, 2:1) 
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showed the formation of a single product (Rf 0.3) and the consumption of starting 
material (Rf 0.5). Triethylamine (5 mL) and methanol (5 mL) were added, and the 
reaction mixture diluted with DCM (20 mL), washed with aqueous sodium hydrogen 
carbonate (2 x 10 mL of a saturated solution), dried (Na2SO4), filtered, and concentrated 
in vacuo. The residue was evaporated with methanol five times at 50 
o
C before being 




3.20 (0.29 g, 78%) as a white foam. [α]D
20
 +3.5 (c, 1.0 in CHCl3); max (KBr disk) 1747, 
1715, 1634 (s, C=O) cm
-1
; δH (400 MHz, CDCl3) 1.02-1.26 (21H, m, 3 x CH(CH3)2), 
2.09 (3H, s, CH3), 3.03-3.08 (1H, m, H-5b), 3.43-3.46 (1H, b, H-6b), 3.65-3.71 (5H, m, 
H-3b, H-5a, H-6c, H-6’c), 3.72 (3H, s, OCH3), 3.72-3.89 (13H, m, H-4b, H-6a, H-6’a, H-
3c, H-4c, H-5c, H-3d, H-4d, H-5d, H-6d, H-6’d), 3.97- 4.17 (5H, m, H-4a, H-6’b, H-2c, 
H-2d, H-3d), 4.28-4.34 (1H, m, H-3a), 4.40-4.68 (15H, m, H-2a, 14 x PhCH2), 4.71 (1H, 
s, H-1c), 4.80-4.92 (4H, m, 4 x PhCH2), 5.17 (1H, s, H-1b), 5.40 (1H, s, H-1d), 5.42-
5.45( 1H, m, H-2b), 5.50 (1H, s, PhCH(O)), 5.61 (1H, d, J1,2 8.2 Hz, H-1a), 6.69-6.72 
(2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-H), 6.88-6.95 (3H, m, 3 x Ar-H), 7.02-7.04 
(2H, m, 2 x Ar-H), 7.33-7.40 (40H, m, 40 x Ar-H), 7.68-7.80 (4H, m, 4 x Ar-H); δC (100 
MHz, CDCl3) 12.0 (d, CH(CH3)2), 18.0 (q, CH(CH3)2), 21.1 (s, CH3), 55.6 (q, OCH3), 
55.7 (d, C-2a), 62.5 (t, C-6c), 66.3 (d, C-5a), 66.5 (d, C-5b), 68.1 (t, C-6a), 68.4 (t, C-6b), 
69.5 (t, C-6d), 71.0 (d, C-2b), 71.4, 71.5, 71.7, 72.0, 72.3, 73.0, 73.7, 74.1, 74.4 (9 x t, 9 
x PhCH2), 72.8 (d, C-5d), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.4 (d, C-4d), 74.5 (d, C-2c), 
Chapter 5  Experimental 
181 
 
74.7 (d, C-4c), 75.1 (d, C-2d), 76.9 (d, C-3a), 78.5 (d, C-4a), 79.2 (d, C-4b), 79.6 (d, C-
2c), 80.2 (d, C-3d), 97.6 (d, C-1a), 98.2 (d, C-1d), 98.5 (d, C-1c), 101.4 (d, C-1b), 114.3, 
118.6, 123.2, 123.3, 123.4, 127.2, 127.3, 127.4, 127.4, 127.5, 127.5, 127.6, 127.7, 127.7, 
127.8, 127.9, 128.0, 128.1, 128.1, 128.2, 128.3, 128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 
128.8, 129.4, 129.6, 131.6, 133.8 (32 x d, 54 x Ar-C), 136.9, 137.1, 137.9, 138.0, 138.1, 
138.4, 138.5, 138.6, 138.6, 138.8, 139.1 (11 x s, 12 x Ar-C), 151.0, 155.5, 169.6 (3 x s, 3 
x C=O); HRMS (ES
+
) Calculated For C113H128NO24Si (MH
+




p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- 
(12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-








A solution of p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-
mannopyranosyl-(12)- 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(13)-2-O-acetyl-4-
O-benzyl--D-mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido--D-
glucopyranoside 3.20 (0.15 g, 0.08 mmol), and 3.18 (0.17 g, 0.16 mmol) in DCM (10 
mL) was added to a flame-dried round bottom flask containing 3Å molecular sieves (0.3 
g). The solution was cooled to -20 °C under an atmosphere of nitrogen, stirred for 30 min 
and NIS (0.04 g, 0.19 mmol) was added. After 10 min, triflic acid (1.0 µL, 0.01mmol) 
was added. After a further 30 min t.l.c. (petrol: ethyl acetate, 2:1) indicated the formation 
of a major product (Rf 0.6) and the complete consumption of alcohol starting material 
3.20 (Rf 0.3). Triethylamine (0.1 mL) was added and the reaction mixture stirred for 10 
min before being filtered through Celite
®
. The filtrate was diluted with DCM (10 mL) 
and washed with sat.aqueous NaHCO3 (10 mL), brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol:ethyl acetate, 2:1) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl-
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6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-
mannopyranosyl-(16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl-6-O-tri-iso-
propylsilyl--D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl-
(13)]--D-mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido--D-
glucopyranoside 3.2 (0.24 g, 72%) as a white foam. [α]D
20
 +11 (c, 1.0 in CHCl3); max 
(KBr disk) 1716, 1635 (s, C=O) cm
-1
; δH (400 MHz, CDCl3) 1.02-1.10 (42H, m, 6 x 
CH(CH3)2), 2.09 (3H, s, CH3), 3.24-3.29 (1H, m, H-5b), 3.40-3.43 (1H, m, H-6b), 3.49-
4.19 (31H, m, H-4a, H-5a, H-6a, H-6’a, H-3b, H-4b, H-6’b, H-2c, H-3c, H-4c, H-5c, H-
6c, H-6’c, H-2d, H-3d, H-4d, H-5d, H-6d, H-6’d, H-2c’, H-3c’, H4c’, H5c’, H-6c’, H-
6’c’, H-2d’, H-3d’, H-4d’, H-5d’, H-6d’, H-6’d’), 3.72 (3H, s, OCH3), 4.23-4.29 (1H, m, 
H-3a), 4.30-4.57 (20H, m, H-2a, 19 x PhCH2), 4.61- 4.69 (5H, m, 5 x PhCH2) 4.71-4.82 
(6H, m, H-1c, H-1c’, 4 x PhCH2), 4.86-4.92 (2H, m, 2 x PhCH2), 5.03(1H, s, H-1b), 5.10 
(1H, s, H-1d’), 5.21 (1H, s, H-1d), 5.42-5.45( 1H, m, H-2b), 5.50 (1H, d, J1,2 8.2 Hz, H-
1a), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-H), 6.88-6.95 (3H, m, 3 x Ar-
H), 7.02-7.04 (2H, m, 2 x Ar-H), 7.33-7.40 (70H, m, 70 x Ar-H), 7.68-7.80 (4H, m, 4 x 
Ar-H); δC (100 MHz, CDCl3) 12.0 (d, CH(CH3)2), 18.0 (q, CH(CH3)2), 21.1 (s, CH3), 
55.6 (q, OCH3), 55.7 (d, C-2a), 62.5 (t, C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 68.1 (d, C-
5b), 69.1 (t, C-6a), 69.2 (t, C-6b), 69.3 (t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-2b), 71.4, 
71.5, 71.8, 71.9, 72.0, 72.1, 72.2, 72.3, 72.3, 73.0, 73.7, 74.3, 74.5, 74.6, 74.7 (15 x t, 15 
x PhCH2), 72.8 (d, C-5d), 73.1 (d, C-5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 (d, C-5c’), 
74.4 (d, C-4d), 74.5 (d, C-4d’), 74.5 (d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 74.8 (d, C-
4c’), 75.1 (d, C-2d), 76.3 (d, C-2d’), 76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-4b), 79.7 
(d, C-2c), 80.0 (d, C-2c’), 80.1 (d, C-3d), 80.2 (d, C-3d’), 97.4 (d, C-1a), 98.2 (d, C-1d), 
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98.6 (d, C-1d’), 99.0 (d, C-1c), 99.6 (d, C-1c’), 101.6 (d, C-1b), 114.3, 118.6, 126.7, 
126.8, 126.9, 127.0, 127.1, 127.1, 127.2, 127.2, 127.3, 127.3, 127.3, 127.4, 127.4, 127.4, 
127.5, 127,5, 127.6, 127.6, 127.7, 127.7, 127.7, 127.8, 127.8, 127.8, 127.9, 127.9, 127.9, 
128.0, 128.1, 128.1, 128.2, 128.2, 128.2, 128.2, 128.3, 128.3, 128.3, 128.4, 128.4, 128.5, 
128.5, 128.5, 128.6, 128.8, 129.4, 129.6, 131.6, 133.8 (50 x d, 84 x Ar-C), 136.9, 137.1, 
137.9, 138.0, 138.0, 138.1, 138.2, 138.2, 138.3, 138.4, 138.5, 138.6, 138.6, 138.7, 138.8, 
139.0, 139.1 (17 x s, 18 x Ar-C), 151.0, 155.2, 169.6 (3 x s, 3 x C=O).  





coupling constants from C-coupled HSQC experiments. They were as follows: C(1a)- 
H(1a) 168 Hz; C(1b)-H(1b) 162 Hz; C(1c)-H(1c) 173 Hz; C(1d)-H(1d) 175 Hz; C(1c’)-
H(1c’) 172 Hz; C(1d’)-H(1d’) 174 Hz. 
 
p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- 
(12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-
[2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6- tri-
O-benzyl-α-D-mannopyranosyl-(13)]--D-mannopyranosyl-(14)-2-acetamido-
3,6-di-O-benzyl-2-deoxy --D-glucopyranoside 3.21 




p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- 
(12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl-(16)-2-O-acetyl-4-O-benzyl-[2,3,4-
tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-
D-mannopyranosyl-(13)]--D-mannopyranosyl-(14)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido--D-glucopyranoside 3.2 (0.08 g, 0.03 mmol) was dissolved in a mixture of 
methanol (4 mL) and ethylene diamine (2 mL), and the solution was refluxed under an 
atmosphere of nitrogen. After 16 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated the 
formation of a single product (Rf 0.25) and the complete consumption of starting 
material (Rf 0.60). The reaction mixture was concentrated in vacuo and co-distilled five 
times with toluene (5 mL). The residue was dissolved in pyridine (2 mL), cooled to 0
o
C 
and acetic anhydride (0.7 mL) was added. The reaction mixture was then stirred at rt 
under an atmosphere of nitrogen. After 20 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated the 
formation of a single product (Rf 0.35) and the complete consumption of amine 
intermediate (Rf 0.25). The reaction mixture was concentrated in vacuo, the residue 
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dissolved in DCM (10 mL), washed with water (10 mL), sodium hydrogen carbonate (2 x 
10 mL of a saturated aqueous solution), dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (petrol: ethyl acetate, 
2:1) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno 
pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-
benzyl-[2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6- 
tri-O-benzyl-α-D-mannopyranosyl-(13)]--D-mannopyranosyl-(14)-2-acetamido-3,6-
di-O-benzyl-2-deoxy --D-glucopyranoside 3.21 (0.06 g, 71%) as a pale yellow foam. 
[α]D
20
 +9 (c, 1.0 in CHCl3); max (KBr disk) 1716, 1635 (s, C=O) cm
-1
; δH (400 MHz, 
CDCl3) 1.01-1.10 (42H, m, 6  CH(CH3)2), 1.45 (3H, s, COCH3), 1.85 (3H, s, CH3), 
3.21-3.27 (1H, m, H-5b), 3.32-3.43 (1H, m, H-6b), 3.49-4.19 (31H, m, H-4a, H-5a, H-6a, 
H-6’a, H-3b, H-4b, H-6’b, H-2c, H-3c, H-4c, H-5c, H-6c, H-6’c, H-2d, H-3d, H-4d, H-
5d, H-6d, H-6’d, H-2c’, H-3c’, H4c’, H5c’, H-6c’, H-6’c’, H-2d’, H-3d’, H-4d’, H-5d’, 
H-6d’, H-6’d’), 3.72 (3H, s, OCH3), 4.23-4.29 (1H, m, H-3a), 4.30-4.57 (20H, m, H-2a, 
19 x PhCH2), 4.61- 4.69 (5H, m, 5 x PhCH2) 4.71-4.82 (6H, m, H-1c, H-1c’, 4 x PhCH2), 
4.86-4.92 (2H, m, 2 x PhCH2), 5.14 (1H, s, H-1b), 5.20 (1H, s, H-1d’), 5.24 (1H, s, H-
1d), 5.42-5.45 (2H, m, H-1a, H-2b), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x 
Ar-H), 7.10-7.37 (75H, m, 70 x Ar-H); δC (100 MHz, CDCl3) 12.0 (d, CH(CH3)2), 18.0 
(q, CH(CH3)2), 21.1 (s, CH3), 23.4 (s, COCH3), 55.6 (q, OCH3), 55.7 (d, C-2a), 62.5 (t, 
C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 68.1 (d, C-5b), 69.1 (t, C-6a), 69.2 (t, C-6b), 69.3 
(t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-2b), 71.4, 71.5, 71.8, 71.9, 72.0, 72.1, 72.2, 72.3, 
72.3, 73.0, 73.7, 74.3, 74.5, 74.6, 74.7 (15 x t, 15 x PhCH2), 72.8 (d, C-5d), 73.1 (d, C-
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5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 (d, C-5c’), 74.4 (d, C-4d), 74.5 (d, C-4d’), 74.5 
(d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 74.8 (d, C-4c’), 75.1 (d, C-2d), 76.3 (d, C-2d’), 
76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-4b), 79.7 (d, C-2c), 80.0 (d, C-2c’), 80.1 (d, C-
3d), 81.4 (d, C-3d’), 96.7 (d, C-1a), 98.2 (d, C-1d), 98.4 (d, C-1d’), 98.6 (d, C-1c), 98.7 
(d, C-1c’), 101.5 (d, C-1b), 114.3, 118.6, 126.9, 127.0, 127.1, 127.1, 127.2, 127.2, 127.3, 
127.3, 127.3, 127.4, 127.4, 127.4, 127.5, 127,5, 127.6, 127.6, 127.7, 127.7, 127.7, 127.8, 
127.8, 127.8, 127.9, 127.9, 127.9, 128.0, 128.1, 128.1, 128.2, 128.2, 128.2, 128.2, 128.3, 
128.3, 128.3, 128.4, 128.4, 128.5, 128.5, 128.5, 128.6, 128.8, 129.4, 129.6, 131.6, 133.8 
(48 x d, 80 x Ar-C), 137.4, 138.0, 138.1, 138.3, 138.4, 138.5, 138.5, 138.6, 138.7, 138.8, 
138.9, 139.0, 139.1, 139.2, 151.6, 155.1 (16 x s, 16 x Ar-C), 169.6, 170.5 (2 x s, 2 x 
C=O); HRMS (ES
+
) Calculated For C170H204NO33Si2 (MH
+




p-Methoxyphenyl 2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-
benzyl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl --D-









p-Methoxyphenyl 2,3,4-tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- 
(12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-
tri-O-benzyl-6-O-tri-iso-propylsilyl--D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-
D-mannopyranosyl-(13)]--D-mannopyranosyl-(14)-2-acetamido-3,6-di-O-benzyl-2-
deoxy --D-glucopyranoside 3.21 (50 mg, 0.02 mmol) was dissolved in anhydrous DCM 
(5 mL) under an atmosphere of nitrogen in a flame-dried flask. The solution was cooled 
to 0 
o
C, and boron trifluoride diethyl etherate (22 μL, 0.18 mmol) was added dropwise. 
The reaction was stirred at 0 
o
C for 1 h, after which time t.l.c. (petrol: ethyl acetate, 1:1) 
indicated the complete consumption of starting material (Rf 0.5) and the formation of a 
single product (Rf 0.3). The reaction mixture was diluted with DCM (10 mL), washed 
with sodium hydrogen carbonate (10 mL of a saturated aqueous solution), dried 
(Na2SO4), filtered, and concentrated in vacuo. The residue was purified by flash column 
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chromatography (petrol:ethyl acetate, 1:1) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl 
--D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (16)-2-O-
acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-
benzyl-α-D-mannopyranosyl- (13)]--D-mannopyranosyl-(14)-2-acetamido-3,6-di-
O-benzyl-2-deoxy --D-glucopyranoside 3.22 (30 mg, 68%) as a white foam. [α]D
20
 +15 
(c, 1.0 in CHCl3); νmax (KBr disk) 3428 (s, N-H stretch), 1746, 1739 (s, C=O) cm
-1
; δH 
(400 MHz, CDCl3) 1.60 (3H, s, COCH3), 1.94 (3H, s, CH3), 3.17-3.20 (1H, m, H-5b), 
3.24-3.31 (1H, m, H-6b), 3.49-4.11 (31H, m, H-4a, H-5a, H-6a, H-6’a, H-3b, H-4b, H-
6’b, H-2c, H-3c, H-4c, H-5c, H-6c, H-6’c, H-2d, H-3d, H-4d, H-5d, H-6d, H-6’d, H-2c’, 
H-3c’, H-4c’, H-5c’, H-6c’, H-6’c’, H-2d’, H-3d’, H-4d’, H-5d’, H-6d’, H-6’d’), 3.72 
(3H, s, OCH3), 4.23-4.29 (1H, m, H-3a), 4.21-4.65 (25H, m, H-2a, 24 x PhCH2), 4.67 
(1H, s, H-1c’) 4.76- 4.89 (6H, m, 6 x PhCH2), 4.77-4.89 (6H, m, 6 x PhCH2), 4.95 (1H, s, 
H-1c), 5.01(1H, s, H-1d’), 5.04 (1H, s, H-1d), 5.16 (1H, s, H-1b), 5.31( 1H, d, J1,2 8.0 Hz, 
H-1a), 5.38-5.40 (1H, m, H-2b), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-
H), 7.10-7.37 (75H, m, 70 x Ar-H); δC (100 MHz, CDCl3) 21.0 (s, CH3), 23.2 (s, 
COCH3), 55.6 (q, OCH3), 55.7 (d, C-2a), 62.5 (t, C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 
68.1 (d, C-5b), 69.1 (t, C-6a), 69.2 (t, C-6b), 69.3 (t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-
2b), 71.4, 71.5, 71.8, 71.9, 72.0, 72.1, 72.2, 72.3, 72.3, 73.0, 73.7, 74.3, 74.5, 74.6, 74.7 
(15 x t, 15 x PhCH2), 72.8 (d, C-5d), 73.1 (d, C-5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 
(d, C-5c’), 74.4 (d, C-4d), 74.5 (d, C-4d’), 74.5 (d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 
74.8 (d, C-4c’), 75.1 (d, C-2d), 76.3 (d, C-2d’), 76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-
4b), 79.7 (d, C-2c), 80.0 (d, C-2c’), 80.1 (d, C-3d), 81.4 (d, C-3d’), 97.1 (d, C-1a), 98.7 
(d, C-1d), 98.8 (d, C-1d’), 99.8 (d, C-1c), 100.0 (d, C-1c’), 101.5 (d, C-1b), 114.3, 118.6, 
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126.9, 127.0, 127.1, 127.1, 127.2, 127.2, 127.3, 127.3, 127.3, 127.4, 127.4, 127.4, 127.5, 
127,5, 127.6, 127.6, 127.7, 127.7, 127.7, 127.8, 127.8, 127.8, 127.9, 127.9, 127.9, 128.0, 
128.1, 128.1, 128.2, 128.2, 128.2, 128.2, 128.3, 128.3, 128.3, 128.4, 128.4, 128.5, 128.5, 
128.5, 128.6, 128.8, 129.4, 129.6, 131.6, 133.8 (48 x d, 80 x Ar-C), 137.4, 138.0, 138.1, 
138.3, 138.4, 138.5, 138.5, 138.6, 138.7, 138.8, 138.9, 139.0, 139.1, 139.2, 151.6, 155.1 
(16 x s, 16 x Ar-C), 169.6, 170.5 (2 x s, 2 x C=O); HRMS (ES
+
) Calculated For 
C152H164NO33 (MH
+




p-Methoxyphenyl 2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-
benzyl -6-O-dibenzyloxyphosphoryl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-
benzyl-[2,3,4-tri-O-benzyl -6-O-dibenzyloxyphosphoryl --D-manno pyranosyl- 
(12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (13)]--D-mannopyranosyl-
(14)-2-acetamido-3,6-di-O-benzyl-2-deoxy --D-glucopyranoside 3.23 
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p-Methoxyphenyl 2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-
α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl --D-manno 
pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-mannopyranosyl- (13)]--D-
mannopyranosyl-(14)-2-acetamido-3,6-di-O-benzyl-2-deoxy --D-glucopyranoside 
3.22 (13 mg, 0.005 mmol) and 1H-tetrazole (0.08 mL of a 0.45 M solution in 
acetonitrile) were added to a flame-dried flask and dissolved in DCM (0. 50 mL). The 
solution was stirred at rt 1h under nitrogen atmosphere. Dibenzyl N, N-diisopripyl 
phosphoramidate (0.014 mL, 0.042 mmol) was added, and the reaction stirred for 18 h. 
After this time t.l.c. (MeOH:DCM, 1:50) indicated complete consumption of alcohol 
starting material (Rf 0.30) and formation of a major product (Rf 0.60). The reaction 
mixture was cooled to -78 
o
C and m-chloroperbenzoic acid (0.01 g, 0.02 mmol) was 
added. The mixture was stirred for 2 h and then warmed to rt, after which time t.l.c. 
(MeOH:DCM, 1:50) indicated complete consumption of the phosphine intermediate (Rf 
0.60) and formation of a major product (Rf 0.25). The reaction was quenched by addition 
of sodium bisulfite (5 mL of a 10% w/v aqueous solution), stirred for 10 min, and 
extracted with DCM (10 mL). The organic extracts were washed with sodium hydrogen 
carbonate (5 mL of a saturated aqueous solution) and brine (5 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (MeOH:DCM, 1:50) to afford p-Methoxyphenyl 2,3,4-tri-O-benzyl --
D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl -6-O-dibenzyloxyphosphoryl-α-D-
mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl -6-O-
dibenzyloxyphosphoryl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-




deoxy --D-glucopyranoside 3.23 (0.015 g, 94% over two steps) as a white foam. [α]D 
20
 
+12 (c, 1.0 in CHCl3); νmax (KBr disk) 3430 (s, N-H stretch), 1744, 1740 (s, C=O) cm
-1
; 
δH (400 MHz, CDCl3) 1.60 (3H, s, COCH3), 1.96 (3H, s, CH3), 3.36-3.48 (2H, m, H-5b, 
H-6b), 3.60-4.15 (31H, m, H-4a, H-5a, H-6a, H-6’a, H-3b, H-4b, H-6’b, H-2c, H-3c, H-
4c, H-5c, H-6c, H-6’c, H-2d, H-3d, H-4d, H-5d, H-6d, H-6’d, H-2c’, H-3c’, H4c’, H5c’, 
H-6c’, H-6’c’, H-2d’, H-3d’, H-4d’, H-5d’, H-6d’, H-6’d’), 3.72 (3H, s, OCH3), 4.23-
4.29 (1H, m, H-3a), 4.21-4.62 (16H, m, H-2a, 16 x PhCH2), 4.01-5.04 (20H, m, H-1c, H-
1c’, H-1d, H-1d’, 16 x PhCH2), 5.32 (1H, s, H-1b), 5.36( 1H, d, J1,2 8.0 Hz, H-1a), 5.58-
5.59 (1H, m, H-2b), 6.69-6.72 (2H, m, 2 x Ar-H), 6.79-6.83 (2H, m, 2 x Ar-H), 7.10-7.37 
(95H, m, 70 x Ar-H); δC (100 MHz, CDCl3) 21.0 (s, CH3), 23.2 (s, COCH3), 55.6 (q, 
OCH3), 55.7 (d, C-2a), 62.5 (t, C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 68.1 (d, C-5b), 69.1 
(t, C-6a), 69.2 (t, C-6b), 69.3 (t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-2b), 71.4, 71.5, 71.8, 
71.9, 72.0, 72.1, 72.2, 72.3, 72.3, 73.0, 73.7, 74.3, 74.5, 74.6, 74.7 (15 x t, 15 x PhCH2), 
72.8 (d, C-5d), 73.1 (d, C-5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 (d, C-5c’), 74.4 (d, C-
4d), 74.5 (d, C-4d’), 74.5 (d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 74.8 (d, C-4c’), 75.1 
(d, C-2d), 76.3 (d, C-2d’), 76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-4b), 79.7 (d, C-2c), 
80.0 (d, C-2c’), 80.1 (d, C-3d), 81.4 (d, C-3d’), 97.1 (d, C-1a), 98.7 (d, C-1d), 99.1 (d, C-
1d’), 99.3 (d, C-1c), 99.8 (d, C-1c’), 101.2 (d, C-1b), 114.3, 118.6, 126.8, 126.9, 126.9,  
127.0, 127.1, 127.1, 127.2, 127.2, 127.2, 127.2, 127.3, 127.3, 127.3, 127.4, 127.4, 127.4, 
127.5, 127.5, 127.5, 127.5, 127.6, 127.6, 127.6, 127.6, 127.6, 127.7, 127.7, 127.7, 127.8, 
127.8, 127.8, 127.9, 127.9, 127.9, 127.9, 127.9, 128.0, 128.0, 128.0, 128.1, 128.1, 128.2, 
128.2, 128.2, 128.3, 128.3, 128.3, 128.3, 128.3, 128.4, 128.4, 128.4, 128.5, 128.5, 128.5, 
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128.6, 128.6 (59 x d, 100 x Ar-C), 135.7, 135.8, 135.8, 135.9, 135.9, 135.9, 138.0, 138.1, 
138.2, 138.2, 138.3, 138.3, 138.4, 138.5, 138.6, 138.7, 138.8, 139.0, 139.2, 151.7, 154.9 
(21 x s, 21 x Ar-C), 169.6, 170.5 (2 x s, 2 x C=O); δP (162 MHz, CDCl3) -1.25, -1.54; 
HRMS (ES
+
) Calculated For C180H191NO39P2 (M+2H)
2+




2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl -6-O-
dibenzyloxyphosphoryl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-
tri-O-benzyl -6-O-dibenzyloxyphosphoryl --D-manno pyranosyl- (12)- 3,4,6- tri-
O-benzyl-α-D-mannopyranosyl- (13)]--D-mannopyranosyl-(14)-2-acetamido-
3,6-di-O-benzyl-2-deoxy --D-glucopyranoside 3.24 
 
p-Methoxyphenyl 2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl -
6-O-dibenzyloxyphosphoryl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-
tri-O-benzyl -6-O-dibenzyloxyphosphoryl --D-manno pyranosyl- (12)- 3,4,6- tri-O-




O-benzyl-2-deoxy --D-glucopyranoside 3.23 (15 mg, 0.005 mmol) was suspended in a 
mixture of acetonitrile (0.8 mL) and water (0.21 mL). Ceric ammonium nitrate (14 mg, 
0.025 mmol) was added, and the reaction mixture stirred at rt. After 1 h, t.l.c. 
(MeOH:DCM, 1:50) indicated complete consumption of starting material (Rf 0.25) and 
formation of a single product (Rf 0.15). The reaction mixture was diluted with DCM (10 
mL) and washed with sodium hydrogen carbonate (2 x 5 mL of a saturated aqueous 
solution), sodium thiosulfate (2 x 5 mL of a 5% w/v aqueous solution), EDTA (2 x 5 mL 
of a 0.1 M aqueous solution) and water (5 mL). The organic extracts were dried 
(Na2SO4), filtered, concentrated in vacuo, and the residue purified by flash column 
chromatography (MeOH:DCM, 1:50) to afford 2,3,4-tri-O-benzyl --D-manno 
pyranosyl- (12)- 3,4,6- tri-O-benzyl -6-O-dibenzyloxyphosphoryl-α-D-
mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-O-benzyl -6-O-
dibenzyloxyphosphoryl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl-α-D-
mannopyranosyl- (13)]--D-mannopyranosyl-(14)-2-acetamido-3,6-di-O-benzyl-2-
deoxy --D-glucopyranoside 3.24 (11.6 mg, 80%) as a pale yellow foam. νmax (KBr disk) 
3430 (s, N-H stretch), 1740, 1735 (s, C=O) cm
-1
; δH (400 MHz, CDCl3) 1.65 (3H, s, 
COCH3), 1.97 (3H, s, CH3), 3.21-4.15 (33H, m, H-5b, H-6b, H-4a, H-5a, H-6a, H-6’a, H-
3b, H-4b, H-6’b, H-2c, H-3c, H-4c, H-5c, H-6c, H-6’c, H-2d, H-3d, H-4d, H-5d, H-6d, 
H-6’d, H-2c’, H-3c’, H4c’, H5c’, H-6c’, H-6’c’, H-2d’, H-3d’, H-4d’, H-5d’, H-6d’, H-
6’d’), 3.72 (3H, s, OCH3), 4.23-4.29 (1H, m, H-3a), 4.21-4.62 (16H, m, H-2a, 16 x 
PhCH2), 4.01-5.04 (21H, m, H-1a, H-1c, H-1c’, H-1d, H-1d’, 16 x PhCH2), 5.27 (1H, s, 
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H-1b), 5.53 (1H, brs, H-2b), 7.10-7.37 (95H, m, 70 x Ar-H) δC (100 MHz, CDCl3) 21.0 
(s, CH3), 23.2 (s, COCH3), 55.7 (d, C-2a), 62.5 (t, C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 
68.1 (d, C-5b), 69.1 (t, C-6a), 69.2 (t, C-6b), 69.3 (t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-
2b), 71.4, 71.5, 71.8, 71.9, 72.0, 72.1, 72.2, 72.3, 72.3, 73.0, 73.7, 74.3, 74.5, 74.6, 74.7 
(15 x t, 15 x PhCH2), 72.8 (d, C-5d), 73.1 (d, C-5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 
(d, C-5c’), 74.4 (d, C-4d), 74.5 (d, C-4d’), 74.5 (d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 
74.8 (d, C-4c’), 75.1 (d, C-2d), 76.3 (d, C-2d’), 76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-
4b), 79.7 (d, C-2c), 80.0 (d, C-2c’), 80.1 (d, C-3d), 81.4 (d, C-3d’), 96.8 (d, C-1a), 99.3 
(d, C-1d), 99.4 (d, C-1d’), 99.5 (d, C-1c), 99.6 (d, C-1c’), 101.2 (d, C-1b), 126.8, 126.9, 
126.9,  127.0, 127.1, 127.1, 127.2, 127.2, 127.2, 127.2, 127.3, 127.3, 127.3, 127.4, 127.4, 
127.4, 127.5, 127.5, 127.5, 127.5, 127.6, 127.6, 127.6, 127.6, 127.6, 127.7, 127.7, 127.7, 
127.8, 127.8, 127.8, 127.9, 127.9, 127.9, 127.9, 127.9, 128.0, 128.0, 128.0, 128.1, 128.1, 
128.2, 128.2, 128.2, 128.2, 128.3, 128.3, 128.3, 128.3, 128.3, 128.4, 128.4, 128.4, 128.5, 
128.5, 128.5, 128.6, 128.6 (57 x d, 95 x Ar-C), 135.7, 135.8, 135.8, 135.9, 135.9, 135.9, 
138.0, 138.1, 138.1, 138.2, 138.2, 138.3, 138.3, 138.4, 138.5, 138.6, 138.7, 138.8, 139.2 
(19 x s, 19 x Ar-C), 169.7, 171.3 (2 x s, 2 x C=O); δP (162 MHz, CDCl3) -1.37, -1.50 
HRMS (ES
+
) Calculated For C173H185NO38P2 [M+2H]
2+




6-O-Phosphate --D-manno pyranosyl- (12) - α-D-mannopyranosyl- (16)- [6-O-
Phosphate --D-manno pyranosyl- (12)-α-D-mannopyranosyl- (13)]--D-
mannopyranosyl-(14) )-2-acetamido-2-deoxy-D-glucopyranose 3.25 




2,3,4-tri-O-benzyl --D-manno pyranosyl- (12)- 3,4,6- tri-O-benzyl -6-O-
dibenzyloxyphosphoryl-α-D-mannopyranosyl- (16)-2-O-acetyl-4-O-benzyl-[2,3,4-tri-
O-benzyl -6-O-dibenzyloxyphosphoryl --D-manno pyranosyl- (12)- 3,4,6- tri-O-
benzyl-α-D-mannopyranosyl- (13)]--D-mannopyranosyl-(14)-2-acetamido-3,6-di-
O-benzyl-2-deoxy --D-glucopyranoside 3.24 (30 mg, 0.01 mmol) in THF (20 mL) was 
added to NH3 (l) (20 mL) at -33° C. The minimum amount of sodium for the mixture to 
turn deep blue was added to the stirred mixture. After 30 min MeOH (4 mL) was added, 
and reaction mixture was stirred for a futher 1 h, warmed to rt, and the solvent was 
removed in vacuo.  Gel filtration of the crude residue on a Sephadex G-10 column 
(eluting with 0.01% NH3) afforded 6-O-Phosphate --D-manno pyranosyl- (12) - α-D-
mannopyranosyl- (16)- [6-O-Phosphate --D-manno pyranosyl- (12)-α-D-
mannopyranosyl- (13)]--D-mannopyranosyl-(14) )-2-acetamido-2-deoxy-D-
glucopyranose 3.25 (10.2 mg, 83%), as a white foam as a mixture of α:β anomers. δH 
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(400 MHz, CDCl3) 1.98 (3H, s, CH3), 3.11-4.19 (35H, m, H-5b, H-6b, H-4a, H-5a, H-6a, 
H-6’a, H-3b, H-4b, H-6’b, H-2c, H-3c, H-4c, H-5c, H-6c, H-6’c, H-2d, H-3d, H-4d, H-
5d, H-6d, H-6’d, H-2c’, H-3c’, H4c’, H5c’, H-6c’, H-6’c’, H-2d’, H-3d’, H-4d’, H-5d’, 
H-6d’, H-6’d’, H-3a, H-2a), 4.92-5.09 (5H, m, H-1a, H-1c, H-1c’, H-1d, H-1d’), 
5.13(1H, bs, H-1a), 5.31 (1H, brs, H-1b); δC (100 MHz, CDCl3) 23.2 (s, COCH3), 55.7 
(d, C-2a), 62.5 (t, C-6c), 62.9 (t, C-6c’), 67.1 (d, C-5a), 68.1 (d, C-5b), 69.1 (t, C-6a), 
69.2 (t, C-6b), 69.3 (t, C-6d), 69.4 ( t, C-6d’), 71.0 (d, C-2b), 72.8 (d, C-5d), 73.1 (d, C-
5d’), 73.2 (d, C-3b), 74.3 (d, C-5c), 74.3 (d, C-5c’), 74.4 (d, C-4d), 74.5 (d, C-4d’), 74.5 
(d, C-2c), 74.6 (d, C-2c’), 74.7 (d, C-4c), 74.8 (d, C-4c’), 75.1 (d, C-2d), 76.3 (d, C-2d’), 
76.9 (d, C-3a), 78.8 (d, C-4a), 79.6 (d, C-4b), 79.7 (d, C-2c), 80.0 (d, C-2c’), 80.1 (d, C-
3d), 81.4 (d, C-3d’), 96.7 (d, C-1a), 99.3 (d, C-1d), 99.4 (d, C-1d’), 99.5 (d, C-1c), 99.6 
(d, C-1c’), 101.2 (d, C-1b), 171.3 (s, C=O); δP (162 MHz, CDCl3) 3.91, 4.13; HRMS 
(ES
+
) Calculated For C38H68NO37P2 (MH
+




2-Methyl [6-O-Phosphate --D-manno pyranosyl- (12)- α-D-mannopyranosyl- 
(16)- [6-O-Phosphate --D-manno pyranosyl- (12)-α-D-mannopyranosyl- 
(13)]--D-mannopyranosyl-(14) )-2-acetamido-1,2-deoxy-D-glucopyrano]-[2,1-
d]-oxazoline 3.1 




6-O-Phosphate --D-manno pyranosyl- (12) - α-D-mannopyranosyl- (16)- [6-O-
Phosphate --D-manno pyranosyl- (12)-α-D-mannopyranosyl- (13)]--D-
mannopyranosyl-(14) )-2-acetamido-2-deoxy-D-glucopyranose 3.25 (4 mg, 0.0034 
mmol) and triethylamine (4.3 µL, 0.03 mmol) were dissolved in D2O (37 µL) and the 
resulting solution was cooled to 0 °C. DMC (1.7 mg, 0.01 mmol) was added to the 
solution and the mixture was stirred for 30 min at the same temperature. Gel filtration of 
the residue on a Sephadex G-10 column eluted with 0.01% NH3 afforded 2-Methyl [6-O-
Phosphate --D-manno pyranosyl- (12)- α-D-mannopyranosyl- (16)- [6-O-Phosphate 
--D-manno pyranosyl- (12)-α-D-mannopyranosyl- (13)]--D-mannopyranosyl-
(14) )-2-acetamido-1,2-deoxy-D-glucopyrano]-[2,1-d]-oxazoline 3.1 (1.8 mg, 95%) as 
a white foam. δH (400 MHz, CDCl3) 1.98 (3H, s, CH3), 3.11-4.19 (35H, m, H-5b, H-6b, 
H-4a, H-5a, H-6a, H-6’a, H-3b, H-4b, H-6’b, H-2c, H-3c, H-4c, H-5c, H-6c, H-6’c, H-
2d, H-3d, H-4d, H-5d, H-6d, H-6’d, H-2c’, H-3c’, H4c’, H5c’, H-6c’, H-6’c’, H-2d’, H-
3d’, H-4d’, H-5d’, H-6d’, H-6’d’, H-3a, H-2a), 4.92-5.09 (5H, m, H-1a, H-1c, H-1c’, H-
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1d, H-1d’), 5.31 (1H, brs, H-1b) 6.08 (1H, d, J1,2 7.3 Hz, H-1a); δP (162 MHz, CDCl3) 
4.46; HRMS (ES
+
) Calculated For C38H67NO37P2 [M-H2O+H]
+




5.4 Experimental for chapter 4 
General procedure for the enzymatic glycosylation of acceptor with oxazoline donor 
Endohexosaminidase-catalysed glycosylations were monitored by HPLC using a Dionex 
1 HPLC instrument using Chromeleon software connected to a Dionex 1 variable 
wavelength detector at 254 nm wavelength. Analytical HPLC (Jupitor 5 μ C-18 column, 
250 x 4.6 mm) was used to monitor the reactions, with 2 μL aliquots taken at appropriate 
time intervals. The column was eluted with 20% MeCN/H2O. The yield was determined 
by integration of the product and acceptor peaks. 
Glycosylation of the tetrasaccharide oxazoline donor 2.1 with Fmoc-Asn(GlcNAc)-
OH 4.1 with Endo A: 
 
A solution of the tetrasaccharide oxazoline 13 (0.762 mg, 0.9µmol) and Fmoc-
Asn(GlcNAc)-OH 14 (0.058 mg, 0.1µmol) was incubated with 2 mU of Endo A in 20 μL 
of sodium phosphate buffer (100 mM, pH 6.5) at 23 °C. After 2 h, RP-HPLC indicated 
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the formation of a new product, which was then purified directly by RP-HPLC to give 
15: (71%, HPLC yield based on acceptor) as a white powder (0.88 mg); analytical 
HPLC: tR = 9.71 min; ESI-MS: calculated for C53H77N4O36P2: 1408.3826. Found: 
1408.3880 (M+H)
+
; C53H76N4NaO36P2: 1430.3646. Found: 1429.3683 (M+Na). 
Glycosylation of the hexasaccharide oxazoline donor 3.1 with Fmoc-Asn(GlcNAc)-
OH 4.1 with Endo A: 
 
A solution of the hexasaccharide oxazoline 3.1 (0.34 mg, 0.30µmol) and Fmoc-
Asn(GlcNAc)-OH 4.1 (0.06 mg, 0.10 µmol) was incubated with 1µg of Endo-A in 20 μL 
of sodium phosphate buffer (100 mM, pH 6.5) at 37 °C. After 2 h, RP-HPLC indicated 
the formation of a new product, which was then purified directly by RP-HPLC to give 
4.3 (12%, HPLC yield based on acceptor); tR = 10.6 min; ESI-MS: calculated for 
C50H87N4O44P2 (M-Fmoc+H)
+ 
: 1507.4932. Found: 1507.4993 (M-Fmoc+H)
+
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Glycosylation of the hexasaccharide oxazoline donor with Fmoc-Asn(GlcNAc)-OH 
using WT Endo M: 
A solution of the hexasaccharide oxazoline 3.1 (0.66 mg, 0.50µmol) and Fmoc-
Asn(GlcNAc)-OH 4.1 (0.06 mg, 0.10 µmol) was incubated with 1µg of WT Endo-M in 
20 μL of sodium phosphate buffer (100 mM, pH 6.5) at 37 °C. After 2 h, RP-HPLC 
indicated the formation of a new product, which was then purified directly by RP-HPLC 
to give 4.3 (6%, HPLC yield based on acceptor); tR = 10.6 min; ESI-MS: calculated for 
C50H87N4O44P2 (M-Fmoc+H)
+ 
: 1509.42. Found: 1509.42(M-Fmoc+H)
+
 
Glycosylation of the hexasaccharide oxazoline donor with Fmoc-Asn(GlcNAc)-OH 
using the N175Q Endo M mutant: 
A solution of the hexasaccharide oxazoline 3.1 (0.66 mg, 0.50µmol) and Fmoc-
Asn(GlcNAc)-OH 4.1 (0.06 mg, 0.10 µmol) was incubated with 1µg of Endo M N175Q 
in 20 μL of sodium phosphate buffer (100 mM, pH 6.5) at 37 °C. After 2 h, RP-HPLC 
indicated the formation of a new product, which was then purified directly by RP-HPLC 
to give 4.3 (8%, HPLC yield based on acceptor); tR = 10.6 min; ESI-MS: calculated for 
C50H87N4O44P2 (M-Fmoc+H)
+
: 1509.42. Found: 1509.42 (M-Fmoc+H)
+
. 
Glycosylation of dRNase B 4.4 with 2.1 
A solution of the tetrasaccharide oxazoline 2.1 (0.229 mg, 0.27µmol) and dRNase B 4.4 
(0.348 mg, 0.03µmol) was incubated with 2 mU of Endo-A in 20 μL of sodium 
phosphate buffer (100 mM, pH 6.5) at 23 °C for 2h to give (M6P)2RNase 4.5. 
C34H61N2O32P2-RNAse B: 14735.4633. Found: 14735.4688 (M+H)
 +
. 
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Glycosylation of dRNase B 4.4 with 3.1 
A solution of the tetrasaccharide oxazoline 3.1 (0.322 mg, 0.27µmol) and dRNase B 4.4 
(0.348 mg, 0.03µmol) was incubated with 2 mU of Endo-A in 20 μL of sodium 
phosphate buffer (100 mM, pH 6.5) at 23 °C for 2h to give (M6P)2RNase 4.6. HRMS 
(ES
+
) Calculated For C38H68NO37P2 (MH
+
) 1192.29. Found (MH
+
) 1192.27. 
Glycosylation of de-glycosylated fabrazyme 4.7 with 2.1 
Fabrazyme (5.0 mg) was deglycosylated with wild type Endo A (50 µg of Endo A) in 5 
μL of sodium phosphate buffer (100 mM, pH 6.5) at 37 °C for 10 h. After Endo A 
mediated hydrolysis was complete the de-glycosylated Fabrazyme (dFab) was purified 
using RP-HPLC to give pure dFab 4.7.  
A solution of the tetrasaccharide oxazoline 2.1 (0.24 mg, 0.28µmol) and dFab 4.7 (0.21 
mg, 0.005µmol) was incubated with 1µg of Endo-A in 20 μL of sodium phosphate buffer 
(100 mM, pH 6.5) at 37 °C for 2h to give double glycosylation of dFab with the addition 
of two tetrasaccharide units – M6P2Fab. HRMS: calculated for (2[M6P-tetra]-
dFab+2H
+
): 48218.30; Found: 48218.30. 
Glycosylation of de-glycosylated fabrazyme 4.7 with 3.1 
A solution of the hexasaccharide oxazoline 3.1 (0.35 mg, 0.30µmol) and dFab 4.7 (0.21 
mg, 0.005µmol) was incubated with 1µg of Endo-A in 20 μL of sodium phosphate buffer 
(100 mM, pH 6.5) at 37 °C for 2h to give double glycosylation of dFab with the addition 
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Lane 1- 0min, Lane 2-15min, Lane 3-30min, Lane 4-1h, Lane 5-2h, Lane 6-4h, Lane 7-
8h, Lane 8-24h, Lane 9-reaction mixture. 
A.2 Immunocytochemical detection of M6P-RNase in HepG2 cells 
HepG2 thawing and culture and maintenance 
Human hepatocellular carcinoma (HepG2) cells were sourced from the laboratory of Prof 
John Evans (University of Otago, Christchurch School of Medicine). All cell culture was 
performed in a Class II Biohazard hood using sterile reagents and consumables. 
1.5x 10
6
 HEPG2 cells in 10% cell culture grade DMSO/growth medium (See page 209) 
were gently thawed from liquid nitrogen store in a 37ºC water bath. When the last ice 
crystals were evident, the cells were gently transferred into 5 mL of fresh pre-warmed 
(37 ºC) growth medium. Cells were spun at 1,000 rpm for 5 minutes at room temperature. 
The supernatant was removed by aspiration and the pellet gently re-suspended in 15 mL 
of growth media and transferred into a T75 flask (Corning) and cultured at 37 ºC/5% CO2 
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in a static tissue culture incubator (Sanyo). Growth media was changed by aspiration and 
replacement of 15 mL of fresh, pre-warmed growth media every 2-3 days. Cells were 
cultured until reaching a confluence of around 70-80%. 
HepG2 passaging 
On reaching 70-80% confluence, cells were trypsinized to liberate the cells from the 
bottom of the flask. To achieve this, HepG2 cells were washed with 5 mL of sterile 
phosphate buffered saline (PBS, Life Technologies), with PBS aspirated, washed again 
with another 5 mL of PBS and removed. Five mL of 0.05% Trypsin/EDTA (Life 
Technologies) was added to the plate and incubated at 37 ºC/5% CO2 for 5 minutes. After 
5 minutes, the flask was inspected under the light microscope to confirm detachment and 
the reaction quenched with addition of 10 mL of fresh, pre-warmed growth media. Cells 
were counted using either a hemocytometer under a light microscope, or using a 
Countess Automated Cell Counter (Life Technologies). Typically cells were split 1/3 
across new T75 flasks and propagated as outlined in section 1.1.  Specific cell numbers 
were also taken forward for immunocytochemical experiments indicated in section 1.3. 
Immunocytochemistry 
HepG2 cells were plated into each well of a LabTek 4 well Chamber Slide (Nunc) at 
75,000 cells/well. Cells were incubated at 37 ºC/5% CO2 for 2 days. After 2 days, each 
well was washed twice with 1 mL of pre-warmed (37 ºC) PBS/well. Cells were incubated 
in the presence of either 1 µM M6P-RNase, µM deglycosylated RNase or media only for 
1-2 hours at 37 ºC/5% CO2. Incubation media altered from standard growth media, with 
  Appendix 
206 
 
FBS removed (MEM, 100U penicillin, 100 µg/ml streptomycin, 250 ng/ml 
amphotericin). Extra wells were also prepared for immunocytochemistry controls. 
After incubation, media was aspirated from the chamber slide wells and washed twice 
with 1mL of PBS per wash. The cells were then fixed by addition of 1 mL 4% 
paraformaldehyde in PBS to each well and incubated at 4 C for 30 min. At the 
conclusion of 30 minutes, the paraformaldehyde was aspirated and the wells washed 
twice with 1mL of PBS per wash with a 5 minute incubation period for each wash. The 
cells were then permeabilized with 0.5 mL 80% methanol/PBS at -20 C for 15 minutes. 
After 15 minutes, the cells were again washed with two 5 minute PBS washes. The cells 
were then blocked with 0.5 mL 3% non-fat dried milk/1% bovine serum albumin in PBS 
for 30 min at room temperature. After 30 minutes, the cells were again washed with two 
5 minute PBS washes. Appropriate wells were co-incubated with 1:10,000 mouse anti-
cation independent mannose-6-phosphate receptor (CI-MPR, Abcam) and 1:10,000 
rabbit anti-RNase A (Abcam) in 0.1% BSA/PBS (0.5 mL/well) and incubated for 1 hour 
at room temperature. After 1 hour, the cells were again washed with two 5 minute PBS 
washes. Both 1:400 goat anti-mouse IgG-Alexa 488 (Life Technologies) and 1:400 goat 
anti-rabbit IgG-Alexa 568 (Life Technologies) in 0.1% BSA/PBS were added to the 
wells (0.5 mL/well) and incubated for 1 hour at room temperature in the dark. After 1 
hour, the cells were again washed with two 5 minute PBS washes. Cells were then 
incubated with 0.5 mL of 300 nM 4',6-diamidino-2-phenylindole (DAPI, Life 
Technologies) in PBS and incubated for 1 minute at room temperature in the dark to stain 
cell nuclei. After 1 minute, the cells were again washed with two 5 minute PBS washes. 
  Appendix 
207 
 
Chambers were then removed and slides mounted with mounting media (Dako, 
Australia) and coverslipped. Imaging was performed using a Leica SP5 confocal laser 
scanning microscope (Wetzlar, Germany) fitted with a 63X NA1.3 glycerol immersion 
lens and excitation at 405, 488, 561 nm (violet, blue, and green respectively) and LAS 
software. Fluorescence on the SP5 system collected in user-defined wavelength bands. 
Fluorescence was emission monitored between 415 and 485 nm using 405 nm excitation 
for DAPI, emission between 555 and 625 nm and 488 nm excitation for CI-MPR, 
emission between 695 and 765 nm with excitation for RNase fluorescence at 561 nm. To 
reduce cross-talk the different fluorophores, images were collected using sequential line 
scanning with only a single excitation wavelength and the corresponding fluorescence 
collected at any one time. At least three images were captured per well with duplicate 
wells per treatment.  
Control wells were included which did not receive either primary or secondary antibody 
or both, to control for background from non-specific binding/background fluorescence. 
Bleed through was also evaluated for each fluorophore. 
A.3 Immunopreciptation 
Binding of CI-MPR to M6P-RNase was also demonstrated. Prior to immunoprecipitation 
experiments, HepG2 cell lysate was prepared in order to capture CI-MPR.  
Preparation of HepG2 cell lysate 
HepG2 cells were cultured to 80% confluence as described in sections 1.1. and 1.2 in a 
T75 flask. Media was aspirated and cells washed twice with 2 mL 1x cold PBS. PBS was 
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aspirated and 1 mL of radioimmunoprecipitation (RIPA) buffer (Sigma) containing 
protease inhibitor cocktail (Roche) was added to the flask which was then scraped with a 
rubber policemen on ice. The contents of the flask were then transferred to a 2 mL 
microcentrifuge tube on ice. The sample was sonicated for 4 x 30 second pulses 
(Hielscher Ultrasonic Processor, 35% amplitude, cycle @ 0.3 = 30% power) while on ice 
using a micro-tip. The sample was then incubated on ice for 30 minutes, vortexing every 
10 min. After 30 minutes the lysate was spun at 14,000 x g for 15 min at 4°C. The 
supernatant, the total protein fraction was retained. Protein was quantitated by 
Bicinchoninic Acid (BCA) Assay according to manufacturer’s instructions (Pierce).  
Lysate was stored at -20 ºC until required. 
Coupling of CI-MPR antibody to Protein A resin 
One hundred µL of Protein A sepharose (GE) was added to each of 3 microcentrifuge 
tubes. The tubes were spun at 1,000 x g for 2 min at 4°C and the supernatant removed. 
The pellet was resuspended in 500 µL RIPA buffer and re-spun. This RIPA wash was 
repeated one more time.  The supernatant was discarded and the pellet resuspended in 99 
µL RIPA on ice and 1 µL of 1 mg/ml mouse anti-CI-MPR (Abcam) antibody added to 
each tube. The tubes were incubated for 2 hours at 4 °C on a tube mixer. After 2 hours, 
the tubes were centrifuged at 2,000 x g for 2 minutes at 4 °C and the supernatant 
discarded. One mL of RIPA buffer was added with gentle agitation and centrifuged at 
3,000 x g for 2 min at 4 °C. This wash step was repeated twice more.  
Addition of HPEG2 cell lysate to anti-CI-MPR conjugated Protein A to capture CI-
MPR 
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Fifty µg of HepG2 lysate prepared in section 1.4.1 was diluted in RIPA buffer to a final 
volume of 100 µL and added to anti-CI-MPR conjugated resin prepared in section 1.4.2 
(9.2 µL lysate (5.43 mg/ml) + 90.8 µL RIPA buffer). The lysate-beads/antibody mixtures 
were incubated 4 °C overnight on tube mixer. After incubation the tubes were 
centrifuged at 2,000 x g for 2 minutes at 4 °C, the supernatant removed and the pellet 
washed with 1 mL RIPA buffer three times to remove non-specific binding. During 
removal of supernatant from the last wash, efforts were made to remove as much wash 
buffer as possible from the pellet.  
Incubation of RNases with immobilized CI-MPR 
The CI-MPR-conjugated resin prepared in section 1.4.2 was incubated with either of the 
three samples below at a final amount of 2 µg in RIPA buffer to a final volume of 100 
µL:  
 a. M6P RNase 
 b. deglycosylated RNase (dRNase) 
 c. No RNase   
The tubes were incubated at 4 °C overnight on tube mixer. After incubation, tubes were 
centrifuged at 2,000 x g for 2 minutes at 4°C. Tubes were washed with 1 mL RIPA buffer 
5x to remove non-specifically bound protein. Efforts were made to remove as much wash 
buffer as possible from the pellet. 
SDS-PAGE and Western Blotting to detect RNase capture by CI-MPR 
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Protein was eluted from the washed pellet in section 1.4.3 by heating the pellet at 50°C 
for 10 minutes in 7.5 µL 4x LDS buffer (Novex gel kit buffer, Life Technologies) + 22.5 
µL RIPA buffer + 5 µL 10x reducing buffer (Novex gel kit buffer, Life Technologies). 
Tubes were spun at 2,000 x g for 2 minutes at room temperature and the supernatant 
retained (Elution 1). The elution steps above were repeated the elution retained (Elution 
2).  
Positive controls were prepared to confirm RNase molecular weight and staining where 
M6P-RNase and dRNase were diluted to 25 ng in RIPA buffer, 4x LDS buffer and 10x 
reducing buffer.  
All samples were incubated at 100 °C for 5 min and loaded onto a 12% Novex Bolt Bis-
Tris Plus Gel (Life Technologies). The gel was resolved in 1x 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (Life Technologies) in a Bolt 
electrophoresis rig (Life Technologies) at 165V for 40 minutes. The gel was removed 
from the cassette and equilibrated in transfer buffer (48 mM Tris base, 39 mM glycine, 
20% methanol, pH 9.2). Nitrocellulose membrane (Bio-Rad) was also equilibrated in 
transfer buffer for 15 minutes.  Following equilibration of both gel and membrane, 
transfer of protein from the SDS-PAGE gel to the nitrocellulose membrane was 
conducted using a Bio-Rad Semi Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell 
(Bio-Rad) at 25V for 15 minutes according to the manufacturer’s instructions. At the 
conclusion of transfer, membrane washed for two 5 minute washes in 20 mL of reverse 
osmosis (RO) water with agitation. Water was removed from the membrane and the 
membrane blocked overnight at 4 °C in 10 mL of blocking buffer from an Anti-Rabbit 
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WesternBreeze Chromogenic Kit (Life Technologies). After incubation, the membrane 
washed for two 5 minute washes in 20 mL of RO water with agitation. Water was 
removed and 2 mL of 1:1000 rabbit anti-RNase (Abcam) diluted in blocking buffer was 
added to the membrane and incubated at room temperature for 1 hour. After 1 hour the 
antibody was removed from the membrane and 20 mL of antibody wash buffer 
(WesternBreeze kit) applied to the membrane and incubated with agitation for 5 minutes 
at room temperature. After 5 minutes the wash buffer was removed from the membrane. 
This washing step was repeated twice more. After washing, 10 mL of pre-diluted alkaline 
phosphatase conjugated anti-rabbit IgG secondary antibody (WesternBreeze kit) was 
applied onto the membrane and incubated at room temperature for 30 minutes. 
Membrane was washed with antibody wash as described above and then washed for two 
5 minute washes in 20 mL of RO water. After the final wash, water was removed and 5 
mL of BCIP/NBT substrate (WesternBreeze kit) added. The membrane was developed at 
room temperature until bands appeared (5-30 minutes) and reaction quenched by two 5 
minute washes in 20 mL of RO water. The membrane was air dried then imaged on a 
ChemiGenius Bioimaging System. 
Growth media 
Minimum Essential Media, MEM 
10% heat-inactivated fetal bovine serum, FBS 
100U penicillin 
100 µg/ml streptomycin 
250 ng/ml amphotericin 
Filter sterilized through a 0.22 um filtration unit. stored at 4 °C.
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